



## Clinical trial results:

**A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advanced HER3-positive solid tumors**

### Summary

|                          |                   |
|--------------------------|-------------------|
| EudraCT number           | 2013-001699-39    |
| Trial protocol           | NL                |
| Global end of trial date | 18 September 2017 |

### Results information

|                                |                   |
|--------------------------------|-------------------|
| Result version number          | v2 (current)      |
| This version publication date  | 20 April 2019     |
| First version publication date | 15 September 2018 |
| Version creation reason        |                   |

### Trial information

#### Trial identification

|                       |        |
|-----------------------|--------|
| Sponsor protocol code | 117158 |
|-----------------------|--------|

#### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN)   | - |

Notes:

### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | GlaxoSmithKline  |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, |
| Public contact               | GSK Response Center, GlaxoSmithKline, 1 866-435-7343,      |
| Scientific contact           | GSK Response Center, GlaxoSmithKline, 1 866-435-7343,      |

Notes:

### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

---

**Results analysis stage**

---

|  |                 |
|--|-----------------|
| Analysis stage                                       | Final           |
| Date of interim/final analysis                       | 19 January 2018 |
| Is this the analysis of the primary completion data? | No              |

---

|                                  |                   |
|----------------------------------|-------------------|
| Global end of trial reached?     | Yes               |
| Global end of trial date         | 18 September 2017 |
| Was the trial ended prematurely? | No                |

---

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To determine the safety and tolerability of GSK2849330 in participants with advanced Human epidermal growth Factor Receptor 3 (HER3)-positive solid tumors.

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

|   |                  |
|---|------------------|
| Actual start date of recruitment                          | 26 November 2013 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | No               |

---

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

|                                      |                  |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | Australia: 17    |
| Country: Number of subjects enrolled | Netherlands: 7   |
| Country: Number of subjects enrolled | United States: 5 |
| Worldwide total number of subjects   | 29               |
| EEA total number of subjects         | 7                |

---

Notes:

---

**Subjects enrolled per age group**

---

|   |    |
|---|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 0  |
| Adolescents (12-17 years)                 | 0  |
| Adults (18-64 years)                      | 17 |
| From 65 to 84 years                       | 11 |
| 85 years and over                         | 1  |

---

## Subject disposition

### Recruitment

Recruitment details:

This is a Phase 1 study of anti-human epidermal growth factor receptor 3 (HER3) antibody, GSK2849330 in participants with advanced solid tumors expressing HER3. The study was conducted in 2 parts-Part1 (dose escalation) and Part2 (dose expansion). The starting dose in Part1 was 1.4 milligrams per kilogram (mg/kg) GSK2849330 given weekly for 28 days

### Pre-assignment

Screening details:

A total of 29 participants were randomized. The study was conducted in three countries. Participants in the GSK2849330 30 mg/kg weekly arm were not double counted with any other Arm.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Not applicable                 |
| Blinding used                | Not blinded                    |

### Arms

|                              |                             |
|------------------------------|-----------------------------|
| Are arms mutually exclusive? | Yes                         |
| <b>Arm title</b>             | GSK2849330 1.4 mg/kg weekly |

Arm description:

Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | GSK2849330            |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

|                  |                                  |
|------------------|----------------------------------|
| <b>Arm title</b> | GSK2849330 3 mg/kg every 2 weeks |
|------------------|----------------------------------|

Arm description:

Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | GSK2849330            |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

|                  |                           |
|------------------|---------------------------|
| <b>Arm title</b> | GSK2849330 3 mg/kg weekly |
|------------------|---------------------------|

Arm description:

Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | GSK2849330            |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

**Dosage and administration details:**

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

|                  |                                   |
|------------------|-----------------------------------|
| <b>Arm title</b> | GSK2849330 10 mg/kg every 2 weeks |
|------------------|-----------------------------------|

**Arm description:**

Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | GSK2849330            |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

**Dosage and administration details:**

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

|                  |                                   |
|------------------|-----------------------------------|
| <b>Arm title</b> | GSK2849330 30 mg/kg every 2 weeks |
|------------------|-----------------------------------|

**Arm description:**

Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | GSK2849330            |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

**Dosage and administration details:**

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

|                  |                            |
|------------------|----------------------------|
| <b>Arm title</b> | GSK2849330 30 mg/kg weekly |
|------------------|----------------------------|

**Arm description:**

Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days.

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | GSK2849330            |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

**Dosage and administration details:**

GSK2849330 100 milligrams per milliliter (100 mg/mL) solution was diluted in 0.9% sodium chloride solution to obtain the appropriate concentration. Participants were administered the appropriate concentration via intravenous infusion.

| Number of subjects in period 1 | GSK2849330 1.4<br>mg/kg weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly |
|--------------------------------|--------------------------------|--|------------------------------|
|                                |                                |  |                              |
| Started                        | 1                              | 3                                      | 2                            |
| Completed                      | 1                              | 1                                      | 1                            |
| Not completed                  | 0                              | 2                                      | 1                            |
| Physician decision             | -                              | 1                                      | -                            |
| Consent withdrawn by subject   | -                              | 1                                      | 1                            |
| Lost to follow-up              | -                              | -                                      | -                            |

| Number of subjects in period 1 | GSK2849330 10<br>mg/kg every 2<br>weeks | GSK2849330 30<br>mg/kg every 2<br>weeks | GSK2849330 30<br>mg/kg weekly |
|--------------------------------|---|---|-------------------------------|
|                                |   |   |                               |
| Started                        | 5                                       | 4                                       | 14                            |
| Completed                      | 2                                       | 1                                       | 8                             |
| Not completed                  | 3                                       | 3                                       | 6                             |
| Physician decision             | 1                                       | 1                                       | 3                             |
| Consent withdrawn by subject   | -                                       | 2                                       | 2                             |
| Lost to follow-up              | 2                                       | -                                       | 1                             |

## Baseline characteristics

### Reporting groups

|  |                                   |
|--|-----------------------------------|
| Reporting group title  | GSK2849330 1.4 mg/kg weekly       |
| Reporting group description:<br>Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days |                                   |
| Reporting group title  | GSK2849330 3 mg/kg every 2 weeks  |
| Reporting group description:<br>Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.  |                                   |
| Reporting group title  | GSK2849330 3 mg/kg weekly         |
| Reporting group description:<br>Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.  |                                   |
| Reporting group title  | GSK2849330 10 mg/kg every 2 weeks |
| Reporting group description:<br>Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days. |                                   |
| Reporting group title  | GSK2849330 30 mg/kg every 2 weeks |
| Reporting group description:<br>Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days  |                                   |
| Reporting group title  | GSK2849330 30 mg/kg weekly        |
| Reporting group description:<br>Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. |                                   |

| Reporting group values   | GSK2849330 1.4 mg/kg weekly | GSK2849330 3 mg/kg every 2 weeks | GSK2849330 3 mg/kg weekly |
|--|-----------------------------|----------------------------------|---------------------------|
| Number of subjects   | 1                           | 3                                | 2                         |
| Age categorical  |                             |                                  |                           |
| Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan (RAP).          |                             |                                  |                           |
| Units: Subjects  |                             |                                  |                           |
| Total  | 1                           | 3                                | 2                         |
| Age continuous   |                             |                                  |                           |
| 99999 indicates standard deviation for 1.4 mg/kg weekly arm could not be calculated as only a single participant was analyzed in this arm. |                             |                                  |                           |
| Units: years   |                             |                                  |                           |
| arithmetic mean  | 63.0                        | 62.3                             | 46.0                      |
| standard deviation   | ± 99999                     | ± 4.04                           | ± 21.21                   |
| Gender categorical   |                             |                                  |                           |
| Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.  |                             |                                  |                           |
| Units: Subjects  |                             |                                  |                           |
| Female   | 0                           | 3                                | 1                         |
| Male   | 1                           | 0                                | 1                         |
| Race/Ethnicity, Customized   |                             |                                  |                           |
| Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.  |                             |                                  |                           |
| Units: Subjects  |                             |                                  |                           |
| Race customized Asian-Central/South Asian Heritage   | 0                           | 0                                | 0                         |

|                       |   |   |   |
|-----------------------|---|---|---|
| Race customized White | 1 | 3 | 2 |
|-----------------------|---|---|---|

| Reporting group values   | GSK2849330 10 mg/kg every 2 weeks | GSK2849330 30 mg/kg every 2 weeks | GSK2849330 30 mg/kg weekly |
|--|-----------------------------------|-----------------------------------|----------------------------|
| Number of subjects   | 5                                 | 4                                 | 14                         |
| Age categorical  |                                   |                                   |                            |
| Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan (RAP).          |                                   |                                   |                            |
| Units: Subjects  |                                   |                                   |                            |
| Total  | 5                                 | 4                                 | 14                         |
| Age continuous   |                                   |                                   |                            |
| 99999 indicates standard deviation for 1.4 mg/kg weekly arm could not be calculated as only a single participant was analyzed in this arm. |                                   |                                   |                            |
| Units: years   |                                   |                                   |                            |
| arithmetic mean  | 66.2                              | 58.3                              | 62.5                       |
| standard deviation   | ± 7.19                            | ± 8.73                            | ± 11.65                    |
| Gender categorical   |                                   |                                   |                            |
| Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.  |                                   |                                   |                            |
| Units: Subjects  |                                   |                                   |                            |
| Female   | 2                                 | 2                                 | 5                          |
| Male   | 3                                 | 2                                 | 9                          |
| Race/Ethnicity, Customized   |                                   |                                   |                            |
| Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.  |                                   |                                   |                            |
| Units: Subjects  |                                   |                                   |                            |
| Race customized Asian-Central/South Asian Heritage   | 0                                 | 0                                 | 1                          |
| Race customized White  | 5                                 | 4                                 | 13                         |

| Reporting group values   | Total |  |  |
|--|-------|--|--|
| Number of subjects   | 29    |  |  |
| Age categorical  |       |  |  |
| Treatment groups with same dose and administration frequency were combined as pre-specified in reporting and analysis plan (RAP).          |       |  |  |
| Units: Subjects  |       |  |  |
| Total  | 29    |  |  |
| Age continuous   |       |  |  |
| 99999 indicates standard deviation for 1.4 mg/kg weekly arm could not be calculated as only a single participant was analyzed in this arm. |       |  |  |
| Units: years   |       |  |  |
| arithmetic mean  |       |  |  |
| standard deviation   | -     |  |  |
| Gender categorical   |       |  |  |
| Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.  |       |  |  |
| Units: Subjects  |       |  |  |
| Female   | 13    |  |  |
| Male   | 16    |  |  |
| Race/Ethnicity, Customized   |       |  |  |
| Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.  |       |  |  |
| Units: Subjects  |       |  |  |
| Race customized Asian-Central/South Asian Heritage   | 1     |  |  |

|                       |    |  |  |
|-----------------------|----|--|--|
| Race customized White | 28 |  |  |
|-----------------------|----|--|--|



## End points

### End points reporting groups

|  |                                   |
|--|-----------------------------------|
| Reporting group title  | GSK2849330 1.4 mg/kg weekly       |
| Reporting group description:<br>Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days |                                   |
| Reporting group title  | GSK2849330 3 mg/kg every 2 weeks  |
| Reporting group description:<br>Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.  |                                   |
| Reporting group title  | GSK2849330 3 mg/kg weekly         |
| Reporting group description:<br>Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.  |                                   |
| Reporting group title  | GSK2849330 10 mg/kg every 2 weeks |
| Reporting group description:<br>Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days. |                                   |
| Reporting group title  | GSK2849330 30 mg/kg every 2 weeks |
| Reporting group description:<br>Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days  |                                   |
| Reporting group title  | GSK2849330 30 mg/kg weekly        |
| Reporting group description:<br>Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. |                                   |

### Primary: Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Parts 1 and 2

|   |   |
|---|---|
| End point title   | Number of participants with adverse events (AEs) and serious adverse events (SAEs)-Parts 1 and 2 <sup>[1]</sup> |
| End point description:<br>An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events that may require medical or surgical intervention to prevent one of the outcomes mentioned; events of possible study treatment-induced liver injury with hyperbilirubinemia; and left ventricular ejection fraction (LVEF) meeting stopping criteria. AEs were collected in All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP. |   |
| End point type  | Primary   |
| End point timeframe:<br>Median of 6.143 weeks of drug exposure  |   |
| Notes:<br>[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.<br>Justification: No statistical analysis were performed.   |   |

| End point values            | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|-----------------------------|-----------------------------------|--|------------------------------|---|
| Subject group type          | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed | 1 <sup>[2]</sup>                  | 3 <sup>[3]</sup>                       | 2 <sup>[4]</sup>             | 5 <sup>[5]</sup>                        |
| Units: Participants         |                                   |  |                              |   |
| AEs                         | 1                                 | 3                                      | 2                            | 5                                       |
| SAEs                        | 0                                 | 1                                      | 0                            | 1                                       |

Notes:

[2] - All Treated Population

[3] - All Treated Population

[4] - All Treated Population

[5] - All Treated Population

| End point values            | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|-----------------------------|---|----------------------------------|--|--|
| Subject group type          | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed | 4 <sup>[6]</sup>                        | 14 <sup>[7]</sup>                |  |  |
| Units: Participants         |   |                                  |  |  |
| AEs                         | 4                                       | 14                               |  |  |
| SAEs                        | 1                                       | 3                                |  |  |

Notes:

[6] - All Treated Population

[7] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of participants with dose-limiting toxicities (DLTs)-Parts 1 and 2

|                 |  |
|-----------------|--|
| End point title | Number of participants with dose-limiting toxicities (DLTs)-<br>Parts 1 and 2 <sup>[8]</sup> |
|-----------------|--|

End point description:

An event was considered a DLT if it occurred within the first 4 weeks (28 days) of treatment, and met one of the following criteria unless it could be established that the event was unrelated to treatment: Grade 3 or greater non-hematologic toxicity; Grade 4 neutropenia lasting >5 days; Febrile neutropenia, of any grade or duration; Grade 4 thrombocytopenia, or Grade 3 thrombocytopenia associated with bleeding; Alanine aminotransferase (ALT) >3 times upper limit of normal (ULN) with bilirubin >2 times ULN; Any Grade 2 or greater toxicity that in the judgment of the investigator and GlaxoSmithKline (GSK) Medical Monitor, would be considered dose-limiting; Grade 3 or greater decrease in LVEF. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 28 days

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

|                             |                                   |  |                              |   |
|-----------------------------|-----------------------------------|--|------------------------------|---|
| <b>End point values</b>     | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
| Subject group type          | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed | 1 <sup>[9]</sup>                  | 3 <sup>[10]</sup>                      | 2 <sup>[11]</sup>            | 5 <sup>[12]</sup>                       |
| Units: Participants         |                                   |  |                              |   |
| Participants                | 0                                 | 0                                      | 0                            | 0                                       |

Notes:

[9] - All Treated Population

[10] - All Treated Population

[11] - All Treated Population

[12] - All Treated Population

|                             |   |                                  |  |  |
|-----------------------------|---|----------------------------------|--|--|
| <b>End point values</b>     | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
| Subject group type          | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed | 4 <sup>[13]</sup>                       | 14 <sup>[14]</sup>               |  |  |
| Units: Participants         |   |                                  |  |  |
| Participants                | 0                                       | 0                                |  |  |

Notes:

[13] - All Treated Population

[14] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of participants with grade change from Baseline in clinical chemistry data-Parts 1 and 2

|                 |   |
|-----------------|---|
| End point title | Number of participants with grade change from Baseline in clinical chemistry data-Parts 1 and 2 <sup>[15]</sup> |
|-----------------|---|

End point description:

Blood samples were collected for analysis of following parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Total bil), calcium, creatinine, gamma glutamyl transferase (GGT), glucose, potassium, magnesium, sodium, phosphorus, uric acid. Laboratory parameters were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Baseline was defined as most recent, non-missing value from central laboratory prior to or on first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. Data for worst-case post Baseline is presented. 99999 indicates data was not available. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

| End point values                                   | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|--|-----------------------------------|--|------------------------------|---|
| Subject group type                                 | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed                        | 1 <sup>[16]</sup>                 | 3 <sup>[17]</sup>                      | 2 <sup>[18]</sup>            | 5 <sup>[19]</sup>                       |
| Units: Participants                                |                                   |  |                              |   |
| Albumin; any Grade increase;<br>n=1,3,2,5,4,14     | 1                                 | 1                                      | 0                            | 3                                       |
| Albumin; increase to Grade 3;<br>n=1,3,2,5,4,14    | 0                                 | 0                                      | 0                            | 0                                       |
| Albumin; increase to Grade 4;<br>n=1,3,2,5,4,14    | 0                                 | 0                                      | 0                            | 0                                       |
| ALP; any grade increase;<br>n=1,3,2,5,4,14         | 1                                 | 0                                      | 1                            | 1                                       |
| ALP; increase to Grade 3;<br>n=1,3,2,5,4,14        | 0                                 | 0                                      | 0                            | 0                                       |
| ALP; increase to Grade 4;<br>n=1,3,2,5,4,14        | 0                                 | 0                                      | 0                            | 0                                       |
| ALT; any Grade increase;<br>n=1,3,2,5,4,14         | 0                                 | 2                                      | 0                            | 2                                       |
| ALT; increase to Grade 3;<br>n=1,3,2,5,4,14        | 0                                 | 0                                      | 0                            | 0                                       |
| ALT; increase to Grade 4;<br>n=1,3,2,5,4,14        | 0                                 | 0                                      | 0                            | 0                                       |
| AST; any Grade increase;<br>n=1,3,2,5,4,14         | 0                                 | 1                                      | 0                            | 2                                       |
| AST; increase to Grade 3;<br>n=1,3,2,5,4,14        | 0                                 | 0                                      | 0                            | 0                                       |
| AST; increase to Grade 4;<br>n=1,3,2,5,4,14        | 0                                 | 0                                      | 0                            | 0                                       |
| Total bil; any Grade increase;<br>n=1,3,2,5,4,14   | 0                                 | 1                                      | 0                            | 1                                       |
| Total bil; increase to Grade 3;<br>n=1,3,2,5,4,14  | 0                                 | 0                                      | 0                            | 0                                       |
| Total bil; increase to Grade 4;<br>n=1,3,2,5,4,14  | 0                                 | 0                                      | 0                            | 0                                       |
| Calcium; any Grade increase;<br>n=1,3,2,5,4,14     | 0                                 | 0                                      | 0                            | 0                                       |
| Calcium; increase to Grade 3;<br>n=1,3,2,5,4,14    | 0                                 | 0                                      | 0                            | 0                                       |
| Calcium; increase to Grade 4;<br>n=1,3,2,5,4,14    | 0                                 | 0                                      | 0                            | 0                                       |
| Creatinine; any Grade increase;<br>n=1,3,2,5,4,14  | 0                                 | 1                                      | 0                            | 1                                       |
| Creatinine; increase to Grade 3;<br>n=1,3,2,5,4,14 | 0                                 | 0                                      | 0                            | 0                                       |
| Creatinine; increase to Grade 4;<br>n=1,3,2,5,4,14 | 0                                 | 0                                      | 0                            | 0                                       |
| GGT; any Grade increase;<br>n=1,3,2,5,4,14         | 1                                 | 0                                      | 1                            | 2                                       |
| GGT; increase to Grade 3;<br>n=1,3,2,5,4,14        | 0                                 | 0                                      | 1                            | 1                                       |
| GGT; increase to Grade 4;<br>n=1,3,2,5,4,14        | 0                                 | 0                                      | 0                            | 0                                       |
| Glucose; any Grade increase;<br>n=1,3,2,5,4,14     | 1                                 | 0                                      | 1                            | 3                                       |
| Glucose; increase to Grade 3;<br>n=1,3,2,5,4,14    | 0                                 | 0                                      | 0                            | 0                                       |
| Glucose; increase to Grade 4;<br>n=1,3,2,5,4,14    | 0                                 | 0                                      | 0                            | 0                                       |
| Potassium; any Grade increase;<br>n=1,3,2,5,4,14   | 0                                 | 2                                      | 0                            | 0                                       |

|  |       |       |       |       |
|--|-------|-------|-------|-------|
| Potassium; increase to Grade 3;<br>n=1,3,2,5,4,14  | 0     | 1     | 0     | 0     |
| Potassium; increase to Grade 4;<br>n=1,3,2,5,4,14  | 0     | 0     | 0     | 0     |
| Magnesium; any Grade increase;<br>n=1,3,2,5,4,14   | 0     | 1     | 0     | 0     |
| Magnesium; increase to Grade 3;<br>n=1,3,2,5,4,14  | 0     | 0     | 0     | 0     |
| Magnesium; increase to Grade 4;<br>n=1,3,2,5,4,14  | 0     | 0     | 0     | 0     |
| Sodium; any Grade increase;<br>n=1,3,2,5,4,14      | 0     | 1     | 0     | 0     |
| Sodium; increase to Grade 3;<br>n=1,3,2,5,4,14     | 0     | 0     | 0     | 0     |
| Sodium; increase to Grade 4;<br>n=1,3,2,5,4,14     | 0     | 0     | 0     | 0     |
| Phosphorus; any Grade increase;<br>n=1,3,2,5,4,14  | 1     | 0     | 0     | 0     |
| Phosphorus; increase to Grade 3;<br>n=1,3,2,5,4,14 | 0     | 0     | 0     | 0     |
| Phosphorus; increase to Grade 4;<br>n=1,3,2,5,4,14 | 0     | 0     | 0     | 0     |
| Uric acid; any Grade increase;<br>n=0,0,0,0,0,1    | 99999 | 99999 | 99999 | 99999 |
| Uric acid; increase to Grade 3;<br>n=0,0,0,0,0,1   | 99999 | 99999 | 99999 | 99999 |
| Uric acid; increase to Grade 4;<br>n=0,0,0,0,0,1   | 99999 | 99999 | 99999 | 99999 |

Notes:

[16] - All Treated Population

[17] - All Treated Population

[18] - All Treated Population

[19] - All Treated Population

| <b>End point values</b>                         | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|---|---|----------------------------------|--|--|
| Subject group type                              | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed                     | 4 <sup>[20]</sup>                       | 14 <sup>[21]</sup>               |  |  |
| Units: Participants                             |   |                                  |  |  |
| Albumin; any Grade increase;<br>n=1,3,2,5,4,14  | 3                                       | 6                                |  |  |
| Albumin; increase to Grade 3;<br>n=1,3,2,5,4,14 | 0                                       | 1                                |  |  |
| Albumin; increase to Grade 4;<br>n=1,3,2,5,4,14 | 0                                       | 0                                |  |  |
| ALP; any grade increase;<br>n=1,3,2,5,4,14      | 1                                       | 7                                |  |  |
| ALP; increase to Grade 3;<br>n=1,3,2,5,4,14     | 1                                       | 1                                |  |  |
| ALP; increase to Grade 4;<br>n=1,3,2,5,4,14     | 0                                       | 0                                |  |  |
| ALT; any Grade increase;<br>n=1,3,2,5,4,14      | 3                                       | 6                                |  |  |
| ALT; increase to Grade 3;<br>n=1,3,2,5,4,14     | 0                                       | 0                                |  |  |
| ALT; increase to Grade 4;<br>n=1,3,2,5,4,14     | 0                                       | 0                                |  |  |
| AST; any Grade increase;<br>n=1,3,2,5,4,14      | 2                                       | 5                                |  |  |

|  |       |   |  |  |
|--|-------|---|--|--|
| AST; increase to Grade 3;<br>n=1,3,2,5,4,14        | 0     | 1 |  |  |
| AST; increase to Grade 4;<br>n=1,3,2,5,4,14        | 0     | 0 |  |  |
| Total bil; any Grade increase;<br>n=1,3,2,5,4,14   | 0     | 2 |  |  |
| Total bil; increase to Grade 3;<br>n=1,3,2,5,4,14  | 0     | 0 |  |  |
| Total bil; increase to Grade 4;<br>n=1,3,2,5,4,14  | 0     | 0 |  |  |
| Calcium; any Grade increase;<br>n=1,3,2,5,4,14     | 2     | 2 |  |  |
| Calcium; increase to Grade 3;<br>n=1,3,2,5,4,14    | 1     | 0 |  |  |
| Calcium; increase to Grade 4;<br>n=1,3,2,5,4,14    | 0     | 0 |  |  |
| Creatinine; any Grade increase;<br>n=1,3,2,5,4,14  | 1     | 2 |  |  |
| Creatinine; increase to Grade 3;<br>n=1,3,2,5,4,14 | 0     | 0 |  |  |
| Creatinine; increase to Grade 4;<br>n=1,3,2,5,4,14 | 0     | 0 |  |  |
| GGT; any Grade increase;<br>n=1,3,2,5,4,14         | 3     | 8 |  |  |
| GGT; increase to Grade 3;<br>n=1,3,2,5,4,14        | 0     | 3 |  |  |
| GGT; increase to Grade 4;<br>n=1,3,2,5,4,14        | 1     | 0 |  |  |
| Glucose; any Grade increase;<br>n=1,3,2,5,4,14     | 2     | 4 |  |  |
| Glucose; increase to Grade 3;<br>n=1,3,2,5,4,14    | 0     | 0 |  |  |
| Glucose; increase to Grade 4;<br>n=1,3,2,5,4,14    | 0     | 0 |  |  |
| Potassium; any Grade increase;<br>n=1,3,2,5,4,14   | 0     | 1 |  |  |
| Potassium; increase to Grade 3;<br>n=1,3,2,5,4,14  | 0     | 0 |  |  |
| Potassium; increase to Grade 4;<br>n=1,3,2,5,4,14  | 0     | 0 |  |  |
| Magnesium; any Grade increase;<br>n=1,3,2,5,4,14   | 2     | 4 |  |  |
| Magnesium; increase to Grade 3;<br>n=1,3,2,5,4,14  | 0     | 0 |  |  |
| Magnesium; increase to Grade 4;<br>n=1,3,2,5,4,14  | 0     | 0 |  |  |
| Sodium; any Grade increase;<br>n=1,3,2,5,4,14      | 3     | 4 |  |  |
| Sodium; increase to Grade 3;<br>n=1,3,2,5,4,14     | 0     | 0 |  |  |
| Sodium; increase to Grade 4;<br>n=1,3,2,5,4,14     | 0     | 0 |  |  |
| Phosphorus; any Grade increase;<br>n=1,3,2,5,4,14  | 0     | 4 |  |  |
| Phosphorus; increase to Grade 3;<br>n=1,3,2,5,4,14 | 0     | 0 |  |  |
| Phosphorus; increase to Grade 4;<br>n=1,3,2,5,4,14 | 0     | 0 |  |  |
| Uric acid; any Grade increase;<br>n=0,0,0,0,0,1    | 99999 | 1 |  |  |
| Uric acid; increase to Grade 3;<br>n=0,0,0,0,0,1   | 99999 | 0 |  |  |

|  |       |   |  |  |
|--|-------|---|--|--|
| Uric acid; increase to Grade 4;<br>n=0,0,0,0,0,1 | 99999 | 1 |  |  |
|--|-------|---|--|--|

Notes:

[20] - All Treated Population

[21] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with change from Baseline in clinical chemistry data with respect to normal range-Parts 1 and 2

|                 |  |
|-----------------|--|
| End point title | Number of participants with change from Baseline in clinical chemistry data with respect to normal range-Parts 1 and 2 <sup>[22]</sup> |
|-----------------|--|

End point description:

Blood samples were collected for analysis of following chemistry parameters: direct bilirubin (D.Bil.), cancer antigen (CA)-125, CA-15.3, CA19-9, chloride, carbon dioxide (CO<sub>2</sub>)/bicarbonate (HCO<sub>3</sub>), luteinizing hormone (LH), total protein and urea or blood urea nitrogen (BUN). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. A laboratory value that is outside the reference range was considered either high abnormal (value above upper limit of the reference range) or low abnormal (value below lower limit of the reference range). Data for worst-case post Baseline is presented. 99999 indicates data was not available. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

| End point values                              | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|---|-----------------------------------|--|------------------------------|---|
| Subject group type                            | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed                   | 1 <sup>[23]</sup>                 | 3 <sup>[24]</sup>                      | 2 <sup>[25]</sup>            | 5 <sup>[26]</sup>                       |
| Units: Participants                           |                                   |  |                              |   |
| D.Bil.; Decrease to Low; n=1,3,2,5,3,14       | 0                                 | 0                                      | 1                            | 0                                       |
| D.Bil.; increase to high; n=1,3,2,5,3,14      | 0                                 | 1                                      | 0                            | 2                                       |
| CA-125; Decrease to Low; n=1,3,0,5,4,0        | 0                                 | 0                                      | 99999                        | 0                                       |
| CA-125; increase to high; n=1,3,0,5,4,0       | 0                                 | 0                                      | 99999                        | 0                                       |
| CA 15.3; Decrease to Low; n=0, 0, 0, 0, 4, 0  | 99999                             | 99999                                  | 99999                        | 99999                                   |
| CA 15.3; increase to high; n=0, 0, 0, 0, 4, 0 | 99999                             | 99999                                  | 99999                        | 99999                                   |
| CA 19-9.; Decrease to Low; n=1,0,0,0,2,0      | 0                                 | 99999                                  | 99999                        | 99999                                   |
| CA 19-9; increase to high; n=1,0,0,0,2,0      | 0                                 | 99999                                  | 99999                        | 99999                                   |
| Chloride; Decrease to Low; n=1,3,2,5,4,14     | 0                                 | 1                                      | 0                            | 1                                       |
| Chloride; increase to high; n=1,3,2,5,4,14    | 0                                 | 0                                      | 0                            | 0                                       |

|  |   |       |   |   |
|--|---|-------|---|---|
| CO2/HCO3.; Decrease to Low;<br>n=1,3,2,5,4,14      | 0 | 0     | 0 | 3 |
| CO2/HCO3.; increase to high;<br>n=1,3,2,5,4,14     | 0 | 1     | 0 | 1 |
| LH; Decrease to Low; n=1,0,2,3,2,7                 | 0 | 99999 | 0 | 0 |
| LH; increase to high; n=1,0,2,3,2,7                | 0 | 99999 | 0 | 0 |
| Total Protein; Decrease to Low;<br>n=1,3,2,5,4,14  | 0 | 1     | 1 | 1 |
| Total Protein; increase to high;<br>n=1,3,2,5,4,14 | 0 | 0     | 0 | 1 |
| Urea/BUN; Decrease to Low;<br>n=1,3,2,5,4,14       | 0 | 0     | 0 | 0 |
| Urea/BUN; increase to high;<br>n=1,3,2,5,4,14      | 0 | 1     | 1 | 0 |

Notes:

[23] - All Treated Population

[24] - All Treated Population

[25] - All Treated Population

[26] - All Treated Population

| End point values                                   | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|--|---|----------------------------------|--|--|
| Subject group type                                 | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed                        | 4 <sup>[27]</sup>                       | 14 <sup>[28]</sup>               |  |  |
| Units: Participants                                |   |                                  |  |  |
| D.Bil.; Decrease to Low; n=1,3,2,5,3,14            | 0                                       | 0                                |  |  |
| D.Bil.; increase to high; n=1,3,2,5,3,14           | 1                                       | 4                                |  |  |
| CA-125; Decrease to Low; n=1,3,0,5,4,0             | 0                                       | 99999                            |  |  |
| CA-125; increase to high; n=1,3,0,5,4,0            | 0                                       | 99999                            |  |  |
| CA 15.3; Decrease to Low; n=0, 0, 0, 0, 4, 0       | 0                                       | 99999                            |  |  |
| CA 15.3; increase to high; n=0, 0, 0, 0, 4, 0      | 0                                       | 99999                            |  |  |
| CA 19-9.; Decrease to Low;<br>n=1,0,0,0,2,0        | 0                                       | 99999                            |  |  |
| CA 19-9; increase to high;<br>n=1,0,0,0,2,0        | 0                                       | 99999                            |  |  |
| Chloride; Decrease to Low;<br>n=1,3,2,5,4,14       | 2                                       | 4                                |  |  |
| Chloride; increase to high;<br>n=1,3,2,5,4,14      | 0                                       | 1                                |  |  |
| CO2/HCO3.; Decrease to Low;<br>n=1,3,2,5,4,14      | 1                                       | 2                                |  |  |
| CO2/HCO3.; increase to high;<br>n=1,3,2,5,4,14     | 0                                       | 7                                |  |  |
| LH; Decrease to Low; n=1,0,2,3,2,7                 | 0                                       | 1                                |  |  |
| LH; increase to high; n=1,0,2,3,2,7                | 0                                       | 3                                |  |  |
| Total Protein; Decrease to Low;<br>n=1,3,2,5,4,14  | 0                                       | 1                                |  |  |
| Total Protein; increase to high;<br>n=1,3,2,5,4,14 | 0                                       | 0                                |  |  |
| Urea/BUN; Decrease to Low;<br>n=1,3,2,5,4,14       | 1                                       | 3                                |  |  |
| Urea/BUN; increase to high;<br>n=1,3,2,5,4,14      | 0                                       | 2                                |  |  |



Notes:

[27] - All Treated Population

[28] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with grade change from Baseline in hematology data-Parts 1 and 2

|                 |   |
|-----------------|---|
| End point title | Number of participants with grade change from Baseline in hematology data-Parts 1 and 2 <sup>[29]</sup> |
|-----------------|---|

End point description:

Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, total neutrophils, platelet count, and white blood cell (WBC). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. Number of participants with any grade increase, increase to Grade 3 and increase to Grade 4 in hematology data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

| End point values                       | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|--|-----------------------------------|--|------------------------------|---|
| Subject group type                     | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed            | 1 <sup>[30]</sup>                 | 3 <sup>[31]</sup>                      | 2 <sup>[32]</sup>            | 5 <sup>[33]</sup>                       |
| Units: Participants                    |                                   |  |                              |   |
| Hemoglobin; any Grade increase         | 0                                 | 1                                      | 0                            | 0                                       |
| Hemoglobin; increase to Grade 3        | 0                                 | 0                                      | 0                            | 0                                       |
| Hemoglobin; increase to Grade 4        | 0                                 | 0                                      | 0                            | 0                                       |
| Lymphocytes; any grade increase        | 0                                 | 0                                      | 1                            | 3                                       |
| Lymphocytes; increase to Grade 3       | 0                                 | 0                                      | 0                            | 0                                       |
| Lymphocytes; increase to Grade 4       | 0                                 | 0                                      | 0                            | 0                                       |
| Total neutrophils; any Grade increase  | 0                                 | 0                                      | 0                            | 1                                       |
| Total neutrophils; increase to Grade 3 | 0                                 | 0                                      | 0                            | 0                                       |
| Total neutrophils; increase to Grade 4 | 0                                 | 0                                      | 0                            | 0                                       |
| Platelet; any Grade increase           | 0                                 | 1                                      | 1                            | 0                                       |
| Platelet; increase to Grade 3          | 0                                 | 0                                      | 0                            | 0                                       |
| Platelet; increase to Grade 4          | 0                                 | 0                                      | 0                            | 0                                       |
| WBC; any Grade increase                | 0                                 | 1                                      | 0                            | 2                                       |
| WBC; increase to Grade 3               | 0                                 | 0                                      | 0                            | 0                                       |
| WBC; increase to Grade 4               | 0                                 | 0                                      | 0                            | 0                                       |

Notes:

[30] - All Treated Population

[31] - All Treated Population

[32] - All Treated Population

[33] - All Treated Population

| End point values                       | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|--|---|----------------------------------|--|--|
| Subject group type                     | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed            | 4 <sup>[34]</sup>                       | 14 <sup>[35]</sup>               |  |  |
| Units: Participants                    |   |                                  |  |  |
| Hemoglobin; any Grade increase         | 3                                       | 7                                |  |  |
| Hemoglobin; increase to Grade 3        | 0                                       | 2                                |  |  |
| Hemoglobin; increase to Grade 4        | 0                                       | 0                                |  |  |
| Lymphocytes; any grade increase        | 1                                       | 5                                |  |  |
| Lymphocytes; increase to Grade 3       | 0                                       | 2                                |  |  |
| Lymphocytes; increase to Grade 4       | 0                                       | 0                                |  |  |
| Total neutrophils; any Grade increase  | 0                                       | 1                                |  |  |
| Total neutrophils; increase to Grade 3 | 0                                       | 0                                |  |  |
| Total neutrophils; increase to Grade 4 | 0                                       | 0                                |  |  |
| Platelet; any Grade increase           | 0                                       | 0                                |  |  |
| Platelet; increase to Grade 3          | 0                                       | 0                                |  |  |
| Platelet; increase to Grade 4          | 0                                       | 0                                |  |  |
| WBC; any Grade increase                | 0                                       | 1                                |  |  |
| WBC; increase to Grade 3               | 0                                       | 0                                |  |  |
| WBC; increase to Grade 4               | 0                                       | 0                                |  |  |

Notes:

[34] - All Treated Population

[35] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of participants with change from Baseline in hematology data with respect to normal range-Parts 1 and 2

|                 |  |
|-----------------|--|
| End point title | Number of participants with change from Baseline in hematology data with respect to normal range-Parts 1 and 2 <sup>[36]</sup> |
|-----------------|--|

End point description:

Blood samples were collected for the analysis of following hematology parameters: basophils, eosinophils, hematocrit, mean corpuscle hemoglobin concentration (MCHC), mean corpuscle hemoglobin (MCH), mean corpuscle volume (MCV), monocytes, red blood cell count (RBC) and reticulocytes. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as value at visit minus Baseline value. Number of participants with change from Baseline in hematology data at worst-case post Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

| End point values                | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|---------------------------------|-----------------------------------|--|------------------------------|---|
| Subject group type              | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed     | 1 <sup>[37]</sup>                 | 3 <sup>[38]</sup>                      | 2 <sup>[39]</sup>            | 5 <sup>[40]</sup>                       |
| Units: Participants             |                                   |  |                              |   |
| Basophils: decrease to low      | 0                                 | 0                                      | 0                            | 0                                       |
| Basophils: increase to high     | 0                                 | 0                                      | 0                            | 0                                       |
| Eosinophils: decrease to low    | 0                                 | 0                                      | 1                            | 0                                       |
| Eosinophils: increase to high   | 0                                 | 0                                      | 0                            | 0                                       |
| Hematocrit: decrease to low     | 0                                 | 0                                      | 0                            | 1                                       |
| Hematocrit: increase to high    | 0                                 | 0                                      | 0                            | 0                                       |
| MCHC: decrease to low           | 1                                 | 0                                      | 0                            | 0                                       |
| MCHC: increase to high          | 0                                 | 0                                      | 0                            | 0                                       |
| MCH: decrease to low            | 1                                 | 1                                      | 0                            | 0                                       |
| MCH: increase to high           | 0                                 | 0                                      | 0                            | 0                                       |
| MCV: decrease to low            | 0                                 | 1                                      | 0                            | 0                                       |
| MCV: increase to high           | 0                                 | 0                                      | 0                            | 0                                       |
| Monocytes: decrease to low      | 0                                 | 0                                      | 0                            | 0                                       |
| Monocytes: increase to high     | 1                                 | 0                                      | 0                            | 0                                       |
| RBC: decrease to low            | 0                                 | 0                                      | 0                            | 3                                       |
| RBC: increase to high           | 0                                 | 0                                      | 0                            | 0                                       |
| Reticulocytes: decrease to low  | 0                                 | 0                                      | 0                            | 1                                       |
| Reticulocytes: increase to high | 0                                 | 0                                      | 0                            | 1                                       |

Notes:

[37] - All Treated Population

[38] - All Treated Population

[39] - All Treated Population

[40] - All Treated Population

| End point values              | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|-------------------------------|---|----------------------------------|--|--|
| Subject group type            | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed   | 4 <sup>[41]</sup>                       | 14 <sup>[42]</sup>               |  |  |
| Units: Participants           |   |                                  |  |  |
| Basophils: decrease to low    | 0                                       | 0                                |  |  |
| Basophils: increase to high   | 0                                       | 0                                |  |  |
| Eosinophils: decrease to low  | 0                                       | 0                                |  |  |
| Eosinophils: increase to high | 0                                       | 2                                |  |  |
| Hematocrit: decrease to low   | 1                                       | 4                                |  |  |
| Hematocrit: increase to high  | 0                                       | 0                                |  |  |
| MCHC: decrease to low         | 0                                       | 3                                |  |  |
| MCHC: increase to high        | 0                                       | 0                                |  |  |
| MCH: decrease to low          | 0                                       | 1                                |  |  |
| MCH: increase to high         | 1                                       | 0                                |  |  |
| MCV: decrease to low          | 0                                       | 1                                |  |  |
| MCV: increase to high         | 0                                       | 1                                |  |  |

|                                 |   |   |  |  |
|---------------------------------|---|---|--|--|
| Monocytes: decrease to low      | 0 | 0 |  |  |
| Monocytes: increase to high     | 0 | 2 |  |  |
| RBC: decrease to low            | 0 | 7 |  |  |
| RBC: increase to high           | 0 | 1 |  |  |
| Reticulocytes: decrease to low  | 0 | 2 |  |  |
| Reticulocytes: increase to high | 2 | 3 |  |  |

Notes:

[41] - All Treated Population

[42] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with change from Baseline in urinalysis data with respect to normal range-Parts 1 and 2

|                 |  |
|-----------------|--|
| End point title | Number of participants with change from Baseline in urinalysis data with respect to normal range-Parts 1 and 2 <sup>[43]</sup> |
|-----------------|--|

End point description:

Urine samples were collected for the analysis of urine potential of hydrogen (pH) and urine specific gravity. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as the most recent, non-missing value from a central laboratory prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. The data for worst-case post Baseline is presented. Only those participants with data available at specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

| End point values                                  | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|---|-----------------------------------|--|------------------------------|---|
| Subject group type                                | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed                       | 1 <sup>[44]</sup>                 | 3 <sup>[45]</sup>                      | 2 <sup>[46]</sup>            | 5 <sup>[47]</sup>                       |
| Units: Participants                               |                                   |  |                              |   |
| Urine pH; decrease to low; n=1, 3, 1, 5, 4, 7     | 0                                 | 0                                      | 0                            | 0                                       |
| Urine pH; increase to high; n=1, 3, 1, 5, 4, 7    | 0                                 | 0                                      | 0                            | 0                                       |
| Specific gravity; decrease to low; n=1,3,1,4,4,8  | 0                                 | 1                                      | 0                            | 0                                       |
| Specific gravity; increase to high; n=1,3,1,4,4,8 | 1                                 | 0                                      | 0                            | 0                                       |

Notes:

[44] - All Treated Population

[45] - All Treated Population

[46] - All Treated Population

[47] - All Treated Population

|                  |                        |                        |  |  |
|------------------|------------------------|------------------------|--|--|
| End point values | GSK2849330<br>30 mg/kg | GSK2849330<br>30 mg/kg |  |  |
|------------------|------------------------|------------------------|--|--|

|   | every 2 weeks     | weekly             |  |  |
|---|-------------------|--------------------|--|--|
| Subject group type                                | Reporting group   | Reporting group    |  |  |
| Number of subjects analysed                       | 4 <sup>[48]</sup> | 14 <sup>[49]</sup> |  |  |
| Units: Participants                               |                   |                    |  |  |
| Urine pH; decrease to low; n=1, 3, 1, 5, 4, 7     | 0                 | 0                  |  |  |
| Urine pH; increase to high; n=1, 3, 1, 5, 4, 7    | 0                 | 1                  |  |  |
| Specific gravity; decrease to low; n=1,3,1,4,4,8  | 0                 | 0                  |  |  |
| Specific gravity; increase to high; n=1,3,1,4,4,8 | 0                 | 0                  |  |  |

Notes:

[48] - All Treated Population

[49] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of participants with change from Baseline in vital signs-Parts 1 and 2

|                 |   |
|-----------------|---|
| End point title | Number of participants with change from Baseline in vital signs-Parts 1 and 2 <sup>[50]</sup> |
|-----------------|---|

End point description:

Vital sign measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). Vital signs were graded according to NCI-CTCAE version 4.0. The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in HR (decrease to <60 beats per minute and increase to >100 beats per minute); increase in SBP from Baseline (>=120 to <140 millimeters of mercury [mmHg] Grade 1; >=140 to <160 mmHg [Grade 2]; >=160 [Grade 3]); increase in DBP from Baseline (>=80 to <90 [Grade 1]; >=90 to <100 [Grade 2]; >=100 mmHg [Grade 3]) and change in temperature from Baseline (increase to >=38 or decrease to <=35 degree Centigrade). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as visit value minus Baseline value. The data for worst-case post Baseline is presented.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and median of 6.143 weeks of drug exposure

Notes:

[50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

| End point values                        | GSK2849330 1.4 mg/kg weekly | GSK2849330 3 mg/kg every 2 weeks | GSK2849330 3 mg/kg weekly | GSK2849330 10 mg/kg every 2 weeks |
|---|-----------------------------|----------------------------------|---------------------------|-----------------------------------|
| Subject group type                      | Reporting group             | Reporting group                  | Reporting group           | Reporting group                   |
| Number of subjects analysed             | 1 <sup>[51]</sup>           | 3 <sup>[52]</sup>                | 2 <sup>[53]</sup>         | 5 <sup>[54]</sup>                 |
| Units: Participants                     |                             |                                  |                           |                                   |
| HR; decrease to <60 beats per minute    | 1                           | 1                                | 0                         | 2                                 |
| HR; increase to >100 beats per minute   | 0                           | 0                                | 1                         | 1                                 |
| Temp; decrease to <=35 degree Celsius   | 0                           | 0                                | 0                         | 1                                 |
| Temp; increase to >=38 degree Celsius   | 0                           | 0                                | 0                         | 0                                 |
| SBP; increase to Grade 1 (120-139 mmHg) | 0                           | 0                                | 2                         | 1                                 |
| SBP; increase to Grade 2 (140-159 mmHg) | 0                           | 0                                | 0                         | 1                                 |

|   |   |   |   |   |
|---|---|---|---|---|
| SBP; increase to Grade 3 ( $\geq 160$ mmHg) | 0 | 1 | 0 | 1 |
| DBP; increase to Grade 1 (80-89 mmHg)       | 0 | 1 | 2 | 3 |
| DBP; increase to Grade 2 (90-99 mmHg)       | 0 | 1 | 0 | 0 |
| DBP; increase to Grade 3 ( $\geq 100$ mmHg) | 0 | 0 | 0 | 1 |

Notes:

[51] - All Treated Population

[52] - All Treated Population

[53] - All Treated Population

[54] - All Treated Population

| End point values                            | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|---|---|----------------------------------|--|--|
| Subject group type                          | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed                 | 4 <sup>[55]</sup>                       | 14 <sup>[56]</sup>               |  |  |
| Units: Participants                         |   |                                  |  |  |
| HR; decrease to $<60$ beats per minute      | 0                                       | 4                                |  |  |
| HR; increase to $>100$ beats per minute     | 0                                       | 5                                |  |  |
| Temp; decrease to $\leq 35$ degree Celsius  | 0                                       | 0                                |  |  |
| Temp; increase to $\geq 38$ degree Celsius  | 0                                       | 4                                |  |  |
| SBP; increase to Grade 1 (120-139 mmHg)     | 2                                       | 3                                |  |  |
| SBP; increase to Grade 2 (140-159 mmHg)     | 0                                       | 4                                |  |  |
| SBP; increase to Grade 3 ( $\geq 160$ mmHg) | 2                                       | 0                                |  |  |
| DBP; increase to Grade 1 (80-89 mmHg)       | 1                                       | 7                                |  |  |
| DBP; increase to Grade 2 (90-99 mmHg)       | 0                                       | 1                                |  |  |
| DBP; increase to Grade 3 ( $\geq 100$ mmHg) | 0                                       | 1                                |  |  |

Notes:

[55] - All Treated Population

[56] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of participants with abnormal electrocardiogram (ECG) findings-Parts 1 and 2

|                 |   |
|-----------------|---|
| End point title | Number of participants with abnormal electrocardiogram (ECG) findings-Parts 1 and 2 <sup>[57]</sup> |
|-----------------|---|

End point description:

A 12-lead ECG was measured using an automated ECG machine after at least 5 minutes of rest for the participant in a semi-recumbent or supine position. Number of participants with abnormal ECG findings at any time post-Baseline is presented. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Median of 6.143 weeks of drug exposure

Notes:

[57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis were performed.

| End point values                    | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|-------------------------------------|-----------------------------------|--|------------------------------|---|
| Subject group type                  | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed         | 1 <sup>[58]</sup>                 | 3 <sup>[59]</sup>                      | 2 <sup>[60]</sup>            | 5 <sup>[61]</sup>                       |
| Units: Participants                 |                                   |  |                              |   |
| Abnormal-not clinically significant | 1                                 | 3                                      | 1                            | 4                                       |
| Abnormal-clinically significant     | 0                                 | 0                                      | 0                            | 0                                       |

Notes:

[58] - All Treated Population

[59] - All Treated Population

[60] - All Treated Population

[61] - All Treated Population

| End point values                    | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|-------------------------------------|---|----------------------------------|--|--|
| Subject group type                  | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed         | 4 <sup>[62]</sup>                       | 14 <sup>[63]</sup>               |  |  |
| Units: Participants                 |   |                                  |  |  |
| Abnormal-not clinically significant | 3                                       | 4                                |  |  |
| Abnormal-clinically significant     | 0                                       | 1                                |  |  |

Notes:

[62] - All Treated Population

[63] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum observed plasma concentration (Cmax) of GSK2849330-Part 1

|                 |  |
|-----------------|--|
| End point title | Maximum observed plasma concentration (Cmax) of<br>GSK2849330-Part 1 |
|-----------------|--|

End point description:

The first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data is defined as Cmax. Blood samples were collected at indicated time points. The analysis was performed on pharmacokinetic (PK) parameter population which comprised of all participants from the PK concentration population (participants who received at least one dose of GSK2849330 and for whom at least one post-dose PK sample was obtained and analyzed) for whom valid and valuable PK parameters were derived. 99999 indicates data was not available. The geometric coefficient of variation could not be calculated as a single participant was analyzed at the specified time point.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

|   |                                   |  |                              |   |
|---|-----------------------------------|--|------------------------------|---|
| <b>End point values</b>                             | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
| Subject group type                                  | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed                         | 1 <sup>[64]</sup>                 | 3 <sup>[65]</sup>                      | 2 <sup>[66]</sup>            | 3 <sup>[67]</sup>                       |
| Units: Nanograms per milliliter                     |                                   |  |                              |   |
| geometric mean (geometric coefficient of variation) |                                   |  |                              |   |
| Nanograms per milliliter                            | 29790.0 (±<br>99999)              | 62495.2 (±<br>34.8)                    | 83845.0 (±<br>24.1)          | 233997.8 (±<br>2.7)                     |

Notes:

[64] - PK Parameter Population

[65] - PK Parameter Population

[66] - PK Parameter Population

[67] - PK Parameter Population

|   |   |                                  |  |  |
|---|---|----------------------------------|--|--|
| <b>End point values</b>                             | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
| Subject group type                                  | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed                         | 3 <sup>[68]</sup>                       | 5 <sup>[69]</sup>                |  |  |
| Units: Nanograms per milliliter                     |   |                                  |  |  |
| geometric mean (geometric coefficient of variation) |   |                                  |  |  |
| Nanograms per milliliter                            | 639127.3 (±<br>45.4)                    | 778470.6 (±<br>14.5)             |  |  |

Notes:

[68] - PK Parameter Population

[69] - PK Parameter Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Cmax of GSK2849330-Part 2

|                 |   |
|-----------------|---|
| End point title | Cmax of GSK2849330-Part 2 <sup>[70]</sup> |
|-----------------|---|

End point description:

PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

Notes:

[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.

|   |                                  |  |  |  |
|---|----------------------------------|--|--|--|
| <b>End point values</b>                             | GSK2849330<br>30 mg/kg<br>weekly |  |  |  |
| Subject group type                                  | Reporting group                  |  |  |  |
| Number of subjects analysed                         | 0 <sup>[71]</sup>                |  |  |  |
| Units: Nanograms per milliliter                     |                                  |  |  |  |
| geometric mean (geometric coefficient of variation) |                                  |  |  |  |



|                          |    |  |  |  |
|--------------------------|----|--|--|--|
| Nanograms per milliliter | () |  |  |  |
|--------------------------|----|--|--|--|

Notes:

[71] - PK Parameter Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Time of occurrence of Cmax (Tmax) for GSK2849330-Part 1

|                 |   |
|-----------------|---|
| End point title | Time of occurrence of Cmax (Tmax) for GSK2849330-Part 1 |
|-----------------|---|

End point description:

The time at which Cmax is observed was determined directly from the raw concentration-time data is defined as Tmax. Blood samples were collected at indicated time points for evaluation of pharmacokinetic parameters.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

| End point values              | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|-------------------------------|-----------------------------------|--|------------------------------|---|
| Subject group type            | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed   | 1 <sup>[72]</sup>                 | 3 <sup>[73]</sup>                      | 2 <sup>[74]</sup>            | 3 <sup>[75]</sup>                       |
| Units: Hours                  |                                   |  |                              |   |
| median (full range (min-max)) |                                   |  |                              |   |
| Hours                         | 2.070 (2.070<br>to 2.070)         | 2.130 (2.000<br>to 6.170)              | 88.035 (6.370<br>to 169.700) | 2.280 (2.130<br>to 6.000)               |

Notes:

[72] - PK Parameter Population

[73] - PK Parameter Population

[74] - PK Parameter Population

[75] - PK Parameter Population

| End point values              | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|-------------------------------|---|----------------------------------|--|--|
| Subject group type            | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed   | 3 <sup>[76]</sup>                       | 5 <sup>[77]</sup>                |  |  |
| Units: Hours                  |   |                                  |  |  |
| median (full range (min-max)) |   |                                  |  |  |
| Hours                         | 3.280 (2.300<br>to 6.230)               | 2.100 (1.830<br>to 2.330)        |  |  |

Notes:

[76] - PK Parameter Population

[77] - PK Parameter Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Tmax for GSK2849330-Part 2

|                 |  |
|-----------------|--|
| End point title | Tmax for GSK2849330-Part 2 <sup>[78]</sup> |
|-----------------|--|

End point description:

PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

Notes:

[78] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.

|                               |                                  |  |  |  |
|-------------------------------|----------------------------------|--|--|--|
| End point values              | GSK2849330<br>30 mg/kg<br>weekly |  |  |  |
| Subject group type            | Reporting group                  |  |  |  |
| Number of subjects analysed   | 0 <sup>[79]</sup>                |  |  |  |
| Units: Hours                  |                                  |  |  |  |
| median (full range (min-max)) |                                  |  |  |  |
| Hours                         | ( to )                           |  |  |  |

Notes:

[79] - PK Parameter Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Area under the concentration time curve (AUC) to a fixed nominal time (AUC[0 to 168]) and AUC(0 to 336) for GSK2849330-Part 1

|                 |   |
|-----------------|---|
| End point title | Area under the concentration time curve (AUC) to a fixed nominal time (AUC[0 to 168]) and AUC(0 to 336) for GSK2849330-Part 1 |
|-----------------|---|

End point description:

The AUC to a fixed nominal time AUC(0-168) and AUC(0-336) were calculated using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Blood samples were collected at indicated time points for determination of PK parameters. 99999 indicates data is not available due to insufficient number of participants. Geometric coefficient of variation could not be calculated as a single participant was analyzed at the specified time point. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles).

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose

| End point values                                    | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|---|-----------------------------------|--|------------------------------|---|
| Subject group type                                  | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed                         | 1 <sup>[80]</sup>                 | 3 <sup>[81]</sup>                      | 2 <sup>[82]</sup>            | 3 <sup>[83]</sup>                       |
| Units: Hours*nanogram per milliliter                |                                   |  |                              |   |
| geometric mean (geometric coefficient of variation) |                                   |  |                              |   |
| AUC(0 to 168); n=1, 3, 2, 3, 3, 5                   | 1962762.0 (± 99999)               | 5787797.8 (± 27.2)                     | 618552.6 (± 20559.2)         | 18185733.6 (± 28.8)                     |
| AUC(0 to 336); 0, 3, 0, 3, 3, 0                     | 99999 (± 99999)                   | 7855808.8 (± 28.7)                     | 99999 (± 99999)              | 23409694.6 (± 39.4)                     |

Notes:

[80] - PK Parameter Population

[81] - PK Parameter Population

[82] - PK Parameter Population

[83] - PK Parameter Population

| End point values                                    | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|---|---|----------------------------------|--|--|
| Subject group type                                  | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed                         | 3 <sup>[84]</sup>                       | 5 <sup>[85]</sup>                |  |  |
| Units: Hours*nanogram per milliliter                |   |                                  |  |  |
| geometric mean (geometric coefficient of variation) |   |                                  |  |  |
| AUC(0 to 168); n=1, 3, 2, 3, 3, 5                   | 54346531.5 (± 30.2)                     | 54388333.7 (± 22.6)              |  |  |
| AUC(0 to 336); 0, 3, 0, 3, 3, 0                     | 72404738.6 (± 34.2)                     | 99999 (± 99999)                  |  |  |

Notes:

[84] - PK Parameter Population

[85] - PK Parameter Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: AUC(0 to 168) and AUC(0 to 336) for GSK2849330-Part 2

|   |   |
|---|---|
| End point title   | AUC(0 to 168) and AUC(0 to 336) for GSK2849330-Part 2 <sup>[86]</sup> |
| End point description:  |   |
| PK parameters for Part 2 were not analyzed due to sparse sampling. The protocol was written in a flexible way to either pursue or not pursue additional analyses in Part 2. |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| Day 1 (pre-dose, 1 and 6 hours post-dose), Day 8, Day 15, Day 29, and every 12 weeks from first dose  |   |

Notes:

[86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Only GSK2849330 30 mg/kg weekly was analyzed in Part 2.

|   |                                  |  |  |  |
|---|----------------------------------|--|--|--|
| <b>End point values</b>                             | GSK2849330<br>30 mg/kg<br>weekly |  |  |  |
| Subject group type                                  | Reporting group                  |  |  |  |
| Number of subjects analysed                         | 0 <sup>[87]</sup>                |  |  |  |
| Units: Hours*nanogram per milliliter                |                                  |  |  |  |
| geometric mean (geometric coefficient of variation) |                                  |  |  |  |
| Hours*nanogram per milliliter                       | ( )                              |  |  |  |

Notes:

[87] - PK Parameter Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Serum HER3 from tumor tissue-Parts 1 and 2

|                 |  |
|-----------------|--|
| End point title | Serum HER3 from tumor tissue-Parts 1 and 2 |
|-----------------|--|

End point description:

Pre-treatment and on-treatment biopsy tissues (tumor and normal skin) were analyzed for markers of HER3 pathway such as HER3 that may indicate a pharmacodynamic (PD) response to GSK2849330. Serum HER3 (soluble HER3) analyses was performed. The analysis was performed on PD population which comprised of all participants who received at least one dose of GSK2849330 and for whom at least one evaluable paired pre-treatment PD sample and on-treatment PD sample were obtained and analyzed. Mean and standard deviation for serum HER3 is presented. 99999 indicates data was not available due to insufficient number of participants. Standard deviation could not be calculated as a single participant was analyzed at the specified time points. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Median of 6.143 weeks of drug exposure

| <b>End point values</b>              | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330<br>3 mg/kg every 2<br>weeks | GSK2849330<br>3 mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|--------------------------------------|-----------------------------------|--|------------------------------|---|
| Subject group type                   | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed          | 1 <sup>[88]</sup>                 | 3 <sup>[89]</sup>                      | 1 <sup>[90]</sup>            | 5 <sup>[91]</sup>                       |
| Units: Nanomoles                     |                                   |  |                              |   |
| arithmetic mean (standard deviation) |                                   |  |                              |   |
| Day 1; pre-dose; n=1, 3, 1, 5, 4, 12 | 13.65 (± 99999)                   | 17.11 (± 2.603)                        | 16.66 (± 99999)              | 14.42 (± 4.004)                         |
| Day 1; 1 hour; n=1, 3, 1, 5, 4, 11   | 11.12 (± 99999)                   | 13.14 (± 2.966)                        | 7.53 (± 99999)               | 10.76 (± 2.228)                         |
| Day 1; 6 hours; n=1, 3, 1, 5, 4, 10  | 9.88 (± 99999)                    | 13.71 (± 2.679)                        | 12.99 (± 99999)              | 11.69 (± 4.058)                         |
| Day 2; n=0, 0, 1, 1, 1, 2            | 99999 (± 99999)                   | 99999 (± 99999)                        | 8.12 (± 99999)               | 13.15 (± 99999)                         |
| Day 8; n=1, 3, 1, 5, 4, 11           | 10.14 (± 99999)                   | 11.59 (± 4.353)                        | 10.87 (± 99999)              | 10.85 (± 3.771)                         |
| Day 15; n=0, 2, 1, 3, 4, 10          | 99999 (± 99999)                   | 10.62 (± 1.110)                        | 7.37 (± 99999)               | 11.38 (± 3.535)                         |
| Day 29; n=1, 3, 1, 4, 4, 8           | 10.99 (± 99999)                   | 12.18 (± 3.695)                        | 7.69 (± 99999)               | 6.60 (± 3.220)                          |
| Follow-up; n=1, 2, 1, 3, 2, 5        | 6.19 (± 99999)                    | 9.22 (± 3.090)                         | 14.86 (± 99999)              | 5.41 (± 1.406)                          |

Notes:

[88] - PD Population

[89] - PD Population

[90] - PD Population

[91] - PD Population

| End point values                     | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|--------------------------------------|---|----------------------------------|--|--|
| Subject group type                   | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed          | 4 <sup>[92]</sup>                       | 12 <sup>[93]</sup>               |  |  |
| Units: Nanomoles                     |   |                                  |  |  |
| arithmetic mean (standard deviation) |   |                                  |  |  |
| Day 1; pre-dose; n=1, 3, 1, 5, 4, 12 | 13.67 (± 4.681)                         | 11.08 (± 5.322)                  |  |  |
| Day 1; 1 hour; n=1, 3, 1, 5, 4, 11   | 9.55 (± 4.437)                          | 5.59 (± 2.709)                   |  |  |
| Day 1; 6 hours; n=1, 3, 1, 5, 4, 10  | 9.39 (± 4.586)                          | 5.35 (± 2.031)                   |  |  |
| Day 2; n=0, 0, 1, 1, 1, 2            | 4.59 (± 99999)                          | 3.50 (± 2.001)                   |  |  |
| Day 8; n=1, 3, 1, 5, 4, 11           | 6.32 (± 2.702)                          | 6.05 (± 2.382)                   |  |  |
| Day 15; n=0, 2, 1, 3, 4, 10          | 9.84 (± 3.127)                          | 4.66 (± 1.402)                   |  |  |
| Day 29; n=1, 3, 1, 4, 4, 8           | 6.91 (± 4.621)                          | 4.13 (± 1.815)                   |  |  |
| Follow-up; n=1, 2, 1, 3, 2, 5        | 3.73 (± 0.424)                          | 4.39 (± 2.975)                   |  |  |

Notes:

[92] - PD Population

[93] - PD Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall response rate (ORR)-Parts 1 and 2

|   |   |
|---|---|
| End point title   | Overall response rate (ORR)-Parts 1 and 2 |
| End point description:  |   |
| <p>ORR was determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). ORR was calculated as the number of participants with best overall response of complete response (CR) and partial response (PR). CR=Disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeter (mm) in the short axis and PR=At least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters (e.g., percent change from Baseline). An estimate to the true response rate for the number of participants analyzed is given. The 95% confidence interval was the exact confidence interval based on binomial proportion for ORR. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.</p> |   |
| End point type  | Secondary                                 |
| End point timeframe:  |   |
| Median of 6.143 weeks of drug exposure  |   |

| End point values                 | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330<br>3 mg/kg every 2<br>weeks | GSK2849330<br>3 mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|----------------------------------|-----------------------------------|--|------------------------------|---|
| Subject group type               | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed      | 1 <sup>[94]</sup>                 | 3 <sup>[95]</sup>                      | 2 <sup>[96]</sup>            | 5 <sup>[97]</sup>                       |
| Units: Participants              |                                   |  |                              |   |
| number (confidence interval 95%) |                                   |  |                              |   |

|              |                 |                 |                 |                 |
|--------------|-----------------|-----------------|-----------------|-----------------|
| Participants | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) | 0 (0.0 to 84.2) | 0 (0.0 to 52.2) |
|--------------|-----------------|-----------------|-----------------|-----------------|

Notes:

[94] - All Treated Population

[95] - All Treated Population

[96] - All Treated Population

[97] - All Treated Population

|                                  |   |                                  |  |  |
|----------------------------------|---|----------------------------------|--|--|
| <b>End point values</b>          | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
| Subject group type               | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed      | 4 <sup>[98]</sup>                       | 14 <sup>[99]</sup>               |  |  |
| Units: Participants              |   |                                  |  |  |
| number (confidence interval 95%) |   |                                  |  |  |
| Participants                     | 0 (0.0 to 60.2)                         | 1 (0.2 to 33.9)                  |  |  |

Notes:

[98] - All Treated Population

[99] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with antibodies to GSK2849330 in serum

|                 |   |
|-----------------|---|
| End point title | Number of participants with antibodies to GSK2849330 in serum |
|-----------------|---|

End point description:

Serum samples were collected for the determination of anti-GSK2849330 antibodies using a validated immunoelectrochemiluminescent (ECL) assay. The assay involved screening, confirmation and titration steps (tiered-testing approach). If serum samples contained anti-GSK2849330 antibodies, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants who tested positive for anti-GSK2849330 antibody in confirmatory testing on Day 1 and at any time post-Baseline is presented. Only those participants with data available at specified time points were analyzed (indicated by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Median of 6.143 weeks of drug exposure

|  |                                   |  |                              |   |
|--|-----------------------------------|--|------------------------------|---|
| <b>End point values</b>                    | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330<br>3 mg/kg every 2<br>weeks | GSK2849330<br>3 mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
| Subject group type                         | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed                | 1 <sup>[100]</sup>                | 3 <sup>[101]</sup>                     | 2 <sup>[102]</sup>           | 5 <sup>[103]</sup>                      |
| Units: Participants                        |                                   |  |                              |   |
| Day1; n=1, 3, 2, 5, 4, 13                  | 0                                 | 0                                      | 0                            | 0                                       |
| Any time post-Baseline; n=1, 3, 1, 5, 4, 7 | 0                                 | 0                                      | 0                            | 0                                       |

Notes:

[100] - All Treated Population

[101] - All Treated Population

[102] - All Treated Population

[103] - All Treated Population

| End point values                           | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|--|---|----------------------------------|--|--|
| Subject group type                         | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed                | 4 <sup>[104]</sup>                      | 14 <sup>[105]</sup>              |  |  |
| Units: Participants                        |   |                                  |  |  |
| Day1; n=1, 3, 2, 5, 4, 13                  | 0                                       | 1                                |  |  |
| Any time post-Baseline; n=1, 3, 1, 5, 4, 7 | 0                                       | 0                                |  |  |

Notes:

[104] - All Treated Population

[105] - All Treated Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of cluster of differentiation (CD) marker

| End point title  | Percentage of cluster of differentiation (CD) marker |
|--|--|
| End point description:   |  |
| Blood samples were collected on Day (D) 1 at pre-dose (pre) and at 1 hour (h) and 6 h post infusion for the analysis of markers to evaluate biological activity of GSK2849330. A pre-dose blood sample was collected on D8, D15 and D29 with additional blood sample collected at progression of disease. CDX241 represent CD45+CD3-CD56+CD16+CD69+CD107+, CDX243=CD45+CD3-CD56+CD16+CD69+CD107-; CDX244=CD45+CD3-CD56+CD16+CD69-CD107+ and CDX245=CD45+CD3-CD56+CD16+CD69-CD107-. For participants in GSK2849330 3 mg/kg weekly arm, two samples (S1 and S2) were collected for D15 analysis. 99999 indicates data was not available due to insufficient participants. Standard deviation could not be calculated as a single participant was analyzed at the specified time point. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles). Treatment groups with same dose and administration frequency were combined as pre-specified in RAP. |  |
| End point type   | Secondary  |
| End point timeframe:   |  |
| Median of 6.143 weeks of drug exposure   |  |

| End point values                     | GSK2849330<br>1.4 mg/kg<br>weekly | GSK2849330 3<br>mg/kg every 2<br>weeks | GSK2849330 3<br>mg/kg weekly | GSK2849330<br>10 mg/kg<br>every 2 weeks |
|--------------------------------------|-----------------------------------|--|------------------------------|---|
| Subject group type                   | Reporting group                   | Reporting group                        | Reporting group              | Reporting group                         |
| Number of subjects analysed          | 1 <sup>[106]</sup>                | 3 <sup>[107]</sup>                     | 1 <sup>[108]</sup>           | 5 <sup>[109]</sup>                      |
| Units: Percentage of CD marker cells |                                   |  |                              |   |
| arithmetic mean (standard deviation) |                                   |  |                              |   |
| CD45+; D1; pre; n=1, 3, 1, 5, 4, 9   | 99.80 (±<br>99999)                | 99.83 (±<br>0.058)                     | 99.90 (±<br>99999)           | 99.76 (±<br>0.434)                      |
| CD45+; D1; 1 h; n=1, 3, 1, 5, 4, 9   | 99.60 (±<br>99999)                | 99.87 (±<br>0.058)                     | 99.80 (±<br>99999)           | 99.76 (±<br>0.434)                      |
| CD45+; D1; 6 h; n=1, 3, 1, 5, 4, 11  | 99.80 (±<br>99999)                | 99.83 (±<br>0.058)                     | 99.90 (±<br>99999)           | 99.8 (± 0.255)                          |
| CD45+; D2; n=0, 0, 1, 2, 0, 1        | 99999 (±<br>99999)                | 99999 (±<br>99999)                     | 99.10 (±<br>99999)           | 99.7 (± 0.424)                          |

|  |                  |                  |                  |                  |
|--|------------------|------------------|------------------|------------------|
| CD45+; D8; n=1, 3, 0, 5, 4, 8                | 100.00 (± 99999) | 99.87 (± 0.058)  | 99999 (± 99999)  | 99.4 (± 1.231)   |
| CD45+; D15; S1; n=1, 3, 1, 5, 4, 9           | 99.80 (± 99999)  | 99.90 (± 0.000)  | 99.9 (± 99999)   | 99.78 (± 0.327)  |
| CD45+; D15; S2; n=0,0,1,0,0,0                | 99999 (± 99999)  | 99999 (± 99999)  | 99.8 (± 99999)   | 99999 (± 99999)  |
| CD45+; D29; n=1, 3, 1, 4, 4, 8               | 99.90 (± 99999)  | 99.93 (± 0.058)  | 100.00 (± 99999) | 99.78 (± 0.222)  |
| CD45+; follow-up (FU); n=1, 2, 0, 3, 1, 4    | 100.00 (± 99999) | 99.85 (± 0.071)  | 99999 (± 99999)  | 99.63 (± 0.551)  |
| CD45+; unscheduled (USC); n=0, 0, 1, 0, 0, 0 | 99999 (± 99999)  | 99999 (± 99999)  | 100.00 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+; D1; pre;n=1, 3, 1, 5, 4, 9        | 62.70 (± 99999)  | 69.00 (± 13.313) | 58.80 (± 99999)  | 86.88 (± 2.580)  |
| CD45+CD3+; D1; 1 h; n=1, 3, 1, 5, 4, 9       | 76.20 (± 99999)  | 73.83 (± 9.646)  | 57.30 (± 99999)  | 87.08 (± 2.153)  |
| CD45+CD3+; D1; 6 h; n=1, 3, 1, 5, 4, 11      | 81.20 (± 99999)  | 72.43 (± 12.784) | 62.70 (± 99999)  | 86.88 (± 2.580)  |
| CD45+CD3+; D2; n=0, 0, 1, 2, 0, 1            | 99999 (± 99999)  | 99999 (± 99999)  | 48.40 (± 99999)  | 86.60 (± 0.566)  |
| CD45+CD3+; D8; n=1, 3, 0, 5, 4, 8            | 72.30 (± 99999)  | 69.67 (± 17.310) | 99999 (± 99999)  | 86.30 (± 1.505)  |
| CD45+CD3+; D15; S1; n=1, 3, 1, 5, 4, 9       | 73.60 (± 99999)  | 68.97 (± 19.410) | 36.8 (± 99999)   | 87.52 (± 1.359)  |
| CD45+CD3+; D15; S2; n=0,0,1,0,0,0            | 99999 (± 99999)  | 99999 (± 99999)  | 48.9 (± 99999)   | 99999 (± 99999)  |
| CD45+CD3+; D29; n=1, 3, 1, 4, 4, 8           | 76.70 (± 99999)  | 69.97 (± 17.609) | 36.20 (± 99999)  | 87.30 (± 1.753)  |
| CD45+CD3+; FU; n=1, 2, 0, 3, 1, 4            | 64.50 (± 99999)  | 77.15 (± 7.425)  | 99999 (± 99999)  | 83.53 (± 7.966)  |
| CD45+CD3+; USC; n=0, 0, 1, 0, 0, 0           | 99999 (± 99999)  | 99999 (± 99999)  | 58.70 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3+CD8+; D1; pre;n=1, 3, 1, 5, 4, 9    | 9.60 (± 99999)   | 21.67 (± 6.929)  | 21.60 (± 99999)  | 35.14 (± 22.721) |
| CD45+CD3+CD8+; D1; 1 h; n=1, 3, 1, 5, 4, 9   | 8.00 (± 99999)   | 20.20 (± 3.538)  | 20.50 (± 99999)  | 31.24 (± 21.617) |
| CD45+CD3+CD8+; D1; 6 h; n=1, 3, 1, 5, 4, 11  | 8.20 (± 99999)   | 17.47 (± 2.548)  | 23.20 (± 99999)  | 30.82 (± 22.379) |
| CD45+CD3+CD8+; D2; n=0, 0, 1, 2, 0, 1        | 99999 (± 99999)  | 99999 (± 99999)  | 21.20 (± 99999)  | 19.70 (± 7.071)  |
| CD45+CD3+CD8+; D8; n=1, 3, 0, 5, 4, 8        | 10.50 (± 99999)  | 22.70 (± 4.987)  | 99999 (± 99999)  | 35.24 (± 22.320) |
| CD45+CD3+CD8+; D15; S1; n=1, 3, 1, 5, 4, 9   | 9.70 (± 99999)   | 20.90 (± 6.843)  | 13 (± 99999)     | 36.46 (± 22.405) |
| CD45+CD3+CD8+; D15; S2; n=0,0,1,0,0,0        | 99999 (± 99999)  | 99999 (± 99999)  | 15.7 (± 99999)   | 99999 (± 99999)  |
| CD45+CD3+CD8+; D29; n=1, 3, 1, 4, 4, 8       | 11.10 (± 99999)  | 20.93 (± 6.110)  | 17.10 (± 99999)  | 40.85 (± 23.034) |
| CD45+CD3+CD8+; FU; n=1, 2, 0, 3, 1, 4        | 7.90 (± 99999)   | 24.55 (± 4.455)  | 99999 (± 99999)  | 45.10 (± 29.487) |
| CD45+CD3+CD8+; USC; n=0, 0, 1, 0, 0, 0       | 99999 (± 99999)  | 99999 (± 99999)  | 21.00 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3+CD8-; D1; pre n=1, 3, 1, 5, 4, 9    | 50.90 (± 99999)  | 45.90 (± 9.124)  | 36.20 (± 99999)  | 50.76 (± 20.204) |
| CD45+CD3+CD8-; D1; 1 h; n=1, 3, 1, 5, 4, 9   | 66.60 (± 99999)  | 52.77 (± 8.732)  | 36.50 (± 99999)  | 54.92 (± 19.213) |
| CD45+CD3+CD8-; D1; 6 h; n=1, 3, 1, 5, 4, 11  | 72.00 (± 99999)  | 54.10 (± 13.421) | 36.40 (± 99999)  | 55.26 (± 19.752) |
| CD45+CD3+CD8-; D2; n=0, 0, 1, 2, 0, 1        | 99999 (± 99999)  | 99999 (± 99999)  | 26.90 (± 99999)  | 66.35 (± 7.425)  |
| CD45+CD3+CD8-; D8; n=1, 3, 0, 5, 4, 8        | 63.00 (± 99999)  | 46.80 (± 12.759) | 99999 (± 99999)  | 50.48 (± 21.133) |



|  |                 |                  |                 |                  |
|--|-----------------|------------------|-----------------|------------------|
| CD45+CD3+CD8-; D15; S1; n=1, 3, 1, 5, 4, 9   | 63.20 (± 99999) | 48.37 (± 12.659) | 24.3 (± 99999)  | 50.56 (± 21.357) |
| CD45+CD3+CD8-; D15; S2; n=0,0,1,0,0,0        | 99999 (± 99999) | 99999 (± 99999)  | 36.1 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3+CD8-; D29; n=1, 3, 1, 4, 4, 8       | 65.40 (± 99999) | 49.10 (± 12.137) | 19.90 (± 99999) | 45.55 (± 21.821) |
| CD45+CD3+CD8-; FU; n=1, 2, 0, 3, 1, 4        | 56.40 (± 99999) | 52.50 (± 3.394)  | 99999 (± 99999) | 38.20 (± 21.565) |
| CD45+CD3+CD8-; USC; n=0, 0, 1, 0, 0, 0       | 99999 (± 99999) | 99999 (± 99999)  | 38.30 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD16+; D1; pre n=1, 3, 1, 5, 4, 9   | 24.3 (± 99999)  | 14.50 (± 7.375)  | 25.20 (± 99999) | 4.96 (± 1.757)   |
| CD45+CD3-CD16+; D1; 1 h; n=1, 3, 1, 5, 4, 9  | 9.40 (± 99999)  | 9.03 (± 5.972)   | 32.50 (± 99999) | 4.44 (± 2.411)   |
| CD45+CD3-CD16+; D1; 6 h; n=1, 3, 1, 5, 4, 11 | 3.10 (± 99999)  | 5.80 (± 6.538)   | 23.80 (± 99999) | 3.30 (± 2.314)   |
| CD45+CD3-CD16+; D2; n=0, 0, 1, 2, 0, 1       | 99999 (± 99999) | 99999 (± 99999)  | 35.30 (± 99999) | 2.50 (± 0.566)   |
| CD45+CD3-CD16+; D8; n=1, 3, 0, 5, 4, 8       | 11.30 (± 99999) | 14.71 (± 12.293) | 99999 (± 99999) | 5.62 (± 3.128)   |
| CD45+CD3-CD16+; D15; S1; n=1, 3, 1, 5, 4, 9  | 11.40 (± 99999) | 13.73 (± 11.816) | 47.7 (± 99999)  | 4.54 (± 3.138)   |
| CD45+CD3-CD16+; D15; S2; n=0,0,1,0,0,0       | 99999 (± 99999) | 99999 (± 99999)  | 7.6 (± 99999)   | 99999 (± 99999)  |
| CD45+CD3-CD16+; D29; n=1, 3, 1, 4, 4, 8      | 11.30 (± 99999) | 11.83 (± 9.530)  | 37.10 (± 99999) | 5.75 (± 2.654)   |
| CD45+CD3-CD16+; FU; n=1, 2, 0, 3, 1, 4       | 20.80 (± 99999) | 6.65 (± 4.031)   | 99999 (± 99999) | 6.67 (± 2.237)   |
| CD45+CD3-CD16+; USC; n=0, 0, 1, 0, 0, 0      | 99999 (± 99999) | 99999 (± 99999)  | 19.50 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD56+; D1; pre; n=1, 3, 1, 5, 4, 9  | 25.70 (± 99999) | 14.03 (± 5.636)  | 25.80 (± 99999) | 5.88 (± 1.221)   |
| CD45+CD3-CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9  | 10.80 (± 99999) | 10.13 (± 4.562)  | 32.80 (± 99999) | 5.30 (± 1.581)   |
| CD45+CD3-CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11 | 4.20 (± 99999)  | 7.47 (± 5.934)   | 26.60 (± 99999) | 4.70 (± 1.913)   |
| CD45+CD3-CD56+; D2; n=0, 0, 1, 2, 0, 1       | 99999 (± 99999) | 99999 (± 99999)  | 42.40 (± 99999) | 4.10 (± 0.141)   |
| CD45+CD3-CD56+; D8; n=1, 3, 0, 5, 4, 8       | 13.70 (± 99999) | 14.43 (± 10.625) | 99999 (± 99999) | 6.16 (± 2.574)   |
| CD45+CD3-CD56+; D15; S1; n=1, 3, 1, 5, 4, 9  | 13.50 (± 99999) | 13.53 (± 11.288) | 50.2 (± 99999)  | 5.96 (± 2.266)   |
| CD45+CD3-CD56+; D15; S2; n=0,0,1,0,0,0       | 99999 (± 99999) | 99999 (± 99999)  | 8.7 (± 99999)   | 99999 (± 99999)  |
| CD45+CD3-CD56+; D29; n=1, 3, 1, 4, 4, 8      | 13.10 (± 99999) | 11.90 (± 8.502)  | 42.30 (± 99999) | 6.18 (± 2.428)   |
| CD45+CD3-CD56+; FU; n=1, 2, 0, 3, 1, 4       | 22.00 (± 99999) | 7.80 (± 1.556)   | 99999 (± 99999) | 8.37 (± 3.493)   |
| CD45+CD3-CD56+; USC; n=0, 0, 1, 0, 0, 0      | 99999 (± 99999) | 99999 (± 99999)  | 22.10 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9  | 3.30 (± 99999)  | 10.17 (± 8.905)  | 2.70 (± 99999)  | 13.18 (± 10.303) |
| CD45+CD3+CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9  | 1.80 (± 99999)  | 8.03 (± 8.410)   | 1.70 (± 99999)  | 10.70 (± 7.601)  |
| CD45+CD3+CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11 | 1.10 (± 99999)  | 6.87 (± 7.566)   | 13.80 (± 99999) | 12.50 (± 11.924) |
| CD45+CD3+CD56+; D2; n=0, 0, 1, 2, 0, 1       | 99999 (± 99999) | 99999 (± 99999)  | 3.50 (± 99999)  | 20.90 (± 14.001) |
| CD45+CD3+CD56+; D8; n=1, 3, 0, 5, 4, 8       | 3.40 (± 99999)  | 10.23 (± 8.977)  | 99999 (± 99999) | 12.36 (± 8.813)  |
| CD45+CD3+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9  | 2.20 (± 99999)  | 8.40 (± 8.118)   | 1.30 (± 99999)  | 13.48 (± 12.640) |

|   |                    |                     |                    |                    |
|---|--------------------|---------------------|--------------------|--------------------|
| CD45+CD3+CD56+; D15; S2;<br>n=0,0,1,0,0,0           | 99999 (±<br>99999) | 99999 (±<br>99999)  | 1.3 (± 99999)      | 99999 (±<br>99999) |
| CD45+CD3+CD56+; D29; n=1, 3, 1, 4,<br>4, 8          | 2.80 (± 99999)     | 9.33 (± 8.629)      | 3.80 (± 99999)     | 8.88 (± 5.197)     |
| CD45+CD3+CD56+; FU; n=1, 2, 0, 3,<br>1, 4           | 2.50 (± 99999)     | 16.20 (±<br>13.294) | 99999 (±<br>99999) | 16.07 (±<br>6.757) |
| CD45+CD3+CD56+; USC; n=0, 0, 1, 0,<br>0, 0          | 99999 (±<br>99999) | 99999 (±<br>99999)  | 1.60 (± 99999)     | 99999 (±<br>99999) |
| CD45+CD3-CD16+CD56+; D1; pre;<br>n=1, 3, 1, 5, 4, 9 | 23.40 (±<br>99999) | 12.23 (±<br>6.307)  | 23.30 (±<br>99999) | 4.48 (± 1.638)     |
| CD45+CD3-CD16+CD56+; D1;1 h;<br>n=1, 3, 1, 5, 4, 9  | 9.10 (± 99999)     | 8.10 (± 5.237)      | 31.10 (±<br>99999) | 3.98 (± 2.244)     |
| CD45+CD3-CD16+CD56+; D1;6 h;<br>n=1,3,1,5,4,11      | 3.00 (± 99999)     | 4.90 (± 5.403)      | 19.70 (±<br>99999) | 2.92 (± 2.348)     |
| CD45+CD3-CD16+CD56+; D2; n=0, 0,<br>1, 2, 0, 1      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 33.60 (±<br>99999) | 2.40 (± 0.566)     |
| CD45+CD3-CD16+CD56+; D8; n=1, 3,<br>0, 5, 4, 8      | 10.80 (±<br>99999) | 12.33 (±<br>10.979) | 99999 (±<br>99999) | 5.00 (± 2.891)     |
| CD45+CD3-CD16+CD56+; D15; S1;<br>n=1, 3, 1, 5, 4, 9 | 10.90 (±<br>99999) | 11.93 (±<br>11.007) | 43.5 (± 99999)     | 4.14 (± 2.926)     |
| CD45+CD3-CD16+CD56+; D15; S2;<br>n=0,0,1,0,0,0      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 5.4 (± 99999)      | 99999 (±<br>99999) |
| CD45+CD3-CD16+CD56+; D29; n=1,<br>3, 1, 4, 4, 8     | 10.80 (±<br>99999) | 10.20 (±<br>8.542)  | 32.90 (±<br>99999) | 5.05 (± 2.357)     |
| CD45+CD3-CD16+CD56+; FU; n=1, 2,<br>0, 3, 1, 4      | 19.30 (±<br>99999) | 5.50 (± 3.111)      | 99999 (±<br>99999) | 6.07 (± 2.566)     |
| CD45+CD3-CD16+CD56+; USC; n=0,<br>0, 1, 0, 0, 0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 18.30 (±<br>99999) | 99999 (±<br>99999) |
| CD45+CD3-CD19+; D1; pre n=1, 3, 1,<br>5, 4, 9       | 9.10 (± 99999)     | 12.67 (±<br>4.936)  | 12.30 (±<br>99999) | 5.36 (± 3.364)     |
| CD45+CD3-CD19+; D1;1 h; n=1, 3, 1,<br>5, 4, 9       | 11.70 (±<br>99999) | 13.77 (±<br>3.323)  | 8.30 (± 99999)     | 6.04 (± 3.492)     |
| CD45+CD3-CD19+; D1;6 h;<br>n=1,3,1,5,4,11           | 11.30 (±<br>99999) | 16.23 (±<br>3.329)  | 6.00 (± 99999)     | 6.36 (± 3.817)     |
| CD45+CD3-CD19+; D2; n=0, 0, 1, 2, 0,<br>1           | 99999 (±<br>99999) | 99999 (±<br>99999)  | 6.40 (± 99999)     | 8.10 (± 0.141)     |
| CD45+CD3-CD19+; D8; n=1, 3, 0, 5, 4,<br>8           | 10.70 (±<br>99999) | 12.77 (±<br>4.701)  | 99999 (±<br>99999) | 5.76 (± 3.895)     |
| CD45+CD3-CD19+; D15; S1; n=1, 3,<br>1, 5, 4, 9      | 10.60 (±<br>99999) | 14.03 (±<br>6.116)  | 7.9 (± 99999)      | 5.10 (± 3.180)     |
| CD45+CD3-CD19+; D15; S2;<br>n=0,0,1,0,0,0           | 99999 (±<br>99999) | 99999 (±<br>99999)  | 26.2 (± 99999)     | 99999 (±<br>99999) |
| CD45+CD3-CD19+; D29; n=1, 3, 1, 4,<br>4, 8          | 8.90 (± 99999)     | 15.37 (±<br>7.392)  | 13.70 (±<br>99999) | 5.10 (± 3.995)     |
| CD45+CD3-CD19+; FU; n=1, 2, 0, 3, 1,<br>4           | 10.00 (±<br>99999) | 12.05 (±<br>4.313)  | 99999 (±<br>99999) | 6.17 (± 8.361)     |
| CD45+CD3-CD19+; USC; n=0, 0, 1, 0,<br>0, 0          | 99999 (±<br>99999) | 99999 (±<br>99999)  | 15.90 (±<br>99999) | 99999 (±<br>99999) |
| CD45+CD14+; D1; pre; n=1, 3, 1, 5, 4,<br>9          | 5.80 (± 99999)     | 4.87 (± 0.971)      | 10.40 (±<br>99999) | 6.58 (± 1.293)     |
| CD45+CD14+; D1;1 h; n=1, 3, 1, 5, 4,<br>9           | 1.40 (± 99999)     | 3.63 (± 2.103)      | 11.30 (±<br>99999) | 5.20 (± 1.461)     |
| CD45+CD14+; D1;6 h; n=1,3,1,5,4,11                  | 4.50 (± 99999)     | 5.37 (± 2.804)      | 11.80 (±<br>99999) | 6.24 (± 1.756)     |
| CD45+CD14+; D2; n=0, 0, 1, 2, 0, 1                  | 99999 (±<br>99999) | 99999 (±<br>99999)  | 5.30 (± 99999)     | 5.10 (± 2.828)     |
| CD45+CD14+; D8; n=1, 3, 0, 5, 4, 8                  | 7.30 (± 99999)     | 6.30 (± 0.872)      | 99999 (±<br>99999) | 6.60 (± 1.594)     |
| CD45+CD14+; D15; S1; n=1, 3, 1, 5,<br>4, 9          | 4.70 (± 99999)     | 5.60 (± 1.652)      | 5.9 (± 99999)      | 6.66 (± 1.108)     |
| CD45+CD14+; D15; S2; n=0,0,1,0,0,0                  | 99999 (±<br>99999) | 99999 (±<br>99999)  | 18.9 (± 99999)     | 99999 (±<br>99999) |

|   |                 |                  |                 |                  |
|---|-----------------|------------------|-----------------|------------------|
| CD45+CD14+; D29; n=1, 3, 1, 4, 4, 8               | 5.00 (± 99999)  | 4.93 (± 0.231)   | 7.60 (± 99999)  | 5.53 (± 1.162)   |
| CD45+CD14+; FU; n=1, 2, 0, 3, 1, 4                | 7.50 (± 99999)  | 5.50 (± 1.273)   | 99999 (± 99999) | 8.03 (± 0.862)   |
| CD45+CD14+; USC; n=0, 0, 1, 0, 0, 0               | 99999 (± 99999) | 99999 (± 99999)  | 8.50 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3-CD16+CD69+; D1; pre; n=1, 3, 1, 5, 4, 9  | 67.92 (± 99999) | 80.37 (± 3.710)  | 83.47 (± 99999) | 80.92 (± 7.038)  |
| CD45+CD3-CD16+CD69+; D1;1 h; n=1, 3, 1, 5, 4, 9   | 76.94 (± 99999) | 79.76 (± 2.213)  | 87.72 (± 99999) | 81.88 (± 8.557)  |
| CD45+CD3-CD16+CD69+; D1;6 h; n=1,3,1,5,4,11       | 77.72 (± 99999) | 76.99 (± 12.536) | 90.79 (± 99999) | 84.25 (± 5.802)  |
| CD45+CD3-CD16+CD69+; D2; n=0, 0, 1, 2, 0, 1       | 99999 (± 99999) | 99999 (± 99999)  | 91.00 (± 99999) | 89.03 (± 3.776)  |
| CD45+CD3-CD16+CD69+; D8; n=1, 3, 0, 5, 4, 8       | 77.29 (± 99999) | 75.83 (± 5.870)  | 99999 (± 99999) | 81.34 (± 10.373) |
| CD45+CD3-CD16+CD69+; D15;S1; n=1, 3, 1, 5, 4, 9   | 81.61 (± 99999) | 79.04 (± 3.286)  | 96.49 (± 99999) | 80.28 (± 6.867)  |
| CD45+CD3-CD16+CD69+; D15;S2; n=0,0,1,0,0,0        | 99999 (± 99999) | 99999 (± 99999)  | 92.76 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD16+CD69+; D29; n=1, 3, 1, 4, 4, 8      | 79.28 (± 99999) | 81.92 (± 2.273)  | 85.01 (± 99999) | 80.73 (± 6.688)  |
| CD45+CD3-CD16+CD69+; FU; n=1, 2, 0, 3, 1, 4       | 77.38 (± 99999) | 84.40 (± 1.506)  | 99999 (± 99999) | 81.52 (± 12.737) |
| CD45+CD3-CD16+CD69+; USC; n=0, 0, 1, 0, 0, 0      | 99999 (± 99999) | 99999 (± 99999)  | 64.88 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD16+CD107+; D1; pre; n=1, 3, 1, 5, 4, 9 | 7.06 (± 99999)  | 13.40 (± 5.851)  | 18.18 (± 99999) | 19.27 (± 13.221) |
| CD45+CD3-CD16+CD107+; D1;1 h; n=1, 3, 1, 5,4,9    | 12.19 (± 99999) | 15.18 (± 8.160)  | 8.77 (± 99999)  | 21.43 (± 13.416) |
| CD45+CD3-CD16+CD107+; D1;6 h; n=1,3,1,5,4,11      | 14.85 (± 99999) | 15.30 (± 6.477)  | 40.79 (± 99999) | 32.01 (± 16.156) |
| CD45+CD3-CD16+CD107+; D2; n=0, 0, 1, 2, 0, 1      | 99999 (± 99999) | 99999 (± 99999)  | 26.00 (± 99999) | 31.96 (± 9.454)  |
| CD45+CD3-CD16+CD107+; D8; n=1, 3, 0, 5, 4, 8      | 33.73 (± 99999) | 6.90 (± 3.044)   | 99999 (± 99999) | 22.42 (± 10.572) |
| CD45+CD3-CD16+CD107+; D15; S1; n=1, 3, 1, 5, 4, 9 | 17.29 (± 99999) | 7.72 (± 4.937)   | 38.6 (± 99999)  | 17.00 (± 8.663)  |
| CD45+CD3-CD16+CD107+; D15; S2; n=0,0,1,0,0,0      | 99999 (± 99999) | 99999 (± 99999)  | 65.89 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD16+CD107+; D29; n=1, 3, 1, 4, 4, 8     | 16.94 (± 99999) | 8.78 (± 3.719)   | 52.86 (± 99999) | 19.08 (± 4.869)  |
| CD45+CD3-CD16+CD107+; FU; n=1, 2, 0, 3, 1, 4      | 14.38 (± 99999) | 22.49 (± 13.902) | 99999 (± 99999) | 31.28 (± 29.410) |
| CD45+CD3-CD16+CD107+; USC; n=0, 0, 1, 0, 0, 0     | 99999 (± 99999) | 99999 (± 99999)  | 16.51 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD16+CD69+CD107+; D1; pre; n=1,3,1,5,4,9 | 6.86 (± 99999)  | 13.33 (± 5.869)  | 18.18 (± 99999) | 19.05 (± 12.990) |
| CD45+CD3-CD16+CD69+CD107+; D1;1 h;n=1,3,1,5,4,9   | 11.81 (± 99999) | 14.86 (± 7.795)  | 8.77 (± 99999)  | 21.29 (± 13.208) |
| CD45+CD3-CD16+CD69+CD107+;D1;6 h;n=1,3,1,5,4,11   | 14.85 (± 99999) | 15.29 (± 6.364)  | 38.16 (± 99999) | 31.96 (± 16.199) |
| CD45+CD3-CD16+CD69+CD107+; D2; n=0,0,1,2,0,1      | 99999 (± 99999) | 99999 (± 99999)  | 26.00 (± 99999) | 31.42 (± 10.218) |
| CD45+CD3-CD16+CD69+CD107+; D8; n=1,3,0,5,4,8      | 32.80 (± 99999) | 6.77 (± 3.013)   | 99999 (± 99999) | 22.35 (± 10.534) |
| CD45+CD3-CD16+CD69+CD107+; D15; S1;n=1,3,1,5,4,9  | 16.92 (± 99999) | 7.60 (± 4.890)   | 38.6 (± 99999)  | 16.94 (± 8.669)  |
| CD45+CD3-CD16+CD69+CD107+; D15; S2;n=0,0,1,0,0, 0 | 99999 (± 99999) | 99999 (± 99999)  | 64.8 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3-CD16+CD69+CD107+; D29; n=1,3,1,4,4,8     | 16.42 (± 99999) | 8.70 (± 3.598)   | 50.41 (± 99999) | 18.76 (± 4.922)  |

|  |                    |                     |                    |                     |
|--|--------------------|---------------------|--------------------|---------------------|
| CD45+CD3-CD16+CD69+CD107+; FU;<br>n=1,2,0,3,1,4      | 14.34 (±<br>99999) | 22.24 (±<br>13.548) | 99999 (±<br>99999) | 31.06 (±<br>29.550) |
| CD45+CD3-CD16+CD69+CD107+;<br>USC; n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 15.77 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD16+CD69+CD107-;<br>D1;pre; n=1,3,1,5,4,9  | 61.07 (±<br>99999) | 67.04 (±<br>7.996)  | 65.29 (±<br>99999) | 61.87 (±<br>9.438)  |
| CD45+CD3-CD16+CD69+CD107-; D1;1<br>h;n=1,3,1,5,4,9   | 65.12 (±<br>99999) | 64.90 (±<br>8.250)  | 78.95 (±<br>99999) | 60.59 (±<br>8.489)  |
| CD45+CD3-CD16+CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11   | 62.87 (±<br>99999) | 61.71 (±<br>10.282) | 52.63 (±<br>99999) | 52.29 (±<br>11.006) |
| CD45+CD3-CD16+CD69+CD107-; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 65.00 (±<br>99999) | 57.62 (±<br>13.987) |
| CD45+CD3-CD16+CD69+CD107-; D8;<br>n=1,3,0,5,4,8      | 44.49 (±<br>99999) | 69.06 (±<br>8.555)  | 99999 (±<br>99999) | 58.99 (±<br>8.379)  |
| CD45+CD3-CD16+CD69+CD107-;<br>D15;S1; n=1,3,1,5,4,9  | 64.68 (±<br>99999) | 71.45 (±<br>1.611)  | 57.89 (±<br>99999) | 63.34 (±<br>4.338)  |
| CD45+CD3-CD16+CD69+CD107-; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 27.96 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD16+CD69+CD107-; D29;<br>n=1,3,1,4,4,8     | 62.87 (±<br>99999) | 73.22 (±<br>4.103)  | 34.60 (±<br>99999) | 61.98 (±<br>6.511)  |
| CD45+CD3-CD16+CD69+CD107-; FU;<br>n=1,2,0,3,1,4      | 63.04 (±<br>99999) | 62.16 (±<br>15.047) | 99999 (±<br>99999) | 50.46 (±<br>18.585) |
| CD45+CD3-CD16+CD69+CD107-; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 49.11 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD16+CD69-CD107+;<br>D1;pre n=1,3,1,5,4,9   | 0.21 (± 99999)     | 0.07 (± 0.115)      | 0.00 (± 99999)     | 0.22 (± 0.265)      |
| CD45+CD3-CD16+CD69-CD107+; D1;1<br>h;n=1,3,1,5,4,9   | 0.38 (± 99999)     | 0.31 (± 0.399)      | 0.00 (± 99999)     | 0.14 (± 0.238)      |
| CD45+CD3-CD16+CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11   | 0.00 (± 99999)     | 0.09 (± 0.162)      | 2.63 (± 99999)     | 0.05 (± 0.069)      |
| CD45+CD3-CD16+CD69-CD107+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 0.00 (± 99999)     | 0.54 (± 0.764)      |
| CD45+CD3-CD16+CD69-CD107+; D8;<br>n=1,3,0,5,4,8      | 0.94 (± 99999)     | 0.14 (± 0.029)      | 99999 (±<br>99999) | 0.07 (± 0.100)      |
| CD45+CD3-CD16+CD69-CD107+;<br>D15;S1; n=1,3,1,5,4,9  | 0.37 (± 99999)     | 0.12 (± 0.102)      | 0.00 (± 99999)     | 0.05 (± 0.121)      |
| CD45+CD3-CD16+CD69-CD107+; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 1.09 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3-CD16+CD69-CD107+; D29;<br>n=1,3,1,4,4,8     | 0.52 (± 99999)     | 0.07 (± 0.127)      | 2.45 (± 99999)     | 0.32 (± 0.326)      |
| CD45+CD3-CD16+CD69-CD107+; FU;<br>n=1,2,0,3,1,4      | 0.03 (± 99999)     | 0.26 (± 0.361)      | 99999 (±<br>99999) | 0.22 (± 0.333)      |
| CD45+CD3-CD16+CD69-CD107+; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 0.74 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3-CD16+CD69-CD107-;<br>D1;pre; n=1,3,1,5,4,9  | 31.87 (±<br>99999) | 19.57 (±<br>3.611)  | 16.53 (±<br>99999) | 18.86 (±<br>7.256)  |
| CD45+CD3-CD16+CD69-CD107-; D1;1<br>h;n=1,3,1,5,4,9   | 22.68 (±<br>99999) | 19.93 (±<br>2.396)  | 12.28 (±<br>99999) | 17.98 (±<br>8.736)  |
| CD45+CD3-CD16+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11   | 22.28 (±<br>99999) | 22.91 (±<br>12.511) | 6.58 (± 99999)     | 15.70 (±<br>5.783)  |
| CD45+CD3-CD16+CD69-CD107-; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 9.00 (± 99999)     | 10.43 (±<br>4.540)  |
| CD45+CD3-CD16+CD69-CD107-; D8;<br>n=1,3,0,5,4,8      | 21.78 (±<br>99999) | 24.03 (±<br>5.842)  | 99999 (±<br>99999) | 18.63 (±<br>10.331) |
| CD45+CD3-CD16+CD69-CD107-; D15;<br>S1;n=1,3,1,5,4,9  | 18.03 (±<br>99999) | 20.84 (±<br>3.338)  | 3.51 (± 99999)     | 19.67 (±<br>6.810)  |
| CD45+CD3-CD16+CD69-CD107-; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 6.15 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3-CD16+CD69-CD107-; D29;<br>n=1,3,1,4,4,8     | 20.20 (±<br>99999) | 18.00 (±<br>2.247)  | 12.53 (±<br>99999) | 18.97 (±<br>6.747)  |
| CD45+CD3-CD16+CD69-CD107-; FU;<br>n=1,2,0,3,1,4      | 22.59 (±<br>99999) | 15.35 (±<br>1.146)  | 99999 (±<br>99999) | 18.34 (±<br>12.586) |

|  |                    |                     |                    |                     |
|--|--------------------|---------------------|--------------------|---------------------|
| CD45+CD3-CD16+CD69-CD107-; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 34.38 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69+; D1;pre;<br>n=1,3,1,5,4,9        | 67.22 (±<br>99999) | 78.33 (±<br>3.952)  | 82.26 (±<br>99999) | 77.55 (±<br>7.943)  |
| CD45+CD3-CD56+CD69+; D1;1<br>h;n=1,3,1,5,4,9         | 75.33 (±<br>99999) | 77.13 (±<br>4.906)  | 86.96 (±<br>99999) | 79.21 (±<br>8.936)  |
| CD45+CD3-CD56+CD69+;D1;6<br>h;n=1,3,1,5,4,11         | 79.56 (±<br>99999) | 74.82 (±<br>11.935) | 92.92 (±<br>99999) | 80.05 (±<br>5.668)  |
| CD45+CD3-CD56+CD69+; D2;<br>n=0,0,1,2,0,1            | 99999 (±<br>99999) | 99999 (±<br>99999)  | 87.50 (±<br>99999) | 84.69 (±<br>5.862)  |
| CD45+CD3-CD56+CD69+; D8;<br>n=1,3,0,5,4,8            | 75.33 (±<br>99999) | 72.08 (±<br>3.948)  | 99999 (±<br>99999) | 77.49 (±<br>9.757)  |
| CD45+CD3-CD56+CD69+; D15;S1;<br>n=1,3,1,5,4,9        | 80.07 (±<br>99999) | 76.83 (±<br>2.746)  | 93.33 (±<br>99999) | 76.69 (±<br>5.772)  |
| CD45+CD3-CD56+CD69+; D15; S2;<br>n=0,0,1,0,0,0       | 99999 (±<br>99999) | 99999 (±<br>99999)  | 90.79 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69+; D29;<br>n=1,3,1,4,4,8           | 76.99 (±<br>99999) | 80.41 (±<br>3.445)  | 83.53 (±<br>99999) | 77.90 (±<br>5.693)  |
| CD45+CD3-CD56+CD69+; FU;<br>n=1,2,0,3,1,4            | 75.72 (±<br>99999) | 83.15 (±<br>0.643)  | 99999 (±<br>99999) | 78.85 (±<br>8.804)  |
| CD45+CD3-CD56+CD69+; USC;<br>n=0,0,1,0,0,0           | 99999 (±<br>99999) | 99999 (±<br>99999)  | 64.59 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD107+; D1; pre;<br>n=1,3,1,5,4,9      | 2.47 (± 99999)     | 11.70 (±<br>5.812)  | 15.32 (±<br>99999) | 16.30 (±<br>12.987) |
| CD45+CD3-CD56+CD107+; D1;1<br>h;n=1,3,1,5,4,9        | 5.13 (± 99999)     | 13.87 (±<br>7.853)  | 6.69 (± 99999)     | 17.11 (±<br>11.990) |
| CD45+CD3-CD56+CD107+;D1;6<br>h;n=1,3,1,5,4,11        | 14.60 (±<br>99999) | 16.66 (±<br>7.368)  | 31.76 (±<br>99999) | 23.41 (±<br>13.644) |
| CD45+CD3-CD56+CD107+; D2;<br>n=0,0,1,2,0,1           | 99999 (±<br>99999) | 99999 (±<br>99999)  | 21.67 (±<br>99999) | 28.04 (±<br>7.347)  |
| CD45+CD3-CD56+CD107+; D8;<br>n=1,3,0,5,4,8           | 32.45 (±<br>99999) | 6.79 (± 2.953)      | 99999 (±<br>99999) | 17.46 (±<br>7.730)  |
| CD45+CD3-CD56+CD107+; D15;S1;<br>n=1,3,1,5,4,9       | 15.54 (±<br>99999) | 6.48 (± 3.558)      | 39.17 (±<br>99999) | 14.18 (±<br>7.919)  |
| CD45+CD3-CD56+CD107+; D15; S2;<br>n=0,0,1,0,0,0      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 54.4 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD107+; D29;<br>n=1,3,1,4,4,8          | 15.85 (±<br>99999) | 7.77 (± 3.841)      | 48.21 (±<br>99999) | 15.09 (±<br>1.735)  |
| CD45+CD3-CD56+CD107+; FU;<br>n=1,2,0,3,1,4           | 13.08 (±<br>99999) | 19.93 (±<br>11.469) | 99999 (±<br>99999) | 26.54 (±<br>22.053) |
| CD45+CD3-CD56+CD107+; USC;<br>n=0,0,1,0,0,0          | 99999 (±<br>99999) | 99999 (±<br>99999)  | 16.45 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69+CD107+; D1;<br>pre n=1,3,1,5,4,9  | 2.45 (± 99999)     | 11.58 (±<br>5.907)  | 15.32 (±<br>99999) | 15.98 (±<br>12.746) |
| CD45+CD3-CD56+CD69+CD107+;<br>D1;1 h;n=1,3,1,5,4,9   | 4.97 (± 99999)     | 13.56 (±<br>7.455)  | 6.96 (± 99999)     | 16.90 (±<br>11.974) |
| CD45+CD3-CD56+CD69+CD107+;D1;6<br>h;n=1,3,1,5,4,11   | 14.60 (±<br>99999) | 15.94 (±<br>6.586)  | 31.76 (±<br>99999) | 23.27 (±<br>13.781) |
| CD45+CD3-CD56+CD69+CD107+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 21.67 (±<br>99999) | 27.36 (±<br>7.460)  |
| CD45+CD3-CD56+CD69+CD107+; D8;<br>n=1,3,0,5,4,8      | 31.18 (±<br>99999) | 6.63 (± 2.770)      | 99999 (±<br>99999) | 17.32 (±<br>7.645)  |
| CD45+CD3-CD56+CD69+CD107+;<br>D15;S1; n=1,3,1,5,4,9  | 15.13 (±<br>99999) | 6.40 (± 3.545)      | 39.17 (±<br>99999) | 14.03 (±<br>7.922)  |
| CD45+CD3-CD56+CD69+CD107+;<br>D15; S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 54.27 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69+CD107+;<br>D29; n=1,3,1,4,4,8     | 15.34 (±<br>99999) | 7.77 (± 3.841)      | 46.54 (±<br>99999) | 14.70 (±<br>1.922)  |
| CD45+CD3-CD56+CD69+CD107+; FU;<br>n=1,2,0,3,1,4      | 13.01 (±<br>99999) | 19.60 (±<br>11.130) | 99999 (±<br>99999) | 26.27 (±<br>22.189) |
| CD45+CD3-CD56+CD69+CD107+;<br>USC; n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 15.52 (±<br>99999) | 99999 (±<br>99999)  |

|  |                    |                     |                    |                     |
|--|--------------------|---------------------|--------------------|---------------------|
| CD45+CD3-CD56+CD69+CD107-; D1;<br>pre; n=1,3,1,5,4,9 | 64.78 (±<br>99999) | 66.74 (±<br>7.360)  | 66.94 (±<br>99999) | 61.56 (±<br>9.286)  |
| CD45+CD3-CD56+CD69+CD107-; D1;1<br>h;n=1,3,1,5,4,9   | 70.36 (±<br>99999) | 63.58 (±<br>7.453)  | 80.00 (±<br>99999) | 62.31 (±<br>7.582)  |
| CD45+CD3-CD56+CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11   | 64.96 (±<br>99999) | 58.88 (±<br>10.865) | 61.18 (±<br>99999) | 56.78 (±<br>8.650)  |
| CD45+CD3-CD56+CD69+CD107-; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 65.83 (±<br>99999) | 57.33 (±<br>13.329) |
| CD45+CD3-CD56+CD69+CD107-;<br>D15;S1; n=1,3,1,5,4,9  | 64.95 (±<br>99999) | 70.43 (±<br>0.830)  | 54.17 (±<br>99999) | 62.66 (±<br>4.313)  |
| CD45+CD3-CD56+CD69+CD107-; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 36.52 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69+CD107-; D8;<br>n=1,3,0,5,4,8      | 44.15 (±<br>99999) | 65.44 (±<br>6.176)  | 99999 (±<br>99999) | 60.18 (±<br>8.140)  |
| CD45+CD3-CD56+CD69+CD107-; D29;<br>n=1,3,1,4,4,8     | 61.65 (±<br>99999) | 72.64 (±<br>2.420)  | 36.99 (±<br>99999) | 63.21 (±<br>4.900)  |
| CD45+CD3-CD56+CD69+CD107-; FU;<br>n=1,2,0,3,1,4      | 62.71 (±<br>99999) | 63.55 (±<br>11.780) | 99999 (±<br>99999) | 52.58 (±<br>16.165) |
| CD45+CD3-CD56+CD69+CD107-; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 49.07 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69-CD107+; D1;<br>pre; n=1,3,1,5,4,9 | 0.03 (± 99999)     | 0.11 (± 0.095)      | 0.00 (± 99999)     | 0.31 (± 0.267)      |
| CD45+CD3-CD56+CD69-CD107+; D1;1<br>h;n=1,3,1,5,4,9   | 0.17 (± 99999)     | 0.31 (± 0.412)      | 0.00 (± 99999)     | 0.21 (± 0.123)      |
| CD45+CD3-CD56+CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11   | 0.00 (± 99999)     | 0.72 (± 0.968)      | 0.00 (± 99999)     | 0.14 (± 0.226)      |
| CD45+CD3-CD56+CD69-CD107+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 0.00 (± 99999)     | 0.68 (± 0.113)      |
| CD45+CD3-CD56+CD69-CD107+; D8;<br>n=1,3,0,5,4,8      | 1.27 (± 99999)     | 0.16 (± 0.182)      | 99999 (±<br>99999) | 0.14 (± 0.186)      |
| CD45+CD3-CD56+CD69-CD107+;<br>D15;S1; n=1,3,1,5,4,9  | 0.41 (± 99999)     | 0.09 (± 0.076)      | 0 (± 99999)        | 0.15 (± 0.145)      |
| CD45+CD3-CD56+CD69-CD107+; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 0.14 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69-CD107+; D29;<br>n=1,3,1,4,4,8     | 0.50 (± 99999)     | 0.00 (± 0.000)      | 1.67 (± 99999)     | 0.39 (± 0.541)      |
| CD45+CD3-CD56+CD69-CD107+; FU;<br>n=1,2,0,3,1,4      | 0.07 (± 99999)     | 0.34 (± 0.332)      | 99999 (±<br>99999) | 0.27 (± 0.379)      |
| CD45+CD3-CD56+CD69-CD107+; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 0.93 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69-CD107-; D1;<br>pre; n=1,3,1,5,4,9 | 32.75 (±<br>99999) | 21.56 (±<br>3.938)  | 17.74 (±<br>99999) | 22.14 (±<br>8.116)  |
| CD45+CD3-CD56+CD69-CD107-; D1;1<br>h;n=1,3,1,5,4,9   | 24.50 (±<br>99999) | 22.55 (±<br>5.154)  | 13.04 (±<br>99999) | 20.58 (±<br>8.921)  |
| CD45+CD3-CD56+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11   | 20.44 (±<br>99999) | 24.46 (±<br>11.748) | 7.06 (± 99999)     | 19.81 (±<br>5.486)  |
| CD45+CD3-CD56+CD69-CD107-; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999)  | 12.50 (±<br>99999) | 14.64 (±<br>5.975)  |
| CD45+CD3-CD56+CD69-CD107-; D8;<br>n=1,3,0,5,4,8      | 23.40 (±<br>99999) | 27.76 (±<br>3.835)  | 99999 (±<br>99999) | 22.37 (±<br>9.797)  |
| CD45+CD3-CD56+CD69-CD107-;<br>D15;S1; n=1,3,1,5,4,9  | 19.57 (±<br>99999) | 23.09 (±<br>2.774)  | 6.67 (± 99999)     | 23.16 (±<br>5.735)  |
| CD45+CD3-CD56+CD69-CD107-; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 9.08 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD69-CD107-; D29;<br>n=1,3,1,4,4,8     | 22.56 (±<br>99999) | 19.59 (±<br>3.445)  | 14.80 (±<br>99999) | 21.73 (±<br>5.751)  |
| CD45+CD3-CD56+CD69-CD107-; FU;<br>n=1,2,0,3,1,4      | 24.28 (±<br>99999) | 16.52 (±<br>0.311)  | 99999 (±<br>99999) | 20.87 (±<br>8.475)  |
| CD45+CD3-CD56+CD69-CD107-; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 34.48 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3-CD56+CD16+CD69+; D1;<br>pre; n=1,3,1,5,4,9  | 67.96 (±<br>99999) | 79.63 (±<br>3.253)  | 83.93 (±<br>99999) | 80.66 (±<br>7.578)  |

|   |                 |                  |                 |                  |
|---|-----------------|------------------|-----------------|------------------|
| CD45+CD3-CD56+CD16+CD69+; D1;1 h;n=1,3,1,5,4,9    | 76.86 (± 99999) | 79.33 (± 2.688)  | 88.07 (± 99999) | 81.64 (± 9.116)  |
| CD45+CD3-CD56+CD16+CD69+;D1;6 h;n=1,3,1,5,4,11    | 78.24 (± 99999) | 76.67 (± 11.942) | 93.65 (± 99999) | 83.35 (± 5.763)  |
| CD45+CD3-CD56+CD16+CD69+; D2; n=0,0,1,2,0,1       | 99999 (± 99999) | 99999 (± 99999)  | 90.53 (± 99999) | 89.13 (± 3.147)  |
| CD45+CD3-CD56+CD16+CD69+; D8; n=1,3,0,5,4,8       | 77.01 (± 99999) | 75.37 (± 5.656)  | 99999 (± 99999) | 80.55 (± 10.272) |
| CD45+CD3-CD56+CD16+CD69+; D15;S1; n=1,3,1,5,4,9   | 81.53 (± 99999) | 78.47 (± 3.127)  | 97.12 (± 99999) | 79.94 (± 6.952)  |
| CD45+CD3-CD56+CD16+CD69+; D15; S2; n=0,0,1,0,0,0  | 99999 (± 99999) | 99999 (± 99999)  | 94.42 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD56+CD16+CD69+; D29; n=1,3,1,4,4,8      | 78.98 (± 99999) | 81.90 (± 2.566)  | 85.89 (± 99999) | 80.16 (± 7.448)  |
| CD45+CD3-CD56+CD16+CD69+; FU; n=1,2,0,3,1,4       | 77.43 (± 99999) | 83.80 (± 1.485)  | 99999 (± 99999) | 81.09 (± 12.356) |
| CD45+CD3-CD56+CD16+CD69+; USC; n=0,0,1,0,0,0      | 99999 (± 99999) | 99999 (± 99999)  | 65.35 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD56+CD16+CD107+; D1;pre; n=1,3,1,5,4,9  | 6.82 (± 99999)  | 12.17 (± 5.660)  | 16.96 (± 99999) | 17.55 (± 13.586) |
| CD45+CD3-CD56+CD16+CD107+; D1;1 h;n=1,3,1,5,4,9   | 12.40 (± 99999) | 14.37 (± 7.788)  | 7.34 (± 99999)  | 19.24 (± 13.929) |
| CD45+CD3-CD56+CD16+CD107+;D1;6 h;n=1,3,1,5,4,11   | 15.03 (± 99999) | 14.86 (± 7.082)  | 31.75 (± 99999) | 27.52 (± 16.167) |
| CD45+CD3-CD56+CD16+CD107+; D2; n=0,0,1,2,0,1      | 99999 (± 99999) | 99999 (± 99999)  | 25.26 (± 99999) | 32.24 (± 9.970)  |
| CD45+CD3-CD56+CD16+CD107+; D8; n=1,3,0,5,4,8      | 33.08 (± 99999) | 6.53 (± 3.339)   | 99999 (± 99999) | 18.59 (± 9.084)  |
| CD45+CD3-CD56+CD16+CD107+; D15;S1; n=1,3,1,5,4,9  | 16.23 (± 99999) | 6.20 (± 4.025)   | 40.38 (± 99999) | 14.69 (± 8.825)  |
| CD45+CD3-CD56+CD16+CD107+; D15; S2; n=0,0,1,0,0,0 | 99999 (± 99999) | 99999 (± 99999)  | 60.94 (± 99999) | 99999 (± 99999)  |
| CD45+CD3-CD56+CD16+CD107+; D29; n=1,3,1,4,4,8     | 16.53 (± 99999) | 8.01 (± 4.316)   | 50.92 (± 99999) | 15.68 (± 2.613)  |
| CD45+CD3-CD56+CD16+CD107+; FU; n=1,2,0,3,1,4      | 13.70 (± 99999) | 19.58 (± 14.078) | 99999 (± 99999) | 29.76 (± 28.400) |
| CD45+CD3-CD56+CD16+CD107+; USC; n=0,0,1,0,0,0     | 99999 (± 99999) | 99999 (± 99999)  | 16.42 (± 99999) | 99999 (± 99999)  |
| CDX241; D1;pre; n=1,3,1,5,4,9                     | 6.63 (± 99999)  | 12.09 (± 5.664)  | 16.96 (± 99999) | 17.32 (± 13.319) |
| CDX241; D1;1h;n=1,3,1,5,4,9                       | 12.01 (± 99999) | 14.02 (± 7.382)  | 7.34 (± 99999)  | 19.15 (± 13.818) |
| CDX241; D1;6h;n=1,3,1,5,4,11                      | 15.03 (± 99999) | 14.75 (± 6.934)  | 31.75 (± 99999) | 27.46 (± 16.219) |
| CDX241; D2; n=0,0,1,2,0,1                         | 99999 (± 99999) | 99999 (± 99999)  | 25.26 (± 99999) | 31.68 (± 10.769) |
| CDX241; D8; n=1,3,0,5,4,8                         | 32.10 (± 99999) | 6.47 (± 3.238)   | 99999 (± 99999) | 18.50 (± 9.029)  |
| CDX241; D15;S1;n=1,3,1,5,4,9                      | 15.97 (± 99999) | 6.13 (± 3.908)   | 40.38 (± 99999) | 14.62 (± 8.827)  |
| CDX241; D15;S2; n=0,0,1,0,0,0                     | 99999 (± 99999) | 99999 (± 99999)  | 60.94 (± 99999) | 99999 (± 99999)  |
| CDX241; D29; n=1,3,1,4,4,8                        | 15.99 (± 99999) | 8.01 (± 4.316)   | 49.39 (± 99999) | 15.40 (± 2.640)  |
| CDX241; FU; n=1,2,0,3,1,4                         | 13.66 (± 99999) | 19.29 (± 13.668) | 99999 (± 99999) | 29.58 (± 28.512) |
| CDX241; USC; n=0,0,1,0,0,0                        | 99999 (± 99999) | 99999 (± 99999)  | 15.64 (± 99999) | 99999 (± 99999)  |
| CDX243; D1; pre; n=1,3,1,5,4,9                    | 61.33 (± 99999) | 67.54 (± 8.092)  | 66.96 (± 99999) | 63.34 (± 9.199)  |
| CDX243; D1;1h; n=1,3,1,5,4,9                      | 64.84 (± 99999) | 65.31 (± 7.929)  | 80.73 (± 99999) | 62.49 (± 8.086)  |

|   |                 |                  |                  |                  |
|---|-----------------|------------------|------------------|------------------|
| CDX243;D1;6h; n=1,3,1,5,4,11              | 63.21 (± 99999) | 61.93 (± 9.710)  | 61.90 (± 99999)  | 55.89 (± 11.139) |
| CDX243; D2; n=0,0,1,2,0,1                 | 99999 (± 99999) | 99999 (± 99999)  | 65.26 (± 99999)  | 57.46 (± 13.909) |
| CDX243; D8; n=1,3,0,5,4,8                 | 44.92 (± 99999) | 68.91 (± 8.623)  | 99999 (± 99999)  | 62.04 (± 7.093)  |
| CDX243; D15;S1; n=1,3,1,5,4,9             | 65.55 (± 99999) | 72.34 (± 0.958)  | 56.73 (± 99999)  | 65.32 (± 4.554)  |
| CDX243; D15;S2; n=0,0,1,0,0,0             | 99999 (± 99999) | 99999 (± 99999)  | 33.48 (± 99999)  | 99999 (± 99999)  |
| CDX243; D29; n=1,3,1,4,4,8                | 62.99 (± 99999) | 73.88 (± 3.073)  | 36.50 (± 99999)  | 64.75 (± 5.261)  |
| CDX243; FU;n=1,2,0,3,1,4                  | 63.77 (± 99999) | 64.51 (± 15.146) | 99999 (± 99999)  | 51.52 (± 18.071) |
| CDX243; USC;n=0,0,1,0,0,0                 | 99999 (± 99999) | 99999 (± 99999)  | 49.72 (± 99999)  | 99999 (± 99999)  |
| CDX244; D1; pre; n=1,3,1,5,4,9            | 0.18 (± 99999)  | 0.08 (± 0.139)   | 0.00 (± 99999)   | 0.23 (± 0.289)   |
| CDX244; D1;1h;n=1,3,1,5,4,9               | 0.39 (± 99999)  | 0.35 (± 0.454)   | 0.00 (± 99999)   | 0.09 (± 0.137)   |
| CDX244; D1;6h;n=1,3,1,5,4,11              | 0.00 (± 99999)  | 0.11 (± 0.191)   | 0.00 (± 99999)   | 0.06 (± 0.089)   |
| CDX244; D2; n=0,0,1,2,0,1                 | 99999 (± 99999) | 99999 (± 99999)  | 0.00 (± 99999)   | 0.57 (± 0.799)   |
| CDX244; D8; n=1,3,0,5,4,8                 | 0.98 (± 99999)  | 0.06 (± 0.110)   | 99999 (± 99999)  | 0.08 (± 0.116)   |
| CDX244; D15;S1;n=1,3,1,5,4,9              | 0.26 (± 99999)  | 0.07 (± 0.115)   | 0.00 (± 99999)   | 1.53 (± 99999)   |
| CDX244; D15;S2n=0,0,1,0,0,0               | 99999 (± 99999) | 99999 (± 99999)  | 0.00 (± 99999)   | 99999 (± 99999)  |
| CDX244; D29; n=1,3,1,4,4,8                | 0.54 (± 99999)  | 0.00 (± 0.000)   | 1.53 (± 99999)   | 0.28 (± 0.392)   |
| CDX244; FU;n=1,2,0,3,1,4                  | 0.04 (± 99999)  | 0.29 (± 0.410)   | 99999 (± 99999)  | 0.18 (± 0.267)   |
| CDX244; USC;n=0,0,1,0,0,0                 | 99999 (± 99999) | 99999 (± 99999)  | 0.79 (± 99999)   | 99999 (± 99999)  |
| CDX245; D1; pre; n=1,3,1,5,4,9            | 31.86 (± 99999) | 20.28 (± 3.144)  | 16.07 (± 99999)  | 19.11 (± 7.819)  |
| CDX245; D1; 1h; n=1,3,1,5,4,9             | 22.75 (± 99999) | 20.32 (± 2.902)  | 11.93 (± 99999)  | 18.27 (± 9.233)  |
| CDX245; D1; 6h; n=1,3,1,5,4,11            | 21.76 (± 99999) | 23.22 (± 11.931) | 6.35 (± 99999)   | 16.59 (± 5.742)  |
| CDX245; D2; n=0,0,1,2,0,1                 | 99999 (± 99999) | 99999 (± 99999)  | 9.47 (± 99999)   | 10.31 (± 3.946)  |
| CDX245; D8; n=1,3,0,5,4,8                 | 22.00 (± 99999) | 24.56 (± 5.547)  | 99999 (± 99999)  | 19.37 (± 10.290) |
| CDX245; D15; S1; n=1,3,1,5,4,9            | 18.22 (± 99999) | 21.46 (± 3.242)  | 2.88 (± 99999)   | 20.00 (± 6.887)  |
| CDX245; D15; S2; n=0,0,1,0,0,0            | 99999 (± 99999) | 99999 (± 99999)  | 5.58 (± 99999)   | 99999 (± 99999)  |
| CDX245; D29; n=1,3,1,4,4,8                | 20.48 (± 99999) | 18.10 (± 2.566)  | 12.58 (± 99999)  | 19.57 (± 7.550)  |
| CDX245; FU; n=1,2,0,3,1,4                 | 22.53 (± 99999) | 15.91 (± 1.075)  | 99999 (± 99999)  | 18.72 (± 12.153) |
| CDX245; USC; n=0,0,1,0,0,0                | 99999 (± 99999) | 99999 (± 99999)  | 33.86 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3+CD56+CD69+;D1pre; n=1,3,1,5,4,9  | 62.80 (± 99999) | 77.83 (± 5.748)  | 84.62 (± 99999)  | 76.05 (± 13.328) |
| CD45+CD3+CD56+CD69+;D1;1 h;n=1,3,1,5,4,9  | 71.21 (± 99999) | 77.91 (± 8.757)  | 100.00 (± 99999) | 74.68 (± 12.530) |
| CD45+CD3+CD56+CD69+;D1;6 h;n=1,3,1,5,4,11 | 77.14 (± 99999) | 76.55 (± 11.000) | 100.00 (± 99999) | 75.64 (± 10.831) |
| CD45+CD3+CD56+CD69+; D2; n=0,0,1,2,0,1    | 99999 (± 99999) | 99999 (± 99999)  | 90.00 (± 99999)  | 79.51 (± 11.823) |
| CD45+CD3+CD56+CD69+; D8; n=1,3,0,5,4,8    | 70.35 (± 99999) | 79.41 (± 6.359)  | 99999 (± 99999)  | 77.26 (± 8.083)  |



|   |                    |                     |                    |                     |
|---|--------------------|---------------------|--------------------|---------------------|
| CD45+CD3+CD56+CD69+; D15;S1;<br>n=1,3,1,5,4,9       | 76.53 (±<br>99999) | 81.26 (±<br>7.195)  | 100 (± 99999)      | 76.72 (±<br>9.716)  |
| CD45+CD3+CD56+CD69+;D15;S2;<br>n=0,0,1,0,0,0        | 99999 (±<br>99999) | 99999 (±<br>99999)  | 90.91 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD56+CD69+; D29;<br>n=1,3,1,4,4,8          | 76.53 (±<br>99999) | 84.46 (±<br>9.848)  | 92.11 (±<br>99999) | 75.11 (±<br>5.695)  |
| CD45+CD3+CD56+CD69+;<br>FU;n=1,2,0,3,1,4            | 76.95 (±<br>99999) | 83.76 (±<br>2.977)  | 99999 (±<br>99999) | 76.93 (±<br>2.841)  |
| CD45+CD3+CD56+CD69+;<br>USC;n=0,0,1,0,0,0           | 99999 (±<br>99999) | 99999 (±<br>99999)  | 73.08 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD56+CD107+;D1pre;<br>n=1,3,1,5,4,9        | 8.10 (± 99999)     | 23.44 (±<br>3.025)  | 30.77 (±<br>99999) | 24.69 (±<br>14.219) |
| CD45+CD3+CD56+CD107+;D1;1<br>h;n=1,3,1,5,4,9        | 16.16 (±<br>99999) | 25.59 (±<br>8.435)  | 16.67 (±<br>99999) | 25.84 (±<br>13.782) |
| CD45+CD3+CD56+CD107+;D1;6<br>h;n=1,3,1,5,4,11       | 17.14 (±<br>99999) | 27.55 (±<br>9.084)  | 77.27 (±<br>99999) | 25.54 (±<br>14.785) |
| CD45+CD3+CD56+CD107+; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999) | 99999 (±<br>99999)  | 50.00 (±<br>99999) | 12.40 (±<br>2.892)  |
| CD45+CD3+CD56+CD107+; D8;<br>n=1,3,0,5,4,8          | 34.51 (±<br>99999) | 25.08 (±<br>12.140) | 99999 (±<br>99999) | 22.70 (±<br>6.042)  |
| CD45+CD3+CD56+CD107+; D15;<br>S1;n=1,3,1,5,4,9      | 24.44 (±<br>99999) | 16.39 (±<br>9.804)  | 66.67 (±<br>99999) | 20.15 (±<br>15.543) |
| CD45+CD3+CD56+CD107+;D15;S2;<br>n=0,0,1,0,0,0       | 99999 (±<br>99999) | 99999 (±<br>99999)  | 91.36 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD56+CD107+; D29;<br>n=1,3,1,4,4,8         | 19.20 (±<br>99999) | 24.61 (±<br>12.809) | 94.74 (±<br>99999) | 21.97 (±<br>16.720) |
| CD45+CD3+CD56+CD107+;<br>FU;n=1,2,0,3,1,4           | 19.60 (±<br>99999) | 27.79 (±<br>8.132)  | 99999 (±<br>99999) | 32.87 (±<br>23.340) |
| CD45+CD3+CD56+CD107+;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999) | 99999 (±<br>99999)  | 20.51 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD56+CD69+CD107+;D1;<br>pre; n=1,3,1,5,4,9 | 8.10 (± 99999)     | 23.26 (±<br>2.974)  | 30.77 (±<br>99999) | 23.85 (±<br>14.628) |
| CD45+CD3+CD56+CD69+CD107+;D1;<br>1 h;n=1,3,1,5,4,9  | 15.15 (±<br>99999) | 25.29 (±<br>8.566)  | 16.67 (±<br>99999) | 24.96 (±<br>14.211) |
| CD45+CD3+CD56+CD69+CD107+;D1;<br>6 h;n=1,3,1,5,4,11 | 17.14 (±<br>99999) | 26.84 (±<br>8.938)  | 77.27 (±<br>99999) | 24.77 (±<br>15.022) |
| CD45+CD3+CD56+CD69+CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 50.00 (±<br>99999) | 12.24 (±<br>3.111)  |
| CD45+CD3+CD56+CD69+CD107+; D8;<br>n=1,3,0,5,4,8     | 32.08 (±<br>99999) | 24.24 (±<br>11.427) | 99999 (±<br>99999) | 22.33 (±<br>5.946)  |
| CD45+CD3+CD56+CD69+CD107+;<br>D15;S1; n=1,3,1,5,4,9 | 24.12 (±<br>99999) | 16.22 (±<br>9.646)  | 66.67 (±<br>99999) | 19.78 (±<br>15.294) |
| CD45+CD3+CD56+CD69+CD107+;D15<br>;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 85.45 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD56+CD69+CD107+;<br>D29; n=1,3,1,4,4,8    | 18.67 (±<br>99999) | 24.31 (±<br>12.597) | 86.84 (±<br>99999) | 21.41 (±<br>16.520) |
| CD45+CD3+CD56+CD69+CD107+;<br>FU;n=1,2,0,3,1,4      | 19.60 (±<br>99999) | 27.48 (±<br>8.217)  | 99999 (±<br>99999) | 31.89 (±<br>22.622) |
| CD45+CD3+CD56+CD69+CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 16.67 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD56+CD69+CD107-;D1;<br>pre; n=1,3,1,5,4,9 | 54.70 (±<br>99999) | 54.57 (±<br>2.810)  | 53.85 (±<br>99999) | 52.20 (±<br>11.519) |
| CD45+CD3+CD56+CD69+CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 56.06 (±<br>99999) | 52.62 (±<br>3.308)  | 83.33 (±<br>99999) | 49.72 (±<br>10.923) |
| CD45+CD3+CD56+CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 60.00 (±<br>99999) | 49.71 (±<br>2.501)  | 22.73 (±<br>99999) | 50.88 (±<br>11.326) |
| CD45+CD3+CD56+CD69+CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 40.00 (±<br>99999) | 67.28 (±<br>8.719)  |
| CD45+CD3+CD56+CD69+CD107-; D8;<br>n=1,3,0,5,4,8     | 38.27 (±<br>99999) | 55.17 (±<br>6.740)  | 99999 (±<br>99999) | 54.92 (±<br>10.367) |
| CD45+CD3+CD56+CD69+CD107-;<br>D15;S1; n=1,3,1,5,4,9 | 52.41 (±<br>99999) | 65.04 (±<br>6.660)  | 33.33 (±<br>99999) | 56.94 (±<br>9.081)  |

|   |                 |                  |                 |                   |
|---|-----------------|------------------|-----------------|-------------------|
| CD45+CD3+CD56+CD69+CD107-;<br>D15;S2;n=0,0,1,0,0,0  | 99999 (± 99999) | 99999 (± 99999)  | 5.45 (± 99999)  | 99999 (± 99999)   |
| CD45+CD3+CD56+CD69+CD107-;<br>D29; n=1,3,1,4,4,8    | 57.87 (± 99999) | 60.14 (± 4.928)  | 5.26 (± 99999)  | 53.70 (± 12.139)  |
| CD45+CD3+CD56+CD69+CD107-;<br>FU;n=1,2,0,3,1,4      | 57.35 (± 99999) | 56.28 (± 5.240)  | 99999 (± 99999) | 45.05 (± 22.028)  |
| CD45+CD3+CD56+CD69+CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (± 99999) | 99999 (± 99999)  | 56.41 (± 99999) | 99999 (± 99999)   |
| CD45+CD3+CD56+CD69-<br>CD107+;D1pre; n=1,3,1,5,4,9  | 0.00 (± 99999)  | 0.19 (± 0.163)   | 0.00 (± 99999)  | 0.84 (± 1.119)    |
| CD45+CD3+CD56+CD69-CD107+;D1;1<br>h;n=1,3,1,5,4,9   | 1.01 (± 99999)  | 0.30 (± 0.295)   | 0.00 (± 99999)  | 0.87 (± 1.493)    |
| CD45+CD3+CD56+CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11  | 0.00 (± 99999)  | 0.72 (± 0.806)   | 0.00 (± 99999)  | 0.77 (± 1.369)    |
| CD45+CD3+CD56+CD69-CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (± 99999) | 99999 (± 99999)  | 0.00 (± 99999)  | 0.16 (± 0.219)    |
| CD45+CD3+CD56+CD69-CD107+; D8;<br>n=1,3,0,5,4,8     | 2.43 (± 99999)  | 0.84 (± 0.716)   | 99999 (± 99999) | 0.37 (± 0.613)    |
| CD45+CD3+CD56+CD69-CD107+;<br>D15;S1;n=1,3,1,5,4,9  | 0.32 (± 99999)  | 0.17 (± 0.300)   | 0.00 (± 99999)  | 0.37 (± 0.288)    |
| CD45+CD3+CD56+CD69-<br>CD107+;D15;S2;n=0,0,1,0,0,0  | 99999 (± 99999) | 99999 (± 99999)  | 5.91 (± 99999)  | 99999 (± 99999)   |
| CD45+CD3+CD56+CD69-CD107+;<br>D29; n=1,3,1,4,4,8    | 0.53 (± 99999)  | 0.29 (± 0.409)   | 7.89 (± 99999)  | 0.57 (± 0.312)    |
| CD45+CD3+CD56+CD69-CD107+;<br>FU;n=1,2,0,3,1,4      | 0.00 (± 99999)  | 0.31 (± 0.085)   | 99999 (± 99999) | 0.98 (± 1.235)    |
| CD45+CD3+CD56+CD69-CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (± 99999) | 99999 (± 99999)  | 3.85 (± 99999)  | 99999 (± 99999)   |
| CD45+CD3+CD56+CD69-CD107-<br>;D1pre; n=1,3,1,5,4,9  | 37.20 (± 99999) | 21.98 (± 5.814)  | 15.38 (± 99999) | 23.11 (± 12.486)  |
| CD45+CD3+CD56+CD69-CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 27.78 (± 99999) | 21.78 (± 8.736)  | 0.00 (± 99999)  | 24.444 (± 11.410) |
| CD45+CD3+CD56+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 22.86 (± 99999) | 22.74 (± 11.250) | 0.00 (± 99999)  | 23.59 (± 9.836)   |
| CD45+CD3+CD56+CD69-CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (± 99999) | 99999 (± 99999)  | 10.00 (± 99999) | 20.34 (± 11.604)  |
| CD45+CD3+CD56+CD69-CD107-; D8;<br>n=1,3,0,5,4,8     | 27.21 (± 99999) | 19.75 (± 7.018)  | 99999 (± 99999) | 22.38 (± 7.709)   |
| CD45+CD3+CD56+CD69-CD107-;<br>D15;S1; n=1,3,1,5,4,9 | 23.15 (± 99999) | 18.56 (± 7.134)  | 0.00 (± 99999)  | 22.91 (± 9.852)   |
| CD45+CD3+CD56+CD69-CD107-<br>;D15;S2;n=0,0,1,0,0,0  | 99999 (± 99999) | 99999 (± 99999)  | 3.18 (± 99999)  | 99999 (± 99999)   |
| CD45+CD3+CD56+CD69-CD107-; D29;<br>n=1,3,1,4,4,8    | 22.93 (± 99999) | 15.25 (± 9.918)  | 0.00 (± 99999)  | 24.33 (± 5.914)   |
| CD45+CD3+CD56+CD69-CD107-;<br>FU;n=1,2,0,3,1,4      | 23.05 (± 99999) | 15.94 (± 2.892)  | 99999 (± 99999) | 22.09 (± 2.249)   |
| CD45+CD3+CD56+CD69-CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (± 99999) | 99999 (± 99999)  | 23.08 (± 99999) | 99999 (± 99999)   |
| CD45+CD3+CD8+CD69+;D1pre;<br>n=1,3,1,5,4,9          | 57.87 (± 99999) | 71.12 (± 1.083)  | 59.62 (± 99999) | 70.19 (± 9.089)   |
| CD45+CD3+CD8+CD69+;D1;1<br>h;n=1,3,1,5,4,9          | 54.45 (± 99999) | 66.55 (± 0.781)  | 66.67 (± 99999) | 68.39 (± 8.060)   |
| CD45+CD3+CD8+CD69+;D1;6<br>h;n=1,3,1,5,4,11         | 70.17 (± 99999) | 64.77 (± 2.867)  | 81.08 (± 99999) | 67.66 (± 7.411)   |
| CD45+CD3+CD8+CD69+; D2;<br>n=0,0,1,2,0,1            | 99999 (± 99999) | 99999 (± 99999)  | 71.67 (± 99999) | 77.60 (± 7.898)   |
| CD45+CD3+CD8+CD69+; D8;<br>n=1,3,0,5,4,8            | 63.60 (± 99999) | 65.38 (± 2.682)  | 99999 (± 99999) | 71.51 (± 5.945)   |
| CD45+CD3+CD8+CD69+; D15;S1;<br>n=1,3,1,5,4,9        | 66.21 (± 99999) | 70.12 (± 3.641)  | 67.74 (± 99999) | 72.11 (± 5.807)   |
| CD45+CD3+CD8+CD69+;<br>D15;S2;n=0,0,1,0,0,0         | 99999 (± 99999) | 99999 (± 99999)  | 69.60 (± 99999) | 99999 (± 99999)   |

|  |                    |                    |                    |                     |
|--|--------------------|--------------------|--------------------|---------------------|
| CD45+CD3+CD8+CD69+; D29;<br>n=1,3,1,4,4,8          | 68.47 (±<br>99999) | 72.13 (±<br>0.599) | 52.66 (±<br>99999) | 68.07 (±<br>4.666)  |
| CD45+CD3+CD8+CD69+;<br>FU;n=1,2,0,3,1,4            | 67.97 (±<br>99999) | 74.76 (±<br>3.903) | 99999 (±<br>99999) | 74.36 (±<br>3.927)  |
| CD45+CD3+CD8+CD69+;<br>USC;n=0,0,1,0,0,0           | 99999 (±<br>99999) | 99999 (±<br>99999) | 45.15 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD107+;D1pre;<br>n=1,3,1,5,4,9        | 9.25 (± 99999)     | 24.58 (±<br>6.553) | 17.31 (±<br>99999) | 24.38 (±<br>10.840) |
| CD45+CD3+CD8+CD107+;D1;1<br>h;n=1,3,1,5,4,9        | 11.02 (±<br>99999) | 21.64 (±<br>7.885) | 4.17 (± 99999)     | 24.87 (±<br>10.264) |
| CD45+CD3+CD8+CD107+;D1;6<br>h;n=1,3,1,5,4,11       | 13.88 (±<br>99999) | 22.21 (±<br>5.668) | 35.14 (±<br>99999) | 21.61 (±<br>12.241) |
| CD45+CD3+CD8+CD107+; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999) | 99999 (±<br>99999) | 25.00 (±<br>99999) | 17.03 (±<br>4.907)  |
| CD45+CD3+CD8+CD107+; D8;<br>n=1,3,0,5,4,8          | 37.70 (±<br>99999) | 19.18 (±<br>3.660) | 99999 (±<br>99999) | 24.12 (±<br>11.200) |
| CD45+CD3+CD8+CD107+; D15;<br>S1;n=1,3,1,5,4,9      | 20.58 (±<br>99999) | 11.59 (±<br>2.973) | 93.55 (±<br>99999) | 21.11 (±<br>14.964) |
| CD45+CD3+CD8+CD107+;<br>D15;S2;n=0,0,1,0,0,0       | 99999 (±<br>99999) | 99999 (±<br>99999) | 90.12 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD107+; D29;<br>n=1,3,1,4,4,8         | 44.48 (±<br>99999) | 18.53 (±<br>2.105) | 66.27 (±<br>99999) | 18.44 (±<br>12.685) |
| CD45+CD3+CD8+CD107+;<br>FU;n=1,2,0,3,1,4           | 21.17 (±<br>99999) | 23.00 (±<br>7.545) | 99999 (±<br>99999) | 34.50 (±<br>27.190) |
| CD45+CD3+CD8+CD107+;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999) | 99999 (±<br>99999) | 13.91 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD69+CD107+;D1pr<br>e; n=1,3,1,5,4,9  | 8.95 (± 99999)     | 23.82 (±<br>6.136) | 16.35 (±<br>99999) | 23.35 (±<br>10.595) |
| CD45+CD3+CD8+CD69+CD107+;D1;1<br>h;n=1,3,1,5,4,9   | 10.13 (±<br>99999) | 20.60 (±<br>7.232) | 4.17 (± 99999)     | 23.63 (±<br>10.069) |
| CD45+CD3+CD8+CD69+CD107+;D1;6<br>h;n=1,3,1,5,4,11  | 13.70 (±<br>99999) | 20.92 (±<br>4.681) | 35.14 (±<br>99999) | 20.61 (±<br>11.463) |
| CD45+CD3+CD8+CD69+CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999) | 99999 (±<br>99999) | 25.00 (±<br>99999) | 16.67 (±<br>4.391)  |
| CD45+CD3+CD8+CD69+CD107+; D8;<br>n=1,3,0,5,4,8     | 33.65 (±<br>99999) | 17.86 (±<br>1.989) | 99999 (±<br>99999) | 23.15 (±<br>10.176) |
| CD45+CD3+CD8+CD69+CD107+;<br>D15;S1; n=1,3,1,5,4,9 | 19.35 (±<br>99999) | 11.35 (±<br>2.815) | 64.52 (±<br>99999) | 20.62 (±<br>14.511) |
| CD45+CD3+CD8+CD69+CD107+;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999) | 66.74 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD69+CD107+; D29;<br>n=1,3,1,4,4,8    | 36.62 (±<br>99999) | 18.16 (±<br>2.172) | 44.97 (±<br>99999) | 17.79 (±<br>12.221) |
| CD45+CD3+CD8+CD69+CD107+;<br>FU;n=1,2,0,3,1,4      | 20.35 (±<br>99999) | 22.43 (±<br>7.177) | 99999 (±<br>99999) | 33.05 (±<br>25.896) |
| CD45+CD3+CD8+CD69+CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999) | 12.34 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD69+CD107-<br>;D1pre; n=1,3,1,5,4,9  | 48.92 (±<br>99999) | 47.30 (±<br>5.590) | 43.27 (±<br>99999) | 46.85 (±<br>9.558)  |
| CD45+CD3+CD8+CD69+CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 44.32 (±<br>99999) | 45.95 (±<br>6.784) | 62.50 (±<br>99999) | 44.76 (±<br>7.470)  |
| CD45+CD3+CD8+CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 56.47 (±<br>99999) | 43.85 (±<br>7.548) | 45.95 (±<br>99999) | 47.05 (±<br>7.908)  |
| CD45+CD3+CD8+CD69+CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999) | 99999 (±<br>99999) | 46.67 (±<br>99999) | 60.93 (±<br>12.282) |
| CD45+CD3+CD8+CD69+CD107-; D8;<br>n=1,3,0,5,4,8     | 29.96 (±<br>99999) | 47.53 (±<br>4.483) | 99999 (±<br>99999) | 48.36 (±<br>11.067) |
| CD45+CD3+CD8+CD69+CD107-; D15;<br>S1;n=1,3,1,5,4,9 | 46.86 (±<br>99999) | 58.77 (±<br>6.439) | 3.23 (± 99999)     | 51.49 (±<br>9.965)  |
| CD45+CD3+CD8+CD69+CD107-; D15;<br>S2;n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999) | 2.86 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD69+CD107-; D29;<br>n=1,3,1,4,4,8    | 31.86 (±<br>99999) | 53.96 (±<br>1.639) | 7.69 (± 99999)     | 50.28 (±<br>9.182)  |

|  |                    |                    |                    |                     |
|--|--------------------|--------------------|--------------------|---------------------|
| CD45+CD3+CD8+CD69+CD107-;<br>FU;n=1,2,0,3,1,4      | 47.63 (±<br>99999) | 52.34 (±<br>3.274) | 99999 (±<br>99999) | 41.31 (±<br>23.301) |
| CD45+CD3+CD8+CD69+CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999) | 32.81 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD69-<br>CD107+;D1pre; n=1,3,1,5,4,9  | 0.30 (± 99999)     | 0.76 (± 0.475)     | 0.96 (± 99999)     | 1.03 (± 1.228)      |
| CD45+CD3+CD8+CD69-CD107+;D1;1<br>h;n=1,3,1,5,4,9   | 0.89 (± 99999)     | 1.03 (± 0.683)     | 0.00 (± 99999)     | 1.24 (± 1.342)      |
| CD45+CD3+CD8+CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11  | 0.19 (± 99999)     | 1.30 (± 1.040)     | 0.00 (± 99999)     | 1.01 (± 1.572)      |
| CD45+CD3+CD8+CD69-CD107+; D8;<br>n=1,3,0,5,4,8     | 4.05 (± 99999)     | 1.32 (± 1.711)     | 99999 (±<br>99999) | 0.97 (± 1.172)      |
| CD45+CD3+CD8+CD69-CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999) | 99999 (±<br>99999) | 0.00 (± 99999)     | 0.37 (± 0.516)      |
| CD45+CD3+CD8+CD69-CD107+;<br>D15;S1;n=1,3,1,5,4,9  | 1.23 (± 99999)     | 0.24 (± 0.163)     | 29.03 (±<br>99999) | 0.48 (± 0.609)      |
| CD45+CD3+CD8+CD69-CD107+;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999) | 23.37 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD69-CD107+; D29;<br>n=1,3,1,4,4,8    | 7.87 (± 99999)     | 0.37 (± 0.078)     | 21.30 (±<br>99999) | 0.65 (± 0.554)      |
| CD45+CD3+CD8+CD69-CD107+;<br>FU;n=1,2,0,3,1,4      | 0.82 (± 99999)     | 0.58 (± 0.361)     | 99999 (±<br>99999) | 1.44 (± 1.298)      |
| CD45+CD3+CD8+CD69-CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999) | 1.57 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD69-CD107-;D1pre;<br>n=1,3,1,5,4,9   | 41.83 (±<br>99999) | 28.12 (±<br>1.219) | 39.42 (±<br>99999) | 28.78 (±<br>8.425)  |
| CD45+CD3+CD8+CD69-CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 44.65 (±<br>99999) | 32.42 (±<br>1.397) | 33.33 (±<br>99999) | 30.37 (±<br>7.516)  |
| CD45+CD3+CD8+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 29.64 (±<br>99999) | 33.94 (±<br>1.914) | 18.92 (±<br>99999) | 31.34 (±<br>7.255)  |
| CD45+CD3+CD8+CD69-CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999) | 99999 (±<br>99999) | 28.33 (±<br>99999) | 22.04 (±<br>7.382)  |
| CD45+CD3+CD8+CD69-CD107-; D8;<br>n=1,3,0,5,4,8     | 32.34 (±<br>99999) | 33.30 (±<br>2.044) | 99999 (±<br>99999) | 27.52 (±<br>6.239)  |
| CD45+CD3+CD8+CD69-CD107-;<br>D15;S1; n=1,3,1,5,4,9 | 32.56 (±<br>99999) | 29.64 (±<br>3.488) | 3.23 (± 99999)     | 27.41 (±<br>6.016)  |
| CD45+CD3+CD8+CD69-CD107-;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999) | 7.03 (± 99999)     | 99999 (±<br>99999)  |
| CD45+CD3+CD8+CD69-CD107-; D29;<br>n=1,3,1,4,4,8    | 23.66 (±<br>99999) | 27.50 (±<br>0.558) | 26.04 (±<br>99999) | 31.28 (±<br>4.954)  |
| CD45+CD3+CD8+CD69-CD107-;<br>FU;n=1,2,0,3,1,4      | 31.20 (±<br>99999) | 24.67 (±<br>4.264) | 99999 (±<br>99999) | 24.19 (±<br>5.014)  |
| CD45+CD3+CD8+CD69-CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999) | 53.28 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD69+;D1pre;<br>n=1,3,1,5,4,9             | 49.72 (±<br>99999) | 64.40 (±<br>2.410) | 61.84 (±<br>99999) | 64.96 (±<br>9.980)  |
| CD45+CD3+CD69+;D1;1<br>h;n=1,3,1,5,4,9             | 50.16 (±<br>99999) | 60.66 (±<br>4.707) | 67.16 (±<br>99999) | 63.58 (±<br>8.122)  |
| CD45+CD3+CD69+;D1;6<br>h;n=1,3,1,5,4,11            | 63.54 (±<br>99999) | 61.49 (±<br>3.426) | 80.00 (±<br>99999) | 62.24 (±<br>7.910)  |
| CD45+CD3+CD69+; D2; n=0,0,1,2,0,1                  | 99999 (±<br>99999) | 99999 (±<br>99999) | 68.61 (±<br>99999) | 69.01 (±<br>3.783)  |
| CD45+CD3+CD69+; D8; n=1,3,0,5,4,8                  | 58.04 (±<br>99999) | 59.29 (±<br>5.515) | 99999 (±<br>99999) | 64.97 (±<br>2.165)  |
| CD45+CD3+CD69+; D15;S1;<br>n=1,3,1,5,4,9           | 53.90 (±<br>99999) | 64.92 (±<br>4.016) | 72.73 (±<br>99999) | 65.08 (±<br>6.604)  |
| CD45+CD3+CD69+; D15;S2;<br>n=0,0,1,0,0,0           | 99999 (±<br>99999) | 99999 (±<br>99999) | 67.36 (±<br>99999) | 99999 (±<br>99999)  |
| CD45+CD3+CD69+; D29;<br>n=1,3,1,4,4,8              | 60.54 (±<br>99999) | 67.97 (±<br>4.090) | 52.79 (±<br>99999) | 61.52 (±<br>6.451)  |
| CD45+CD3+CD69+; FU;n=1,2,0,3,1,4                   | 54.72 (±<br>99999) | 68.87 (±<br>8.259) | 99999 (±<br>99999) | 68.45 (±<br>0.841)  |

|  |                 |                 |                 |                  |
|--|-----------------|-----------------|-----------------|------------------|
| CD45+CD3+CD69+; USC;n=0,0,1,0,0,0                | 99999 (± 99999) | 99999 (± 99999) | 42.30 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD107+; D1pre; n=1,3,1,5,4,9            | 3.28 (± 99999)  | 13.70 (± 6.236) | 11.66 (± 99999) | 13.13 (± 10.732) |
| CD45+CD3+CD107+; D1; 1 h;n=1,3,1,5,4,9           | 3.17 (± 99999)  | 12.63 (± 8.846) | 1.49 (± 99999)  | 12.84 (± 10.971) |
| CD45+CD3+CD107+; D1; 6 h;n=1,3,1,5,4,11          | 5.74 (± 99999)  | 11.98 (± 6.511) | 24.50 (± 99999) | 12.53 (± 10.804) |
| CD45+CD3+CD107+; D2; n=0,0,1,2,0,1               | 99999 (± 99999) | 99999 (± 99999) | 15.33 (± 99999) | 6.17 (± 2.397)   |
| CD45+CD3+CD107+; D8; n=1,3,0,5,4,8               | 19.48 (± 99999) | 9.93 (± 4.733)  | 99999 (± 99999) | 12.31 (± 7.851)  |
| CD45+CD3+CD107+; D15; S1; n=1,3,1,5,4,9          | 10.68 (± 99999) | 4.32 (± 2.680)  | 76.14 (± 99999) | 9.84 (± 7.608)   |
| CD45+CD3+CD107+; D15; S2; n=0,0,1,0,0,0          | 99999 (± 99999) | 99999 (± 99999) | 84.64 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD107+; D29; n=1,3,1,4,4,8              | 11.62 (± 99999) | 9.24 (± 3.455)  | 54.47 (± 99999) | 11.88 (± 12.246) |
| CD45+CD3+CD107+; FU;n=1,2,0,3,1,4                | 6.07 (± 99999)  | 11.19 (± 6.124) | 99999 (± 99999) | 27.28 (± 11.058) |
| CD45+CD3+CD107+; USC;n=0,0,1,0,0,0               | 99999 (± 99999) | 99999 (± 99999) | 11.62 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD69+CD107+; D1pre; n=1,3,1,5,4,9       | 3.22 (± 99999)  | 13.33 (± 5.965) | 11.31 (± 99999) | 12.68 (± 10.738) |
| CD45+CD3+CD69+CD107+; D1; 1 h;n=1,3,1,5,4,9      | 3.04 (± 99999)  | 12.15 (± 8.408) | 1.49 (± 99999)  | 12.33 (± 10.922) |
| CD45+CD3+CD69+CD107+; D1; 6 h;n=1,3,1,5,4,11     | 5.63 (± 99999)  | 11.29 (± 5.756) | 24.50 (± 99999) | 12.00 (± 10.573) |
| CD45+CD3+CD69+CD107+; D2; n=0,0,1,2,0,1          | 99999 (± 99999) | 99999 (± 99999) | 15.33 (± 99999) | 6.02 (± 2.220)   |
| CD45+CD3+CD69+CD107+; D8; n=1,3,0,5,4,8          | 17.91 (± 99999) | 9.29 (± 3.881)  | 99999 (± 99999) | 11.95 (± 7.603)  |
| CD45+CD3+CD69+CD107+; D15; S1 ; n=1,3,1,5,4,9    | 9.81 (± 99999)  | 4.25 (± 2.622)  | 62.5 (± 99999)  | 9.63 (± 7.568)   |
| CD45+CD3+CD69+CD107+; D15; S2; n=0,0,1,0,0,0     | 99999 (± 99999) | 99999 (± 99999) | 61.21 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD69+CD107+; D29; n=1,3,1,4,4,8         | 10.28 (± 99999) | 9.07 (± 3.421)  | 40.50 (± 99999) | 11.47 (± 11.821) |
| CD45+CD3+CD69+CD107+; FU;n=1,2,0,3,1,4           | 5.92 (± 99999)  | 10.98 (± 5.961) | 99999 (± 99999) | 26.15 (± 10.446) |
| CD45+CD3+CD69+CD107+; USC;n=0,0,1,0,0,0          | 99999 (± 99999) | 99999 (± 99999) | 10.47 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD69+CD107-; D1pre; n=1,3,1,5,4,9       | 46.49 (± 99999) | 51.06 (± 3.578) | 50.53 (± 99999) | 52.28 (± 8.029)  |
| CD45+CD3+CD69+CD107-; D1; 1 h;n=1,3,1,5,4,9      | 47.13 (± 99999) | 48.51 (± 4.092) | 65.67 (± 99999) | 51.25 (± 7.800)  |
| CD45+CD3+CD69+CD107-; D1; 6 h;n=1,3,1,5,4,11     | 57.91 (± 99999) | 50.20 (± 6.989) | 55.50 (± 99999) | 50.24 (± 5.794)  |
| CD45+CD3+CD69+CD107-; D2; n=0,0,1,2,0,1          | 99999 (± 99999) | 99999 (± 99999) | 53.28 (± 99999) | 62.99 (± 6.003)  |
| CD45+CD3+CD69+CD107-; D8; n=1,3,0,5,4,8          | 40.13 (± 99999) | 50.00 (± 5.550) | 99999 (± 99999) | 53.02 (± 7.641)  |
| CD45+CD3+CD69+CD107-; D15; S1; n=1,3,1,5,4,9     | 44.09 (± 99999) | 60.67 (± 5.732) | 10.23 (± 99999) | 55.45 (± 4.502)  |
| CD45+CD3+CD69+CD107-; D15; S2;n=0, 0, 1, 0, 0, 0 | 99999 (± 99999) | 99999 (± 99999) | 6.15 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3+CD69+CD107-; D29; n=1,3,1,4,4,8         | 50.26 (± 99999) | 58.89 (± 0.756) | 12.29 (± 99999) | 50.05 (± 6.415)  |
| CD45+CD3+CD69+CD107-; FU;n=1,2,0,3,1,4           | 48.79 (± 99999) | 57.90 (± 2.298) | 99999 (± 99999) | 42.29 (± 9.606)  |
| CD45+CD3+CD69+CD107-; USC;n=0,0,1,0,0,0          | 99999 (± 99999) | 99999 (± 99999) | 31.83 (± 99999) | 99999 (± 99999)  |

|   |                    |                    |                    |                    |
|---|--------------------|--------------------|--------------------|--------------------|
| CD45+CD3+CD69-CD107+;D1pre;<br>n=1,3,1,5,4,9    | 0.06 (± 99999)     | 0.36 (± 0.277)     | 0.35 (± 99999)     | 0.45 (± 0.579)     |
| CD45+CD3+CD69-CD107+;D1;1<br>h;n=1,3,1,5,4,9    | 0.13 (± 99999)     | 0.47 (± 0.451)     | 0.00 (± 99999)     | 0.50 (± 0.615)     |
| CD45+CD3+CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11   | 0.11 (± 99999)     | 0.69 (± 0.777)     | 0.00 (± 99999)     | 0.54 (± 0.844)     |
| CD45+CD3+CD69-CD107+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999) | 0.00 (± 99999)     | 0.15 (± 0.177)     |
| CD45+CD3+CD69-CD107+; D8;<br>n=1,3,0,5,4,8      | 1.57 (± 99999)     | 0.64 (± 0.861)     | 99999 (±<br>99999) | 0.35 (± 3.392)     |
| CD45+CD3+CD69-CD107+; D15; S1;<br>n=1,3,1,5,4,9 | 0.86 (± 99999)     | 0.07 (± 0.059)     | 13.64 (±<br>99999) | 0.21 (± 0.187)     |
| CD45+CD3+CD69-CD107+; D15;S2;<br>n=0,0,1,0,0,0  | 99999 (±<br>99999) | 99999 (±<br>99999) | 23.43 (±<br>99999) | 99999 (±<br>99999) |
| CD45+CD3+CD69-CD107+; D29;<br>n=1,3,1,4,4,8     | 1.34 (± 99999)     | 0.17 (± 0.042)     | 13.97 (±<br>99999) | 0.41 (± 0.476)     |
| CD45+CD3+CD69-CD107+;<br>FU;n=1,2,0,3,1,4       | 0.15 (± 99999)     | 0.23 (± 0.163)     | 99999 (±<br>99999) | 1.13 (± 0.705)     |
| CD45+CD3+CD69-CD107+;<br>USC;n=0,0,1,0,0,0      | 99999 (±<br>99999) | 99999 (±<br>99999) | 1.16 (± 99999)     | 99999 (±<br>99999) |
| CD45+CD3+CD69-CD107-;D1pre;<br>n=1,3,1,5,4,9    | 50.23 (±<br>99999) | 35.23 (±<br>2.664) | 37.81 (±<br>99999) | 34.58 (±<br>9.638) |
| CD45+CD3+CD69-CD107-;D1;1<br>h;n=1,3,1,5,4,9    | 49.71 (±<br>99999) | 38.87 (±<br>5.156) | 32.84 (±<br>99999) | 35.91 (±<br>7.854) |
| CD45+CD3+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11   | 36.35 (±<br>99999) | 37.83 (±<br>3.625) | 20.00 (±<br>99999) | 37.23 (±<br>7.810) |
| CD45+CD3+CD69-CD107-; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999) | 31.39 (±<br>99999) | 30.85 (±<br>3.606) |
| CD45+CD3+CD69-CD107-; D8;<br>n=1,3,0,5,4,8      | 40.39 (±<br>99999) | 40.07 (±<br>5.758) | 99999 (±<br>99999) | 34.67 (±<br>2.320) |
| CD45+CD3+CD69-CD107-; D15;S1;<br>n=1,3,1,5,4,9  | 45.24 (±<br>99999) | 35.01 (±<br>3.981) | 13.64 (±<br>99999) | 34.71 (±<br>6.524) |
| CD45+CD3+CD69-CD107-; D15;<br>S2;n=0,0,1,0,0,0  | 99999 (±<br>99999) | 99999 (±<br>99999) | 9.2 (± 99999)      | 99999 (±<br>99999) |
| CD45+CD3+CD69-CD107-; D29;<br>n=1,3,1,4,4,8     | 38.12 (±<br>99999) | 31.87 (±<br>4.127) | 33.24 (±<br>99999) | 38.07 (±<br>6.801) |
| CD45+CD3+CD69-CD107-;<br>FU;n=1,2,0,3,1,4       | 45.14 (±<br>99999) | 30.91 (±<br>8.422) | 99999 (±<br>99999) | 30.43 (±<br>1.483) |
| CD45+CD3+CD69-CD107-;<br>USC;n=0,0,1,0,0,0      | 99999 (±<br>99999) | 99999 (±<br>99999) | 56.55 (±<br>99999) | 99999 (±<br>99999) |
| CD45+CD3+CD8-CD69+;D1pre;<br>n=1,3,1,5,4,9      | 47.90 (±<br>99999) | 61.18 (±<br>3.198) | 63.79 (±<br>99999) | 60.39 (±<br>9.372) |
| CD45+CD3+CD8-CD69+;D1;1<br>h;n=1,3,1,5,4,9      | 49.15 (±<br>99999) | 58.34 (±<br>5.829) | 67.19 (±<br>99999) | 60.93 (±<br>7.196) |
| CD45+CD3+CD8-CD69+;D1;6<br>h;n=1,3,1,5,4,11     | 62.61 (±<br>99999) | 60.24 (±<br>3.832) | 77.59 (±<br>99999) | 58.97 (±<br>6.452) |
| CD45+CD3+CD8-CD69+; D2;<br>n=0,0,1,2,0,1        | 99999 (±<br>99999) | 99999 (±<br>99999) | 67.11 (±<br>99999) | 63.36 (±<br>5.169) |
| CD45+CD3+CD8-CD69+; D8;<br>n=1,3,0,5,4,8        | 57.28 (±<br>99999) | 56.36 (±<br>7.227) | 99999 (±<br>99999) | 61.41 (±<br>3.385) |
| CD45+CD3+CD8-CD69+; D15;<br>S1;n=1,3,1,5,4,9    | 47.62 (±<br>99999) | 64.16 (±<br>6.272) | 75.86 (±<br>99999) | 61.57 (±<br>4.769) |
| CD45+CD3+CD8-CD69+; D15;<br>S2;n=0,0,1,0,0,0    | 99999 (±<br>99999) | 99999 (±<br>99999) | 66.87 (±<br>99999) | 99999 (±<br>99999) |
| CD45+CD3+CD8-CD69+; D29;<br>n=1,3,1,4,4,8       | 59.17 (±<br>99999) | 66.23 (±<br>5.538) | 54.82 (±<br>99999) | 57.72 (±<br>3.694) |
| CD45+CD3+CD8-CD69+;<br>FU;n=1,2,0,3,1,4         | 52.89 (±<br>99999) | 65.54 (±<br>8.811) | 99999 (±<br>99999) | 62.68 (±<br>3.581) |
| CD45+CD3+CD8-CD69+;<br>USC;n=0,0,1,0,0,0        | 99999 (±<br>99999) | 99999 (±<br>99999) | 41.04 (±<br>99999) | 99999 (±<br>99999) |
| CD45+CD3+CD8-CD107+;D1pre;<br>n=1,3,1,5,4,9     | 1.89 (± 99999)     | 8.52 (± 6.264)     | 8.62 (± 99999)     | 9.13 (± 7.030)     |

|  |                 |                  |                 |                  |
|--|-----------------|------------------|-----------------|------------------|
| CD45+CD3+CD8-CD107+;D1;1<br>h;n=1,3,1,5,4,9        | 2.05 (± 99999)  | 9.13 (± 9.350)   | 0.00 (± 99999)  | 8.77 (± 6.304)   |
| CD45+CD3+CD8-CD107+;D1;6<br>h;n=1,3,1,5,4,11       | 4.79 (± 99999)  | 8.43 (± 6.165)   | 14.66 (± 99999) | 10.25 (± 7.708)  |
| CD45+CD3+CD8-CD107+; D2;<br>n=0,0,1,2,0,1          | 99999 (± 99999) | 99999 (± 99999)  | 7.89 (± 99999)  | 22.06 (± 12.183) |
| CD45+CD3+CD8-CD107+; D8;<br>n=1,3,0,5,4,8          | 16.59 (± 99999) | 5.43 (± 4.942)   | 99999 (± 99999) | 8.44 (± 5.762)   |
| CD45+CD3+CD8-CD107+; D15;<br>S1;n=1,3,1,5,4,9      | 8.04 (± 99999)  | 4.31 (± 2.868)   | 67.24 (± 99999) | 7.32 (± 4.700)   |
| CD45+CD3+CD8-CD107+; D15;S2;<br>n=0,0,1,0,0,0      | 99999 (± 99999) | 99999 (± 99999)  | 79.79 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD8-CD107+; D29;<br>n=1,3,1,4,4,8         | 6.04 (± 99999)  | 5.33 (± 3.967)   | 45.69 (± 99999) | 7.99 (± 2.600)   |
| CD45+CD3+CD8-CD107+;<br>FU;n=1,2,0,3,1,4           | 3.99 (± 99999)  | 12.22 (± 14.015) | 99999 (± 99999) | 16.79 (± 8.978)  |
| CD45+CD3+CD8-CD107+;<br>USC;n=0,0,1,0,0,0          | 99999 (± 99999) | 99999 (± 99999)  | 10.62 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD8-<br>CD69+CD107+;D1pre; n=1,3,1,5,4,9  | 1.88 (± 99999)  | 8.34 (± 6.086)   | 8.62 (± 99999)  | 8.66 (± 6.705)   |
| CD45+CD3+CD8-CD69+CD107+;D1;1<br>h;n=1,3,1,5,4,9   | 2.03 (± 99999)  | 8.84 (± 8.957)   | 0.00 (± 99999)  | 8.39 (± 6.132)   |
| CD45+CD3+CD8-CD69+CD107+;D1;6<br>h;n=1,3,1,5,4,11  | 4.69 (± 99999)  | 7.99 (± 5.509)   | 14.66 (± 99999) | 9.81 (± 7.518)   |
| CD45+CD3+CD8-CD69+CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (± 99999) | 99999 (± 99999)  | 7.89 (± 99999)  | 20.45 (± 10.684) |
| CD45+CD3+CD8-CD69+CD107+; D8;<br>n=1,3,0,5,4,8     | 15.40 (± 99999) | 5.16 (± 4.542)   | 99999 (± 99999) | 8.22 (± 5.569)   |
| CD45+CD3+CD8-CD69+CD107+; D15;<br>S1;n=1,3,1,5,4,9 | 7.37 (± 99999)  | 4.28 (± 2.851)   | 62.07 (± 99999) | 7.09 (± 4.543)   |
| CD45+CD3+CD8-CD69+CD107+;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (± 99999) | 99999 (± 99999)  | 58.06 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD8-CD69+CD107+; D29;<br>n=1,3,1,4,4,8    | 5.81 (± 99999)  | 5.26 (± 3.913)   | 38.58 (± 99999) | 7.39 (± 1.938)   |
| CD45+CD3+CD8-CD69+CD107+;<br>FU;n=1,2,0,3,1,4      | 3.94 (± 99999)  | 11.93 (± 13.598) | 99999 (± 99999) | 16.09 (± 8.306)  |
| CD45+CD3+CD8-CD69+CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (± 99999) | 99999 (± 99999)  | 9.71 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3+CD8-CD69+CD107-;D1pre;<br>n=1,3,1,5,4,9   | 46.02 (± 99999) | 52.84 (± 2.952)  | 55.17 (± 99999) | 51.72 (± 7.637)  |
| CD45+CD3+CD8-CD69+CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 47.12 (± 99999) | 49.48 (± 3.288)  | 67.19 (± 99999) | 52.53 (± 6.408)  |
| CD45+CD3+CD8-CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 57.92 (± 99999) | 52.25 (± 6.443)  | 62.93 (± 99999) | 49.16 (± 4.649)  |
| CD45+CD3+CD8-CD69+CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (± 99999) | 99999 (± 99999)  | 59.21 (± 99999) | 42.91 (± 5.515)  |
| CD45+CD3+CD8-CD69+CD107-; D8;<br>n=1,3,0,5,4,8     | 41.88 (± 99999) | 51.21 (± 6.451)  | 99999 (± 99999) | 53.19 (± 5.196)  |
| CD45+CD3+CD8-CD69+CD107-;<br>D15;S1; n=1,3,1,5,4,9 | 40.25 (± 99999) | 59.88 (± 3.546)  | 13.79 (± 99999) | 54.48 (± 6.572)  |
| CD45+CD3+CD8-CD69+CD107-;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (± 99999) | 99999 (± 99999)  | 8.81 (± 99999)  | 99999 (± 99999)  |
| CD45+CD3+CD8-CD69+CD107-; D29;<br>n=1,3,1,4,4,8    | 53.36 (± 99999) | 60.98 (± 1.681)  | 16.24 (± 99999) | 50.33 (± 5.623)  |
| CD45+CD3+CD8-CD69+CD107-;<br>FU;n=1,2,0,3,1,4      | 48.95 (± 99999) | 53.62 (± 4.794)  | 99999 (± 99999) | 46.59 (± 4.968)  |
| CD45+CD3+CD8-CD69+CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (± 99999) | 99999 (± 99999)  | 31.33 (± 99999) | 99999 (± 99999)  |
| CD45+CD3+CD8-CD69-CD107+;D1pre;<br>n=1,3,1,5,4,9   | 0.01 (± 99999)  | 0.17 (± 0.180)   | 0.00 (± 99999)  | 0.47 (± 0.607)   |
| CD45+CD3+CD8-CD69-CD107+;D1;1<br>h;n=1,3,1,5,4,9   | 0.03 (± 99999)  | 0.27 (± 0.414)   | 0.00 (± 99999)  | 0.38 (± 0.526)   |

|  |                    |                     |                     |                    |
|--|--------------------|---------------------|---------------------|--------------------|
| CD45+CD3+CD8-CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11  | 0.11 (± 99999)     | 0.44 (± 0.691)      | 0.00 (± 99999)      | 0.44 (± 0.695)     |
| CD45+CD3+CD8-CD69-CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 0.00 (± 99999)      | 1.62 (± 1.492)     |
| CD45+CD3+CD8-CD69-CD107+; D8;<br>n=1,3,0,5,4,8     | 1.19 (± 99999)     | 0.27 (± 0.406)      | 99999 (±<br>99999)  | 0.22 (± 0.239)     |
| CD45+CD3+CD8-CD69-CD107+;<br>D15;S1; n=1,3,1,5,4,9 | 0.66 (± 99999)     | 0.02 (± 0.020)      | 5.17 (± 99999)      | 0.23 (± 0.217)     |
| CD45+CD3+CD8-CD69-CD107+;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 21.74 (±<br>99999)  | 99999 (±<br>99999) |
| CD45+CD3+CD8-CD69-CD107+; D29;<br>n=1,3,1,4,4,8    | 0.24 (± 99999)     | 0.08 (± 0.057)      | 7.11 (± 99999)      | 0.60 (± 0.787)     |
| CD45+CD3+CD8-CD69-CD107+;<br>FU;n=1,2,0,3,1,4      | 0.05 (± 99999)     | 0.30 (± 0.417)      | 99999 (±<br>99999)  | 0.70 (± 0.729)     |
| CD45+CD3+CD8-CD69-CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 0.91 (± 99999)      | 99999 (±<br>99999) |
| CD45+CD3+CD8-CD69-CD107-;D1pre;<br>n=1,3,1,5,4,9   | 52.08 (±<br>99999) | 38.64 (±<br>3.370)  | 36.21 (±<br>99999)  | 39.14 (±<br>9.186) |
| CD45+CD3+CD8-CD69-CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 50.83 (±<br>99999) | 41.39 (±<br>6.239)  | 32.81 (±<br>99999)  | 38.69 (±<br>6.983) |
| CD45+CD3+CD8-CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 37.28 (±<br>99999) | 39.32 (±<br>4.165)  | 22.41 (±<br>99999)  | 40.59 (±<br>6.401) |
| CD45+CD3+CD8-CD69-CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 32.89 (±<br>99999)  | 35.03 (±<br>6.661) |
| CD45+CD3+CD8-CD69-CD107-; D8;<br>n=1,3,0,5,4,8     | 41.53 (±<br>99999) | 43.36 (±<br>7.367)  | 99999 (±<br>99999)  | 38.37 (±<br>3.532) |
| CD45+CD3+CD8-CD69-CD107-;<br>D15;S1;n=1,3,1,5,4,9  | 51.72 (±<br>99999) | 35.82 (±<br>6.285)  | 18.97 (±<br>99999)  | 38.20 (±<br>4.657) |
| CD45+CD3+CD8-CD69-CD107-;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999)  | 11.4 (± 99999)      | 99999 (±<br>99999) |
| CD45+CD3+CD8-CD69-CD107-; D29;<br>n=1,3,1,4,4,8    | 40.59 (±<br>99999) | 33.69 (±<br>5.590)  | 38.07 (±<br>99999)  | 41.69 (±<br>3.048) |
| CD45+CD3+CD8-CD69-CD107-;<br>FU;n=1,2,0,3,1,4      | 47.06 (±<br>99999) | 34.17 (±<br>9.228)  | 99999 (±<br>99999)  | 36.61 (±<br>4.300) |
| CD45+CD3+CD8-CD69-CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999) | 99999 (±<br>99999)  | 58.05 (±<br>99999)  | 99999 (±<br>99999) |
| CD45+CD3-CD19+CD69+;D1pre;<br>n=1,3,1,5,4,9        | 75.76 (±<br>99999) | 67.04 (±<br>8.518)  | 84.75 (±<br>99999)  | 70.41 (±<br>7.715) |
| CD45+CD3-CD19+CD69+;D1;1<br>h;n=1,3,1,5,4,9        | 80.05 (±<br>99999) | 66.03 (±<br>12.856) | 100.00 (±<br>99999) | 72.80 (±<br>9.542) |
| CD45+CD3-CD19+CD69+;D1;6<br>h;n=1,3,1,5,4,11       | 78.69 (±<br>99999) | 69.97 (±<br>8.412)  | 84.21 (±<br>99999)  | 68.55 (±<br>5.810) |
| CD45+CD3-CD19+CD69+; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999) | 99999 (±<br>99999)  | 100.00 (±<br>99999) | 71.53 (±<br>0.721) |
| CD45+CD3-CD19+CD69+; D8;<br>n=1,3,0,5,4,8          | 72.44 (±<br>99999) | 62.85 (±<br>5.952)  | 99999 (±<br>99999)  | 70.60 (±<br>5.653) |
| CD45+CD3-CD19+CD69+; D15;S1;<br>n=1,3,1,5,4,9      | 71.85 (±<br>99999) | 64.28 (±<br>7.449)  | 89.47 (±<br>99999)  | 70.07 (±<br>6.942) |
| CD45+CD3-CD19+CD69+;<br>D15;S2;n=0,0,1,0,0,0       | 99999 (±<br>99999) | 99999 (±<br>99999)  | 85.95 (±<br>99999)  | 99999 (±<br>99999) |
| CD45+CD3-CD19+CD69+; D29;<br>n=1,3,1,4,4,8         | 74.65 (±<br>99999) | 72.22 (±<br>17.828) | 66.18 (±<br>99999)  | 68.83 (±<br>5.767) |
| CD45+CD3-CD19+CD69+;<br>FU;n=1,2,0,3,1,4           | 74.67 (±<br>99999) | 68.44 (±<br>5.268)  | 99999 (±<br>99999)  | 73.60 (±<br>7.363) |
| CD45+CD3-CD19+CD69+;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999) | 99999 (±<br>99999)  | 60.00 (±<br>99999)  | 99999 (±<br>99999) |
| CD45+CD14+CD69+;D1pre;<br>n=1,3,1,5,4,9            | 99.66 (±<br>99999) | 99.57 (±<br>0.371)  | 100.00 (±<br>99999) | 99.27 (±<br>0.308) |
| CD45+CD14+CD69+;D1;1<br>h;n=1,3,1,5,4,9            | 99.86 (±<br>99999) | 99.54 (±<br>0.204)  | 99.55 (±<br>99999)  | 99.42 (±<br>0.202) |
| CD45+CD14+CD69+;D1;6<br>h;n=1,3,1,5,4,11           | 99.45 (±<br>99999) | 99.19 (±<br>0.239)  | 99.78 (±<br>99999)  | 99.28 (±<br>0.393) |



|  |                    |                    |                     |                    |
|--|--------------------|--------------------|---------------------|--------------------|
| CD45+CD14+CD69+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999) | 99999 (±<br>99999) | 100.00 (±<br>99999) | 99.16 (±<br>1.018) |
| CD45+CD14+CD69+; D8;<br>n=1,3,0,5,4,8      | 99.41 (±<br>99999) | 99.49 (±<br>0.297) | 99999 (±<br>99999)  | 99.15 (±<br>0.763) |
| CD45+CD14+CD69+; D15; S1;<br>n=1,3,1,5,4,9 | 99.37 (±<br>99999) | 99.70 (±<br>0.145) | 100.00 (±<br>99999) | 99.71 (±<br>0.311) |
| CD45+CD14+CD69+; D15; S2;<br>n=0,0,1,0,0,0 | 99999 (±<br>99999) | 99999 (±<br>99999) | 99.74 (±<br>99999)  | 99999 (±<br>99999) |
| CD45+CD14+CD69+; D29;<br>n=1,3,1,4,4,8     | 99.66 (±<br>99999) | 99.61 (±<br>0.391) | 98.85 (±<br>99999)  | 99.53 (±<br>0.379) |
| CD45+CD14+CD69+; FU;n=1,2,0,3,1,4          | 99.71 (±<br>99999) | 99.66 (±<br>0.028) | 99999 (±<br>99999)  | 99.62 (±<br>0.219) |
| CD45+CD14+CD69+;<br>USC;n=0,0,1,0,0,0      | 99999 (±<br>99999) | 99999 (±<br>99999) | 96.17 (±<br>99999)  | 99999 (±<br>99999) |

Notes:

[106] - PD Population

[107] - PD Population

[108] - PD Population

[109] - PD Population

| End point values                             | GSK2849330<br>30 mg/kg<br>every 2 weeks | GSK2849330<br>30 mg/kg<br>weekly |  |  |
|--|---|----------------------------------|--|--|
| Subject group type                           | Reporting group                         | Reporting group                  |  |  |
| Number of subjects analysed                  | 4 <sup>[110]</sup>                      | 12 <sup>[111]</sup>              |  |  |
| Units: Percentage of CD marker cells         |   |                                  |  |  |
| arithmetic mean (standard deviation)         |   |                                  |  |  |
| CD45+; D1; pre; n=1, 3, 1, 5, 4, 9           | 99.93 (±<br>0.050)                      | 101.57 (±<br>6.268)              |  |  |
| CD45+; D1; 1 h; n=1, 3, 1, 5, 4, 9           | 99.93 (±<br>0.050)                      | 101.13 (±<br>4.656)              |  |  |
| CD45+; D1; 6 h; n=1, 3, 1, 5, 4, 11          | 99.93 (±<br>0.096)                      | 101.02 (±<br>3.978)              |  |  |
| CD45+; D2; n=0, 0, 1, 2, 0, 1                | 99999 (±<br>99999)                      | 99.80 (±<br>99999)               |  |  |
| CD45+; D8; n=1, 3, 0, 5, 4, 8                | 99.80 (±<br>0.400)                      | 99.75 (±<br>0.576)               |  |  |
| CD45+; D15;S1; n=1, 3, 1, 5, 4, 9            | 99.78 (±<br>0.320)                      | 100.33 (±<br>2.495)              |  |  |
| CD45+; D15; S2; n=0,0,1,0,0,0                | 99999 (±<br>99999)                      | 99999 (±<br>99999)               |  |  |
| CD45+; D29; n=1, 3, 1, 4, 4, 8               | 99.75 (±<br>0.436)                      | 100.80 (±<br>3.746)              |  |  |
| CD45+; follow-up (FU); n=1, 2, 0, 3, 1, 4    | 99.30 (±<br>99999)                      | 101.60 (±<br>4.827)              |  |  |
| CD45+; unscheduled (USC); n=0, 0, 1, 0, 0, 0 | 99999 (±<br>99999)                      | 99999 (±<br>99999)               |  |  |
| CD45+CD3+; D1; pre;n=1, 3, 1, 5, 4, 9        | 71.98 (±<br>10.832)                     | 72.91 (±<br>8.027)               |  |  |
| CD45+CD3+; D1; 1 h; n=1, 3, 1, 5, 4, 9       | 75.80 (±<br>6.933)                      | 74.36 (±<br>9.552)               |  |  |
| CD45+CD3+; D1; 6 h; n=1, 3, 1, 5, 4, 11      | 77.83 (±<br>5.065)                      | 72.16 (±<br>10.282)              |  |  |
| CD45+CD3+; D2; n=0, 0, 1, 2, 0, 1            | 99999 (±<br>99999)                      | 77.00 (±<br>99999)               |  |  |
| CD45+CD3+; D8; n=1, 3, 0, 5, 4, 8            | 77.53 (±<br>7.566)                      | 75.31 (±<br>8.234)               |  |  |
| CD45+CD3+; D15; S1; n=1, 3, 1, 5, 4, 9       | 76.08 (±<br>8.844)                      | 76.50 (±<br>5.723)               |  |  |

|  |                  |                  |  |  |
|--|------------------|------------------|--|--|
| CD45+CD3+; D15; S2; n=0,0,1,0,0,0            | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+; D29; n=1, 3, 1, 4, 4, 8           | 73.58 (± 9.783)  | 74.49 (± 12.798) |  |  |
| CD45+CD3+; FU; n=1, 2, 0, 3, 1, 4            | 42.50 (± 99999)  | 70.13 (± 11.425) |  |  |
| CD45+CD3+; USC; n=0, 0, 1, 0, 0, 0           | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD8+; D1; pre; n=1, 3, 1, 5, 4, 9   | 24.95 (± 13.644) | 25.39 (± 11.076) |  |  |
| CD45+CD3+CD8+; D1; 1 h; n=1, 3, 1, 5, 4, 9   | 20.48 (± 10.935) | 23.18 (± 10.434) |  |  |
| CD45+CD3+CD8+; D1; 6 h; n=1, 3, 1, 5, 4, 11  | 23.38 (± 11.738) | 22.86 (± 11.701) |  |  |
| CD45+CD3+CD8+; D2; n=0, 0, 1, 2, 0, 1        | 99999 (± 99999)  | 40.60 (± 99999)  |  |  |
| CD45+CD3+CD8+; D8; n=1, 3, 0, 5, 4, 8        | 24.60 (± 12.511) | 23.76 (± 9.382)  |  |  |
| CD45+CD3+CD8+; D15; S1; n=1, 3, 1, 5, 4, 9   | 26.25 (± 13.843) | 27.00 (± 11.668) |  |  |
| CD45+CD3+CD8+; D15; S2; n=0,0,1,0,0,0        | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD8+; D29; n=1, 3, 1, 4, 4, 8       | 23.05 (± 11.997) | 20.40 (± 13.234) |  |  |
| CD45+CD3+CD8+; FU; n=1, 2, 0, 3, 1, 4        | 6.30 (± 99999)   | 31.88 (± 4.661)  |  |  |
| CD45+CD3+CD8+; USC; n=0, 0, 1, 0, 0, 0       | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD8-; D1; pre n=1, 3, 1, 5, 4, 9    | 45.58 (± 4.365)  | 47.71 (± 14.059) |  |  |
| CD45+CD3+CD8-; D1; 1 h; n=1, 3, 1, 5, 4, 9   | 53.90 (± 6.349)  | 51.10 (± 17.633) |  |  |
| CD45+CD3+CD8-; D1; 6 h; n=1, 3, 1, 5, 4, 11  | 53.28 (± 10.943) | 49.26 (± 17.654) |  |  |
| CD45+CD3+CD8-; D2; n=0, 0, 1, 2, 0, 1        | 99999 (± 99999)  | 36.60 (± 99999)  |  |  |
| CD45+CD3+CD8-; D8; n=1, 3, 0, 5, 4, 8        | 51.70 (± 11.040) | 51.48 (± 8.065)  |  |  |
| CD45+CD3+CD8-; D15; S1; n=1, 3, 1, 5, 4, 9   | 49.60 (± 9.910)  | 49.08 (± 13.029) |  |  |
| CD45+CD3+CD8-; D15; S2; n=0,0,1,0,0,0        | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD8-; D29; n=1, 3, 1, 4, 4, 8       | 50.43 (± 3.402)  | 54.63 (± 13.806) |  |  |
| CD45+CD3+CD8-; FU; n=1, 2, 0, 3, 1, 4        | 36.90 (± 99999)  | 37.53 (± 16.020) |  |  |
| CD45+CD3+CD8-; USC; n=0, 0, 1, 0, 0, 0       | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3-CD16+; D1; pre n=1, 3, 1, 5, 4, 9   | 13.83 (± 12.467) | 10.63 (± 8.253)  |  |  |
| CD45+CD3-CD16+; D1; 1 h; n=1, 3, 1, 5, 4, 9  | 8.00 (± 8.198)   | 8.90 (± 6.203)   |  |  |
| CD45+CD3-CD16+; D1; 6 h; n=1, 3, 1, 5, 4, 11 | 6.43 (± 4.407)   | 7.44 (± 4.569)   |  |  |
| CD45+CD3-CD16+; D2; n=0, 0, 1, 2, 0, 1       | 99999 (± 99999)  | 4.10 (± 99999)   |  |  |
| CD45+CD3-CD16+; D8; n=1, 3, 0, 5, 4, 8       | 9.23 (± 5.762)   | 11.23 (± 7.852)  |  |  |
| CD45+CD3-CD16+; D15; S1; n=1, 3, 1, 5, 4, 9  | 9.50 (± 6.470)   | 10.33 (± 7.555)  |  |  |
| CD45+CD3-CD16+; D15; S2; n=0,0,1,0,0,0       | 99999 (± 99999)  | 99999 (± 99999)  |  |  |

|  |                  |                  |  |  |
|--|------------------|------------------|--|--|
| CD45+CD3-CD16+; D29; n=1, 3, 1, 4, 4, 8          | 10.73 (± 9.999)  | 11.93 (± 7.323)  |  |  |
| CD45+CD3-CD16+; FU; n=1, 2, 0, 3, 1, 4           | 43.50 (± 99999)  | 10.03 (± 10.920) |  |  |
| CD45+CD3-CD16+; USC; n=0, 0, 1, 0, 0, 0          | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3-CD56+; D1; pre; n=1, 3, 1, 5, 4, 9      | 15.93 (± 11.588) | 12.16 (± 7.479)  |  |  |
| CD45+CD3-CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9      | 10.50 (± 7.470)  | 10.74 (± 6.300)  |  |  |
| CD45+CD3-CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11     | 9.43 (± 3.079)   | 10.71 (± 7.319)  |  |  |
| CD45+CD3-CD56+; D2; n=0, 0, 1, 2, 0, 1           | 99999 (± 99999)  | 5.60 (± 99999)   |  |  |
| CD45+CD3-CD56+; D8; n=1, 3, 0, 5, 4, 8           | 11.10 (± 4.808)  | 12.33 (± 7.733)  |  |  |
| CD45+CD3-CD56+; D15; S1; n=1, 3, 1, 5, 4, 9      | 11.73 (± 6.548)  | 8.39 (± 4.622)   |  |  |
| CD45+CD3-CD56+; D15; S2; n=0,0,1,0,0,0           | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3-CD56+; D29; n=1, 3, 1, 4, 4, 8          | 13.73 (± 9.582)  | 12.48 (± 9.517)  |  |  |
| CD45+CD3-CD56+; FU; n=1, 2, 0, 3, 1, 4           | 44.20 (± 99999)  | 11.95 (± 8.912)  |  |  |
| CD45+CD3-CD56+; USC; n=0, 0, 1, 0, 0, 0          | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9      | 6.20 (± 4.774)   | 4.67 (± 2.707)   |  |  |
| CD45+CD3+CD56+; D1; 1 h; n=1, 3, 1, 5, 4, 9      | 6.65 (± 7.102)   | 4.20 (± 3.321)   |  |  |
| CD45+CD3+CD56+; D1; 6 h; n=1, 3, 1, 5, 4, 11     | 8.50 (± 10.745)  | 4.17 (± 3.299)   |  |  |
| CD45+CD3+CD56+; D2; n=0, 0, 1, 2, 0, 1           | 99999 (± 99999)  | 7.00 (± 99999)   |  |  |
| CD45+CD3+CD56+; D8; n=1, 3, 0, 5, 4, 8           | 5.83 (± 2.756)   | 3.49 (± 2.801)   |  |  |
| CD45+CD3+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9      | 8.15 (± 3.746)   | 4.43 (± 3.015)   |  |  |
| CD45+CD3+CD56+; D15; S2; n=0,0,1,0,0,0           | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD56+; D29; n=1, 3, 1, 4, 4, 8          | 11.78 (± 9.751)  | 2.91 (± 2.635)   |  |  |
| CD45+CD3+CD56+; FU; n=1, 2, 0, 3, 1, 4           | 3.50 (± 99999)   | 5.10 (± 2.665)   |  |  |
| CD45+CD3+CD56+; USC; n=0, 0, 1, 0, 0, 0          | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3-CD16+CD56+; D1; pre; n=1, 3, 1, 5, 4, 9 | 13.25 (± 12.307) | 9.58 (± 7.480)   |  |  |
| CD45+CD3-CD16+CD56+; D1;1 h; n=1, 3, 1, 5, 4, 9  | 7.65 (± 8.118)   | 7.98 (± 5.768)   |  |  |
| CD45+CD3-CD16+CD56+; D1;6 h; n=1,3,1,5,4,11      | 6.10 (± 4.221)   | 6.22 (± 4.445)   |  |  |
| CD45+CD3-CD16+CD56+; D2; n=0, 0, 1, 2, 0, 1      | 99999 (± 99999)  | 4.10 (± 99999)   |  |  |
| CD45+CD3-CD16+CD56+; D8; n=1, 3, 0, 5, 4, 8      | 8.68 (± 5.465)   | 8.96 (± 6.217)   |  |  |
| CD45+CD3-CD16+CD56+; D15; S1; n=1, 3, 1, 5, 4, 9 | 8.88 (± 6.357)   | 6.54 (± 4.360)   |  |  |
| CD45+CD3-CD16+CD56+; D15; S2; n=0,0,1,0,0,0      | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3-CD16+CD56+; D29; n=1, 3, 1, 4, 4, 8     | 10.18 (± 9.932)  | 9.30 (± 6.776)   |  |  |

|  |                 |                  |  |  |
|--|-----------------|------------------|--|--|
| CD45+CD3-CD16+CD56+; FU; n=1, 2, 0, 3, 1, 4      | 41.90 (± 99999) | 9.20 (± 9.937)   |  |  |
| CD45+CD3-CD16+CD56+; USC; n=0, 0, 1, 0, 0, 0     | 99999 (± 99999) | 99999 (± 99999)  |  |  |
| CD45+CD3-CD19+; D1; pre n=1, 3, 1, 5, 4, 9       | 9.48 (± 4.769)  | 8.39 (± 3.194)   |  |  |
| CD45+CD3-CD19+; D1;1 h; n=1, 3, 1, 5, 4, 9       | 11.53 (± 6.211) | 9.18 (± 3.819)   |  |  |
| CD45+CD3-CD19+; D1;6 h; n=1,3,1,5,4,11           | 10.83 (± 6.636) | 9.00 (± 4.988)   |  |  |
| CD45+CD3-CD19+; D2; n=0, 0, 1, 2, 0, 1           | 99999 (± 99999) | 10.90 (± 99999)  |  |  |
| CD45+CD3-CD19+; D8; n=1, 3, 0, 5, 4, 8           | 9.63 (± 4.786)  | 7.65 (± 4.176)   |  |  |
| CD45+CD3-CD19+; D15; S1; n=1, 3, 1, 5, 4, 9      | 9.25 (± 4.339)  | 8.90 (± 4.170)   |  |  |
| CD45+CD3-CD19+; D15; S2; n=0,0,1,0,0,0           | 99999 (± 99999) | 99999 (± 99999)  |  |  |
| CD45+CD3-CD19+; D29; n=1, 3, 1, 4, 4, 8          | 10.53 (± 6.106) | 7.44 (± 4.324)   |  |  |
| CD45+CD3-CD19+; FU; n=1, 2, 0, 3, 1, 4           | 8.90 (± 99999)  | 8.33 (± 6.019)   |  |  |
| CD45+CD3-CD19+; USC; n=0, 0, 1, 0, 0, 0          | 99999 (± 99999) | 99999 (± 99999)  |  |  |
| CD45+CD14+; D1; pre; n=1, 3, 1, 5, 4, 9          | 7.15 (± 2.029)  | 4.87 (± 1.406)   |  |  |
| CD45+CD14+; D1;1 h; n=1, 3, 1, 5, 4, 9           | 4.68 (± 2.926)  | 3.52 (± 1.713)   |  |  |
| CD45+CD14+; D1;6 h; n=1,3,1,5,4,11               | 5.80 (± 2.389)  | 5.23 (± 2.581)   |  |  |
| CD45+CD14+; D2; n=0, 0, 1, 2, 0, 1               | 99999 (± 99999) | 4.40 (± 99999)   |  |  |
| CD45+CD14+; D8; n=1, 3, 0, 5, 4, 8               | 7.10 (± 2.223)  | 5.40 (± 2.115)   |  |  |
| CD45+CD14+; D15; S1; n=1, 3, 1, 5, 4, 9          | 6.93 (± 1.823)  | 5.47 (± 3.061)   |  |  |
| CD45+CD14+; D15; S2; n=0,0,1,0,0,0               | 99999 (± 99999) | 99999 (± 99999)  |  |  |
| CD45+CD14+; D29; n=1, 3, 1, 4, 4, 8              | 6.68 (± 2.241)  | 4.61 (± 1.108)   |  |  |
| CD45+CD14+; FU; n=1, 2, 0, 3, 1, 4               | 2.70 (± 99999)  | 4.98 (± 1.692)   |  |  |
| CD45+CD14+; USC; n=0, 0, 1, 0, 0, 0              | 99999 (± 99999) | 99999 (± 99999)  |  |  |
| CD45+CD3-CD16+CD69+; D1; pre; n=1, 3, 1, 5, 4, 9 | 82.50 (± 3.378) | 75.71 (± 15.845) |  |  |
| CD45+CD3-CD16+CD69+; D1;1 h; n=1, 3, 1, 5, 4, 9  | 86.01 (± 3.898) | 78.53 (± 16.993) |  |  |
| CD45+CD3-CD16+CD69+; D1;6 h; n=1,3,1,5,4,11      | 84.57 (± 4.448) | 79.79 (± 12.178) |  |  |
| CD45+CD3-CD16+CD69+; D2; n=0, 0, 1, 2, 0, 1      | 99999 (± 99999) | 88.05 (± 99999)  |  |  |
| CD45+CD3-CD16+CD69+; D8; n=1, 3, 0, 5, 4, 8      | 79.91 (± 2.014) | 70.93 (± 21.532) |  |  |
| CD45+CD3-CD16+CD69+; D15;S1; n=1, 3, 1, 5, 4, 9  | 81.68 (± 7.216) | 78.53 (± 20.178) |  |  |
| CD45+CD3-CD16+CD69+; D15;S2; n=0,0,1,0,0,0       | 99999 (± 99999) | 99999 (± 99999)  |  |  |
| CD45+CD3-CD16+CD69+; D29; n=1, 3, 1, 4, 4, 8     | 83.00 (± 6.240) | 74.56 (± 17.788) |  |  |
| CD45+CD3-CD16+CD69+; FU; n=1, 2, 0, 3, 1, 4      | 76.46 (± 99999) | 80.85 (± 19.555) |  |  |
| CD45+CD3-CD16+CD69+; USC; n=0, 0, 1, 0, 0, 0     | 99999 (± 99999) | 99999 (± 99999)  |  |  |

|  |                     |                     |  |  |
|--|---------------------|---------------------|--|--|
| CD45+CD3-CD16+CD107+; D1; pre;<br>n=1, 3, 1, 5, 4, 9 | 23.96 (±<br>12.309) | 25.04 (±<br>30.481) |  |  |
| CD45+CD3-CD16+CD107+; D1;1 h;<br>n=1, 3, 1, 5,4,9    | 24.66 (±<br>13.827) | 23.16 (±<br>24.866) |  |  |
| CD45+CD3-CD16+CD107+; D1;6 h;<br>n=1,3,1,5,4,11      | 21.55 (±<br>12.001) | 21.82 (±<br>17.204) |  |  |
| CD45+CD3-CD16+CD107+; D2; n=0,<br>0, 1, 2, 0, 1      | 99999 (±<br>99999)  | 30.82 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD107+; D8; n=1,<br>3, 0, 5, 4, 8      | 14.43 (±<br>1.615)  | 27.85 (±<br>27.884) |  |  |
| CD45+CD3-CD16+CD107+; D15; S1;<br>n=1, 3, 1, 5, 4, 9 | 18.30 (±<br>3.558)  | 21.68 (±<br>15.816) |  |  |
| CD45+CD3-CD16+CD107+; D15; S2;<br>n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD107+; D29; n=1,<br>3, 1, 4, 4, 8     | 27.70 (±<br>12.686) | 17.22 (±<br>6.799)  |  |  |
| CD45+CD3-CD16+CD107+; FU; n=1,<br>2, 0, 3, 1, 4      | 11.64 (±<br>99999)  | 27.42 (±<br>15.633) |  |  |
| CD45+CD3-CD16+CD107+; USC; n=0,<br>0, 1, 0, 0, 0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69+CD107+; D1;<br>pre; n=1,3,1,5,4,9 | 23.53 (±<br>11.967) | 24.68 (±<br>30.659) |  |  |
| CD45+CD3-CD16+CD69+CD107+;<br>D1;1 h;n=1,3,1,5,4,9   | 24.42 (±<br>13.709) | 22.85 (±<br>24.965) |  |  |
| CD45+CD3-CD16+CD69+CD107+;D1;6<br>h;n=1,3,1,5,4,11   | 21.33 (±<br>11.655) | 21.34 (±<br>17.411) |  |  |
| CD45+CD3-CD16+CD69+CD107+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999)  | 30.19 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69+CD107+; D8;<br>n=1,3,0,5,4,8      | 14.40 (±<br>1.591)  | 27.19 (±<br>27.949) |  |  |
| CD45+CD3-CD16+CD69+CD107+;<br>D15; S1;n=1,3,1,5,4,9  | 18.11 (±<br>3.584)  | 21.11 (±<br>16.206) |  |  |
| CD45+CD3-CD16+CD69+CD107+;<br>D15; S2;n=0,0,1,0,0, 0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69+CD107+;<br>D29; n=1,3,1,4,4,8     | 27.36 (±<br>12.492) | 16.08 (±<br>6.127)  |  |  |
| CD45+CD3-CD16+CD69+CD107+; FU;<br>n=1,2,0,3,1,4      | 11.56 (±<br>99999)  | 27.16 (±<br>15.866) |  |  |
| CD45+CD3-CD16+CD69+CD107+;<br>USC; n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69+CD107-;<br>D1;pre; n=1,3,1,5,4,9  | 58.97 (±<br>12.115) | 51.03 (±<br>22.210) |  |  |
| CD45+CD3-CD16+CD69+CD107-; D1;1<br>h;n=1,3,1,5,4,9   | 61.59 (±<br>10.979) | 55.68 (±<br>18.837) |  |  |
| CD45+CD3-CD16+CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11   | 63.25 (±<br>9.771)  | 58.44 (±<br>14.956) |  |  |
| CD45+CD3-CD16+CD69+CD107-; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999)  | 57.86 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69+CD107-; D8;<br>n=1,3,0,5,4,8      | 65.52 (±<br>2.097)  | 43.74 (±<br>17.564) |  |  |
| CD45+CD3-CD16+CD69+CD107-;<br>D15;S1; n=1,3,1,5,4,9  | 63.57 (±<br>6.498)  | 57.42 (±<br>15.273) |  |  |
| CD45+CD3-CD16+CD69+CD107-; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69+CD107-; D29;<br>n=1,3,1,4,4,8     | 55.64 (±<br>6.702)  | 58.48 (±<br>19.691) |  |  |
| CD45+CD3-CD16+CD69+CD107-; FU;<br>n=1,2,0,3,1,4      | 64.90 (±<br>99999)  | 53.69 (±<br>9.671)  |  |  |
| CD45+CD3-CD16+CD69+CD107-; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69-CD107+;<br>D1;pre n=1,3,1,5,4,9   | 0.43 (± 0.395)      | 0.36 (± 0.740)      |  |  |

|  |                     |                     |  |  |
|--|---------------------|---------------------|--|--|
| CD45+CD3-CD16+CD69-CD107+; D1;1<br>h;n=1,3,1,5,4,9   | 0.24 (± 0.441)      | 0.32 (± 0.494)      |  |  |
| CD45+CD3-CD16+CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11   | 0.23 (± 0.403)      | 0.48 (± 1.014)      |  |  |
| CD45+CD3-CD16+CD69-CD107+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999)  | 0.63 (± 99999)      |  |  |
| CD45+CD3-CD16+CD69-CD107+; D8;<br>n=1,3,0,5,4,8      | 0.04 (± 0.041)      | 0.66 (± 0.524)      |  |  |
| CD45+CD3-CD16+CD69-CD107+;<br>D15;S1; n=1,3,1,5,4,9  | 0.19 (± 0.236)      | 0.56 (± 0.890)      |  |  |
| CD45+CD3-CD16+CD69-CD107+; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69-CD107+; D29;<br>n=1,3,1,4,4,8     | 0.34 (± 0.241)      | 1.14 (± 1.844)      |  |  |
| CD45+CD3-CD16+CD69-CD107+; FU;<br>n=1,2,0,3,1,4      | 0.09 (± 99999)      | 0.27 (± 0.324)      |  |  |
| CD45+CD3-CD16+CD69-CD107+; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69-CD107-;<br>D1;pre; n=1,3,1,5,4,9  | 17.07 (±<br>3.528)  | 23.98 (±<br>15.442) |  |  |
| CD45+CD3-CD16+CD69-CD107-; D1;1<br>h;n=1,3,1,5,4,9   | 13.75 (±<br>3.880)  | 21.36 (±<br>16.671) |  |  |
| CD45+CD3-CD16+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11   | 15.21 (±<br>4.603)  | 19.98 (±<br>11.842) |  |  |
| CD45+CD3-CD16+CD69-CD107-; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999)  | 11.32 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69-CD107-; D8;<br>n=1,3,0,5,4,8      | 20.05 (±<br>2.014)  | 28.47 (±<br>21.443) |  |  |
| CD45+CD3-CD16+CD69-CD107-; D15;<br>S1;n=1,3,1,5,4,9  | 18.13 (±<br>7.060)  | 20.92 (±<br>19.349) |  |  |
| CD45+CD3-CD16+CD69-CD107-; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD16+CD69-CD107-; D29;<br>n=1,3,1,4,4,8     | 16.67 (±<br>6.466)  | 24.35 (±<br>16.239) |  |  |
| CD45+CD3-CD16+CD69-CD107-; FU;<br>n=1,2,0,3,1,4      | 23.54 (±<br>99999)  | 18.89 (±<br>19.247) |  |  |
| CD45+CD3-CD16+CD69-CD107-; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+; D1;pre;<br>n=1,3,1,5,4,9        | 77.94 (±<br>6.341)  | 71.81 (±<br>14.980) |  |  |
| CD45+CD3-CD56+CD69+; D1;1<br>h;n=1,3,1,5,4,9         | 80.38 (±<br>5.074)  | 73.55 (±<br>18.249) |  |  |
| CD45+CD3-CD56+CD69+;D1;6<br>h;n=1,3,1,5,4,11         | 79.33 (±<br>8.307)  | 74.28 (±<br>14.068) |  |  |
| CD45+CD3-CD56+CD69+; D2;<br>n=0,0,1,2,0,1            | 99999 (±<br>99999)  | 84.79 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+; D8;<br>n=1,3,0,5,4,8            | 75.71 (±<br>6.039)  | 64.20 (±<br>17.380) |  |  |
| CD45+CD3-CD56+CD69+; D15;S1;<br>n=1,3,1,5,4,9        | 77.05 (±<br>1.250)  | 74.14 (±<br>18.976) |  |  |
| CD45+CD3-CD56+CD69+; D15; S2;<br>n=0,0,1,0,0,0       | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+; D29;<br>n=1,3,1,4,4,8           | 78.39 (±<br>3.376)  | 72.21 (±<br>20.172) |  |  |
| CD45+CD3-CD56+CD69+; FU;<br>n=1,2,0,3,1,4            | 76.62 (±<br>99999)  | 75.78 (±<br>15.172) |  |  |
| CD45+CD3-CD56+CD69+; USC;<br>n=0,0,1,0,0,0           | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD107+; D1; pre;<br>n=1,3,1,5,4,9      | 20.36 (±<br>10.285) | 15.35 (±<br>12.755) |  |  |
| CD45+CD3-CD56+CD107+; D1;1<br>h;n=1,3,1,5,4,9        | 18.36 (±<br>8.295)  | 13.92 (±<br>14.620) |  |  |

|   |                     |                     |  |  |
|---|---------------------|---------------------|--|--|
| CD45+CD3-CD56+CD107+; D1; 6<br>h; n=1,3,1,5,4,11      | 19.50 (±<br>10.930) | 17.82 (±<br>13.218) |  |  |
| CD45+CD3-CD56+CD107+; D2;<br>n=0,0,1,2,0,1            | 99999 (±<br>99999)  | 26.27 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD107+; D8;<br>n=1,3,0,5,4,8            | 12.81 (±<br>2.027)  | 15.17 (±<br>12.783) |  |  |
| CD45+CD3-CD56+CD107+; D15; S1;<br>n=1,3,1,5,4,9       | 13.95 (±<br>4.221)  | 16.02 (±<br>10.352) |  |  |
| CD45+CD3-CD56+CD107+; D15; S2;<br>n=0,0,1,0,0,0       | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD107+; D29;<br>n=1,3,1,4,4,8           | 22.89 (±<br>7.527)  | 17.13 (±<br>5.406)  |  |  |
| CD45+CD3-CD56+CD107+; FU;<br>n=1,2,0,3,1,4            | 11.46 (±<br>99999)  | 23.63 (±<br>17.232) |  |  |
| CD45+CD3-CD56+CD107+; USC;<br>n=0,0,1,0,0,0           | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+CD107+; D1;<br>pre n=1,3,1,5,4,9   | 19.90 (±<br>9.878)  | 15.06 (±<br>12.804) |  |  |
| CD45+CD3-CD56+CD69+CD107+;<br>D1; 1 h; n=1,3,1,5,4,9  | 17.72 (±<br>8.423)  | 13.60 (±<br>14.641) |  |  |
| CD45+CD3-CD56+CD69+CD107+; D1; 6<br>h; n=1,3,1,5,4,11 | 19.15 (±<br>10.796) | 15.67 (±<br>9.351)  |  |  |
| CD45+CD3-CD56+CD69+CD107+; D2;<br>n=0,0,1,2,0,1       | 99999 (±<br>99999)  | 25.81 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+CD107+; D8;<br>n=1,3,0,5,4,8       | 12.69 (±<br>2.047)  | 14.33 (±<br>12.481) |  |  |
| CD45+CD3-CD56+CD69+CD107+;<br>D15; S1; n=1,3,1,5,4,9  | 13.80 (±<br>4.123)  | 15.58 (±<br>10.540) |  |  |
| CD45+CD3-CD56+CD69+CD107+;<br>D15; S2; n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+CD107+;<br>D29; n=1,3,1,4,4,8      | 22.55 (±<br>7.441)  | 15.59 (±<br>4.963)  |  |  |
| CD45+CD3-CD56+CD69+CD107+; FU;<br>n=1,2,0,3,1,4       | 11.38 (±<br>99999)  | 23.00 (±<br>16.629) |  |  |
| CD45+CD3-CD56+CD69+CD107+;<br>USC; n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+CD107-; D1;<br>pre; n=1,3,1,5,4,9  | 58.04 (±<br>12.938) | 56.75 (±<br>10.180) |  |  |
| CD45+CD3-CD56+CD69+CD107-; D1; 1<br>h; n=1,3,1,5,4,9  | 62.66 (±<br>8.744)  | 59.95 (±<br>15.044) |  |  |
| CD45+CD3-CD56+CD69+CD107-; D1; 6<br>h; n=1,3,1,5,4,11 | 60.18 (±<br>9.203)  | 58.62 (±<br>14.204) |  |  |
| CD45+CD3-CD56+CD69+CD107-; D2;<br>n=0,0,1,2,0,1       | 99999 (±<br>99999)  | 58.99 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+CD107-;<br>D15; S1; n=1,3,1,5,4,9  | 63.25 (±<br>5.044)  | 58.55 (±<br>14.595) |  |  |
| CD45+CD3-CD56+CD69+CD107-; D15;<br>S2; n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69+CD107-; D8;<br>n=1,3,0,5,4,8       | 63.02 (±<br>5.005)  | 49.87 (±<br>13.422) |  |  |
| CD45+CD3-CD56+CD69+CD107-; D29;<br>n=1,3,1,4,4,8      | 55.84 (±<br>6.851)  | 56.62 (±<br>21.533) |  |  |
| CD45+CD3-CD56+CD69+CD107-; FU;<br>n=1,2,0,3,1,4       | 65.24 (±<br>99999)  | 52.78 (±<br>12.864) |  |  |
| CD45+CD3-CD56+CD69+CD107-; USC;<br>n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69-CD107+; D1;<br>pre; n=1,3,1,5,4,9  | 0.46 (± 0.425)      | 0.29 (± 0.558)      |  |  |
| CD45+CD3-CD56+CD69-CD107+; D1; 1<br>h; n=1,3,1,5,4,9  | 0.64 (± 0.660)      | 0.32 (± 0.364)      |  |  |
| CD45+CD3-CD56+CD69-CD107+; D1; 6<br>h; n=1,3,1,5,4,11 | 0.35 (± 0.262)      | 2.15 (± 5.749)      |  |  |

|  |                     |                     |  |  |
|--|---------------------|---------------------|--|--|
| CD45+CD3-CD56+CD69-CD107+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999)  | 0.46 (± 99999)      |  |  |
| CD45+CD3-CD56+CD69-CD107+; D8;<br>n=1,3,0,5,4,8      | 0.11 (± 0.109)      | 0.84 (± 1.031)      |  |  |
| CD45+CD3-CD56+CD69-CD107+;<br>D15;S1; n=1,3,1,5,4,9  | 0.15 (± 0.174)      | 0.44 (± 0.638)      |  |  |
| CD45+CD3-CD56+CD69-CD107+; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69-CD107+; D29;<br>n=1,3,1,4,4,8     | 0.35 (± 0.145)      | 1.54 (± 2.079)      |  |  |
| CD45+CD3-CD56+CD69-CD107+; FU;<br>n=1,2,0,3,1,4      | 0.08 (± 99999)      | 0.62 (± 0.678)      |  |  |
| CD45+CD3-CD56+CD69-CD107+; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69-CD107-; D1;<br>pre; n=1,3,1,5,4,9 | 21.60 (±<br>6.379)  | 27.91 (±<br>14.759) |  |  |
| CD45+CD3-CD56+CD69-CD107-; D1;1<br>h;n=1,3,1,5,4,9   | 18.99 (±<br>4.842)  | 26.13 (±<br>18.140) |  |  |
| CD45+CD3-CD56+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11   | 20.36 (±<br>8.302)  | 23.56 (±<br>13.128) |  |  |
| CD45+CD3-CD56+CD69-CD107-; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999)  | 14.75 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69-CD107-; D8;<br>n=1,3,0,5,4,8      | 24.18 (±<br>5.949)  | 34.96 (±<br>16.868) |  |  |
| CD45+CD3-CD56+CD69-CD107-;<br>D15;S1; n=1,3,1,5,4,9  | 22.81 (±<br>1.095)  | 25.43 (±<br>18.427) |  |  |
| CD45+CD3-CD56+CD69-CD107-; D15;<br>S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD69-CD107-; D29;<br>n=1,3,1,4,4,8     | 21.27 (±<br>3.470)  | 26.26 (±<br>18.208) |  |  |
| CD45+CD3-CD56+CD69-CD107-; FU;<br>n=1,2,0,3,1,4      | 23.30 (±<br>99999)  | 23.60 (±<br>15.370) |  |  |
| CD45+CD3-CD56+CD69-CD107-; USC;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD16+CD69+; D1;<br>pre; n=1,3,1,5,4,9  | 82.35 (±<br>3.605)  | 75.53 (±<br>16.495) |  |  |
| CD45+CD3-CD56+CD16+CD69+; D1;1<br>h;n=1,3,1,5,4,9    | 85.57 (±<br>3.640)  | 77.45 (±<br>18.036) |  |  |
| CD45+CD3-CD56+CD16+CD69+;D1;6<br>h;n=1,3,1,5,4,11    | 83.95 (±<br>4.687)  | 78.92 (±<br>13.044) |  |  |
| CD45+CD3-CD56+CD16+CD69+; D2;<br>n=0,0,1,2,0,1       | 99999 (±<br>99999)  | 87.90 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD16+CD69+; D8;<br>n=1,3,0,5,4,8       | 79.75 (±<br>2.003)  | 70.62 (±<br>21.607) |  |  |
| CD45+CD3-CD56+CD16+CD69+;<br>D15;S1; n=1,3,1,5,4,9   | 80.67 (±<br>5.845)  | 79.09 (±<br>19.651) |  |  |
| CD45+CD3-CD56+CD16+CD69+; D15;<br>S2; n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD16+CD69+; D29;<br>n=1,3,1,4,4,8      | 82.36 (±<br>4.976)  | 74.62 (±<br>18.799) |  |  |
| CD45+CD3-CD56+CD16+CD69+; FU;<br>n=1,2,0,3,1,4       | 76.73 (±<br>99999)  | 80.93 (±<br>19.159) |  |  |
| CD45+CD3-CD56+CD16+CD69+; USC;<br>n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD16+CD107+;<br>D1;pre; n=1,3,1,5,4,9  | 22.71 (±<br>12.190) | 23.18 (±<br>31.567) |  |  |
| CD45+CD3-CD56+CD16+CD107+;<br>D1;1 h;n=1,3,1,5,4,9   | 23.33 (±<br>14.182) | 20.40 (±<br>26.478) |  |  |
| CD45+CD3-CD56+CD16+CD107+;D1;6<br>h;n=1,3,1,5,4,11   | 20.47 (±<br>12.384) | 19.35 (±<br>17.934) |  |  |
| CD45+CD3-CD56+CD16+CD107+; D2;<br>n=0,0,1,2,0,1      | 99999 (±<br>99999)  | 30.57 (±<br>99999)  |  |  |



|  |                     |                     |  |  |
|--|---------------------|---------------------|--|--|
| CD45+CD3-CD56+CD16+CD107+; D8;<br>n=1,3,0,5,4,8      | 13.90 (±<br>2.089)  | 26.69 (±<br>33.377) |  |  |
| CD45+CD3-CD56+CD16+CD107+;<br>D15;S1; n=1,3,1,5,4,9  | 14.72 (±<br>4.613)  | 21.04 (±<br>17.138) |  |  |
| CD45+CD3-CD56+CD16+CD107+;<br>D15; S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD56+CD16+CD107+;<br>D29; n=1,3,1,4,4,8     | 25.75 (±<br>9.873)  | 18.09 (±<br>7.210)  |  |  |
| CD45+CD3-CD56+CD16+CD107+; FU;<br>n=1,2,0,3,1,4      | 11.68 (±<br>99999)  | 25.61 (±<br>14.702) |  |  |
| CD45+CD3-CD56+CD16+CD107+;<br>USC; n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CDX241; D1;pre; n=1,3,1,5,4,9                        | 22.27 (±<br>11.808) | 22.97 (±<br>31.676) |  |  |
| CDX241; D1;1h;n=1,3,1,5,4,9                          | 23.12 (±<br>14.060) | 20.23 (±<br>26.492) |  |  |
| CDX241; D1;6h;n=1,3,1,5,4,11                         | 20.23 (±<br>12.033) | 19.06 (±<br>18.044) |  |  |
| CDX241; D2; n=0,0,1,2,0,1                            | 99999 (±<br>99999)  | 29.94 (±<br>99999)  |  |  |
| CDX241; D8; n=1,3,0,5,4,8                            | 13.88 (±<br>2.075)  | 26.20 (±<br>33.362) |  |  |
| CDX241; D15;S1;n=1,3,1,5,4,9                         | 14.55 (±<br>4.521)  | 20.62 (±<br>17.353) |  |  |
| CDX241; D15;S2; n=0,0,1,0,0,0                        | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CDX241; D29; n=1,3,1,4,4,8                           | 25.56 (±<br>9.917)  | 16.64 (±<br>6.597)  |  |  |
| CDX241; FU; n=1,2,0,3,1,4                            | 11.59 (±<br>99999)  | 25.41 (±<br>14.820) |  |  |
| CDX241; USC; n=0,0,1,0,0,0                           | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CDX243; D1; pre; n=1,3,1,5,4,9                       | 60.08 (±<br>11.697) | 52.56 (±<br>22.645) |  |  |
| CDX243; D1;1h; n=1,3,1,5,4,9                         | 62.45 (±<br>11.395) | 57.22 (±<br>19.058) |  |  |
| CDX243;D1;6h; n=1,3,1,5,4,11                         | 63.72 (±<br>9.993)  | 59.86 (±<br>14.378) |  |  |
| CDX243; D2; n=0,0,1,2,0,1                            | 99999 (±<br>99999)  | 57.96 (±<br>99999)  |  |  |
| CDX243; D8; n=1,3,0,5,4,8                            | 65.87 (±<br>2.821)  | 44.43 (±<br>22.911) |  |  |
| CDX243; D15;S1; n=1,3,1,5,4,9                        | 66.13 (±<br>9.524)  | 58.47 (±<br>16.070) |  |  |
| CDX243; D15;S2; n=0,0,1,0,0,0                        | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CDX243; D29; n=1,3,1,4,4,8                           | 56.80 (±<br>5.697)  | 57.98 (±<br>21.467) |  |  |
| CDX243; FU;n=1,2,0,3,1,4                             | 65.13 (±<br>99999)  | 55.52 (±<br>9.421)  |  |  |
| CDX243; USC;n=0,0,1,0,0,0                            | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CDX244; D1; pre; n=1,3,1,5,4,9                       | 0.45 (± 0.422)      | 0.21 (± 0.505)      |  |  |
| CDX244; D1;1h;n=1,3,1,5,4,9                          | 0.22 (± 0.391)      | 0.17 (± 0.319)      |  |  |
| CDX244; D1;6h;n=1,3,1,5,4,11                         | 0.24 (± 0.423)      | 0.30 (± 0.682)      |  |  |
| CDX244; D2; n=0,0,1,2,0,1                            | 99999 (±<br>99999)  | 0.64 (± 99999)      |  |  |
| CDX244; D8; n=1,3,0,5,4,8                            | 0.02 (± 0.045)      | 0.49 (± 0.601)      |  |  |
| CDX244; D15;S1;n=1,3,1,5,4,9                         | 0.71 (± 0.204)      | 0.42 (± 0.632)      |  |  |
| CDX244; D15;S2n=0,0,1,0,0,0                          | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |

|  |                  |                  |  |  |
|--|------------------|------------------|--|--|
| CDX244; D29; n=1,3,1,4,4,8                   | 0.19 (± 0.194)   | 1.46 (± 1.849)   |  |  |
| CDX244; FU; n=1,2,0,3,1,4                    | 0.09 (± 99999)   | 0.20 (± 0.189)   |  |  |
| CDX244; USC; n=0,0,1,0,0,0                   | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CDX245; D1; pre; n=1,3,1,5,4,9               | 17.21 (± 3.797)  | 24.26 (± 16.218) |  |  |
| CDX245; D1; 1h; n=1,3,1,5,4,9                | 14.21 (± 3.682)  | 22.37 (± 17.894) |  |  |
| CDX245; D1; 6h; n=1,3,1,5,4,11               | 15.82 (± 4.876)  | 20.79 (± 12.726) |  |  |
| CDX245; D2; n=0,0,1,2,0,1                    | 99999 (± 99999)  | 11.46 (± 99999)  |  |  |
| CDX245; D8; n=1,3,0,5,4,8                    | 20.23 (± 1.977)  | 28.88 (± 21.510) |  |  |
| CDX245; D15; S1; n=1,3,1,5,4,9               | 19.16 (± 5.695)  | 20.48 (± 19.116) |  |  |
| CDX245; D15; S2; n=0,0,1,0,0,0               | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CDX245; D29; n=1,3,1,4,4,8                   | 17.45 (± 4.991)  | 23.93 (± 16.995) |  |  |
| CDX245; FU; n=1,2,0,3,1,4                    | 23.19 (± 99999)  | 18.88 (± 18.996) |  |  |
| CDX245; USC; n=0,0,1,0,0,0                   | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD56+CD69+; D1pre; n=1,3,1,5,4,9    | 80.50 (± 5.553)  | 72.52 (± 20.777) |  |  |
| CD45+CD3+CD56+CD69+; D1; 1h; n=1,3,1,5,4,9   | 76.76 (± 7.819)  | 69.96 (± 23.711) |  |  |
| CD45+CD3+CD56+CD69+; D1; 6h; n=1,3,1,5,4,11  | 77.96 (± 9.405)  | 73.92 (± 20.707) |  |  |
| CD45+CD3+CD56+CD69+; D2; n=0,0,1,2,0,1       | 99999 (± 99999)  | 81.34 (± 99999)  |  |  |
| CD45+CD3+CD56+CD69+; D8; n=1,3,0,5,4,8       | 77.76 (± 3.671)  | 71.42 (± 17.583) |  |  |
| CD45+CD3+CD56+CD69+; D15; S1; n=1,3,1,5,4,9  | 75.78 (± 3.311)  | 72.29 (± 22.078) |  |  |
| CD45+CD3+CD56+CD69+; D15; S2; n=0,0,1,0,0,0  | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD56+CD69+; D29; n=1,3,1,4,4,8      | 79.47 (± 4.516)  | 73.25 (± 19.837) |  |  |
| CD45+CD3+CD56+CD69+; FU; n=1,2,0,3,1,4       | 78.84 (± 99999)  | 78.73 (± 13.208) |  |  |
| CD45+CD3+CD56+CD69+; USC; n=0,0,1,0,0,0      | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD56+CD107+; D1pre; n=1,3,1,5,4,9   | 25.59 (± 10.582) | 21.94 (± 11.569) |  |  |
| CD45+CD3+CD56+CD107+; D1; 1h; n=1,3,1,5,4,9  | 20.17 (± 7.408)  | 19.38 (± 9.838)  |  |  |
| CD45+CD3+CD56+CD107+; D1; 6h; n=1,3,1,5,4,11 | 18.38 (± 7.558)  | 27.83 (± 16.580) |  |  |
| CD45+CD3+CD56+CD107+; D2; n=0,0,1,2,0,1      | 99999 (± 99999)  | 21.27 (± 99999)  |  |  |
| CD45+CD3+CD56+CD107+; D8; n=1,3,0,5,4,8      | 23.85 (± 15.031) | 25.37 (± 9.055)  |  |  |
| CD45+CD3+CD56+CD107+; D15; S1; n=1,3,1,5,4,9 | 22.75 (± 9.361)  | 24.77 (± 13.389) |  |  |
| CD45+CD3+CD56+CD107+; D15; S2; n=0,0,1,0,0,0 | 99999 (± 99999)  | 99999 (± 99999)  |  |  |
| CD45+CD3+CD56+CD107+; D29; n=1,3,1,4,4,8     | 26.64 (± 16.501) | 25.47 (± 7.825)  |  |  |
| CD45+CD3+CD56+CD107+; FU; n=1,2,0,3,1,4      | 16.40 (± 99999)  | 26.92 (± 16.312) |  |  |

|   |                     |                     |  |  |
|---|---------------------|---------------------|--|--|
| CD45+CD3+CD56+CD107+;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69+CD107+;D1;<br>pre; n=1,3,1,5,4,9 | 24.97 (±<br>10.148) | 21.16 (±<br>11.995) |  |  |
| CD45+CD3+CD56+CD69+CD107+;D1;<br>1 h;n=1,3,1,5,4,9  | 19.58 (±<br>6.559)  | 18.93 (±<br>9.947)  |  |  |
| CD45+CD3+CD56+CD69+CD107+;D1;<br>6 h;n=1,3,1,5,4,11 | 17.89 (±<br>7.034)  | 26.49 (±<br>16.563) |  |  |
| CD45+CD3+CD56+CD69+CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999)  | 20.90 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69+CD107+; D8;<br>n=1,3,0,5,4,8     | 23.10 (±<br>14.534) | 24.68 (±<br>9.353)  |  |  |
| CD45+CD3+CD56+CD69+CD107+;<br>D15;S1; n=1,3,1,5,4,9 | 22.25 (±<br>9.194)  | 23.91 (±<br>13.531) |  |  |
| CD45+CD3+CD56+CD69+CD107+;D15<br>;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69+CD107+;<br>D29; n=1,3,1,4,4,8    | 25.87 (±<br>15.887) | 23.72 (±<br>7.717)  |  |  |
| CD45+CD3+CD56+CD69+CD107+;<br>FU;n=1,2,0,3,1,4      | 15.87 (±<br>99999)  | 26.51 (±<br>16.034) |  |  |
| CD45+CD3+CD56+CD69+CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69+CD107-;D1;<br>pre; n=1,3,1,5,4,9 | 55.53 (±<br>15.219) | 51.35 (±<br>15.196) |  |  |
| CD45+CD3+CD56+CD69+CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 57.19 (±<br>10.200) | 51.04 (±<br>17.281) |  |  |
| CD45+CD3+CD56+CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 60.07 (±<br>13.763) | 47.43 (±<br>15.287) |  |  |
| CD45+CD3+CD56+CD69+CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999)  | 60.45 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69+CD107-; D8;<br>n=1,3,0,5,4,8     | 54.67 (±<br>12.323) | 46.74 (±<br>9.237)  |  |  |
| CD45+CD3+CD56+CD69+CD107-;<br>D15;S1; n=1,3,1,5,4,9 | 53.53 (±<br>10.408) | 48.38 (±<br>17.947) |  |  |
| CD45+CD3+CD56+CD69+CD107-<br>;D15;S2;n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69+CD107-;<br>D29; n=1,3,1,4,4,8    | 53.61 (±<br>15.433) | 49.53 (±<br>16.556) |  |  |
| CD45+CD3+CD56+CD69+CD107-;<br>FU;n=1,2,0,3,1,4      | 62.96 (±<br>99999)  | 52.22 (±<br>5.130)  |  |  |
| CD45+CD3+CD56+CD69+CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69-<br>CD107+;D1pre; n=1,3,1,5,4,9  | 0.62 (± 0.761)      | 0.77 (± 1.157)      |  |  |
| CD45+CD3+CD56+CD69-CD107+;D1;1<br>h;n=1,3,1,5,4,9   | 0.59 (± 0.889)      | 0.45 (± 0.501)      |  |  |
| CD45+CD3+CD56+CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11  | 0.49 (± 0.666)      | 1.35 (± 2.225)      |  |  |
| CD45+CD3+CD56+CD69-CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999)  | 0.37 (± 99999)      |  |  |
| CD45+CD3+CD56+CD69-CD107+; D8;<br>n=1,3,0,5,4,8     | 0.75 (± 0.573)      | 0.69 (± 0.656)      |  |  |
| CD45+CD3+CD56+CD69-CD107+;<br>D15;S1;n=1,3,1,5,4,9  | 0.51 (± 0.307)      | 0.87 (± 1.194)      |  |  |
| CD45+CD3+CD56+CD69-<br>CD107+;D15;S2;n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69-CD107+;<br>D29; n=1,3,1,4,4,8    | 0.77 (± 0.697)      | 1.75 (± 2.925)      |  |  |
| CD45+CD3+CD56+CD69-CD107+;<br>FU;n=1,2,0,3,1,4      | 0.53 (± 99999)      | 0.41 (± 0.407)      |  |  |
| CD45+CD3+CD56+CD69-CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |

|   |                     |                     |  |  |
|---|---------------------|---------------------|--|--|
| CD45+CD3+CD56+CD69-CD107-;<br>D1pre; n=1,3,1,5,4,9  | 18.88 (±<br>5.007)  | 26.71 (±<br>19.740) |  |  |
| CD45+CD3+CD56+CD69-CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 22.65 (±<br>7.631)  | 29.59 (±<br>23.473) |  |  |
| CD45+CD3+CD56+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 21.55 (±<br>8.954)  | 24.74 (±<br>19.457) |  |  |
| CD45+CD3+CD56+CD69-CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999)  | 18.28 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69-CD107-; D8;<br>n=1,3,0,5,4,8     | 21.49 (±<br>4.140)  | 27.89 (±<br>17.180) |  |  |
| CD45+CD3+CD56+CD69-CD107-;<br>D15;S1; n=1,3,1,5,4,9 | 23.72 (±<br>3.040)  | 26.84 (±<br>21.388) |  |  |
| CD45+CD3+CD56+CD69-CD107-;<br>D15;S2;n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD56+CD69-CD107-; D29;<br>n=1,3,1,4,4,8    | 19.76 (±<br>4.920)  | 25.00 (±<br>18.022) |  |  |
| CD45+CD3+CD56+CD69-CD107-;<br>FU;n=1,2,0,3,1,4      | 20.63 (±<br>99999)  | 20.86 (±<br>13.394) |  |  |
| CD45+CD3+CD56+CD69-CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+;D1pre;<br>n=1,3,1,5,4,9          | 69.48 (±<br>7.473)  | 64.41 (±<br>15.841) |  |  |
| CD45+CD3+CD8+CD69+;D1;1<br>h;n=1,3,1,5,4,9          | 69.27 (±<br>10.664) | 62.62 (±<br>18.568) |  |  |
| CD45+CD3+CD8+CD69+;D1;6<br>h;n=1,3,1,5,4,11         | 69.44 (±<br>10.476) | 64.10 (±<br>16.568) |  |  |
| CD45+CD3+CD8+CD69+; D2;<br>n=0,0,1,2,0,1            | 99999 (±<br>99999)  | 73.16 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+; D8;<br>n=1,3,0,5,4,8            | 69.15 (±<br>2.032)  | 59.81 (±<br>14.230) |  |  |
| CD45+CD3+CD8+CD69+; D15;S1;<br>n=1,3,1,5,4,9        | 65.46 (±<br>2.301)  | 58.44 (±<br>20.646) |  |  |
| CD45+CD3+CD8+CD69+;<br>D15;S2;n=0,0,1,0,0,0         | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+; D29;<br>n=1,3,1,4,4,8           | 70.42 (±<br>3.658)  | 60.96 (±<br>16.314) |  |  |
| CD45+CD3+CD8+CD69+;<br>FU;n=1,2,0,3,1,4             | 70.80 (±<br>99999)  | 70.63 (±<br>13.052) |  |  |
| CD45+CD3+CD8+CD69+;<br>USC;n=0,0,1,0,0,0            | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD107+;D1pre;<br>n=1,3,1,5,4,9         | 19.50 (±<br>5.678)  | 12.96 (±<br>7.622)  |  |  |
| CD45+CD3+CD8+CD107+;D1;1<br>h;n=1,3,1,5,4,9         | 17.86 (±<br>7.915)  | 12.10 (±<br>9.816)  |  |  |
| CD45+CD3+CD8+CD107+;D1;6<br>h;n=1,3,1,5,4,11        | 17.74 (±<br>6.679)  | 14.58 (±<br>7.973)  |  |  |
| CD45+CD3+CD8+CD107+; D2;<br>n=0,0,1,2,0,1           | 99999 (±<br>99999)  | 15.65 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD107+; D8;<br>n=1,3,0,5,4,8           | 19.58 (±<br>10.034) | 13.53 (±<br>7.177)  |  |  |
| CD45+CD3+CD8+CD107+; D15;<br>S1;n=1,3,1,5,4,9       | 18.52 (±<br>6.515)  | 14.52 (±<br>11.560) |  |  |
| CD45+CD3+CD8+CD107+;<br>D15;S2;n=0,0,1,0,0,0        | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD107+; D29;<br>n=1,3,1,4,4,8          | 22.28 (±<br>10.800) | 16.01 (±<br>7.377)  |  |  |
| CD45+CD3+CD8+CD107+;<br>FU;n=1,2,0,3,1,4            | 20.65 (±<br>99999)  | 24.54 (±<br>20.530) |  |  |
| CD45+CD3+CD8+CD107+;<br>USC;n=0,0,1,0,0,0           | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+CD107+;D1pr<br>e; n=1,3,1,5,4,9   | 18.89 (±<br>5.513)  | 12.42 (±<br>7.519)  |  |  |

|  |                     |                     |  |  |
|--|---------------------|---------------------|--|--|
| CD45+CD3+CD8+CD69+CD107+; D1; 1<br>h; n=1,3,1,5,4,9  | 17.10 (±<br>7.592)  | 11.51 (±<br>9.671)  |  |  |
| CD45+CD3+CD8+CD69+CD107+; D1; 6<br>h; n=1,3,1,5,4,11 | 16.83 (±<br>6.502)  | 13.49 (±<br>8.242)  |  |  |
| CD45+CD3+CD8+CD69+CD107+; D2;<br>n=0,0,1,2,0,1       | 99999 (±<br>99999)  | 15.59 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+CD107+; D8;<br>n=1,3,0,5,4,8       | 18.62 (±<br>9.229)  | 12.58 (±<br>6.811)  |  |  |
| CD45+CD3+CD8+CD69+CD107+;<br>D15; S1; n=1,3,1,5,4,9  | 17.46 (±<br>5.818)  | 13.79 (±<br>11.461) |  |  |
| CD45+CD3+CD8+CD69+CD107+;<br>D15; S2; n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+CD107+; D29;<br>n=1,3,1,4,4,8      | 21.18 (±<br>9.942)  | 14.79 (±<br>7.086)  |  |  |
| CD45+CD3+CD8+CD69+CD107+;<br>FU; n=1,2,0,3,1,4       | 20.35 (±<br>99999)  | 22.91 (±<br>18.370) |  |  |
| CD45+CD3+CD8+CD69+CD107+;<br>USC; n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+CD107-<br>; D1pre; n=1,3,1,5,4,9   | 50.59 (±<br>11.155) | 51.99 (±<br>13.129) |  |  |
| CD45+CD3+CD8+CD69+CD107-; D1; 1<br>h; n=1,3,1,5,4,9  | 52.17 (±<br>7.570)  | 51.12 (±<br>15.653) |  |  |
| CD45+CD3+CD8+CD69+CD107-; D1; 6<br>h; n=1,3,1,5,4,11 | 52.61 (±<br>7.942)  | 50.61 (±<br>11.996) |  |  |
| CD45+CD3+CD8+CD69+CD107-; D2;<br>n=0,0,1,2,0,1       | 99999 (±<br>99999)  | 57.57 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+CD107-; D8;<br>n=1,3,0,5,4,8       | 50.52 (±<br>8.995)  | 47.22 (±<br>12.334) |  |  |
| CD45+CD3+CD8+CD69+CD107-; D15;<br>S1; n=1,3,1,5,4,9  | 47.99 (±<br>7.314)  | 44.65 (±<br>18.062) |  |  |
| CD45+CD3+CD8+CD69+CD107-; D15;<br>S2; n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69+CD107-; D29;<br>n=1,3,1,4,4,8      | 49.25 (±<br>12.319) | 46.17 (±<br>14.907) |  |  |
| CD45+CD3+CD8+CD69+CD107-;<br>FU; n=1,2,0,3,1,4       | 50.44 (±<br>99999)  | 47.72 (±<br>13.474) |  |  |
| CD45+CD3+CD8+CD69+CD107-;<br>USC; n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69-<br>CD107+; D1pre; n=1,3,1,5,4,9   | 0.61 (± 0.493)      | 0.54 (± 0.575)      |  |  |
| CD45+CD3+CD8+CD69-CD107+; D1; 1<br>h; n=1,3,1,5,4,9  | 0.76 (± 0.919)      | 0.59 (± 0.605)      |  |  |
| CD45+CD3+CD8+CD69-CD107+; D1; 6<br>h; n=1,3,1,5,4,11 | 0.91 (± 0.629)      | 1.09 (± 1.070)      |  |  |
| CD45+CD3+CD8+CD69-CD107+; D8;<br>n=1,3,0,5,4,8       | 0.96 (± 1.007)      | 0.95 (± 1.058)      |  |  |
| CD45+CD3+CD8+CD69-CD107+; D2;<br>n=0,0,1,2,0,1       | 99999 (±<br>99999)  | 0.06 (± 99999)      |  |  |
| CD45+CD3+CD8+CD69-CD107+;<br>D15; S1; n=1,3,1,5,4,9  | 1.05 (± 0.920)      | 0.73 (± 0.435)      |  |  |
| CD45+CD3+CD8+CD69-CD107+;<br>D15; S2; n=0,0,1,0,0,0  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69-CD107+; D29;<br>n=1,3,1,4,4,8      | 1.10 (± 0.919)      | 1.22 (± 1.347)      |  |  |
| CD45+CD3+CD8+CD69-CD107+;<br>FU; n=1,2,0,3,1,4       | 0.29 (± 99999)      | 1.63 (± 2.326)      |  |  |
| CD45+CD3+CD8+CD69-CD107+;<br>USC; n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69-CD107-; D1pre;<br>n=1,3,1,5,4,9    | 29.92 (±<br>7.082)  | 35.04 (±<br>15.444) |  |  |
| CD45+CD3+CD8+CD69-CD107-; D1; 1<br>h; n=1,3,1,5,4,9  | 29.97 (±<br>10.290) | 36.79 (±<br>18.243) |  |  |

|  |                     |                     |  |  |
|--|---------------------|---------------------|--|--|
| CD45+CD3+CD8+CD69-CD107-; D1;6<br>h;n=1,3,1,5,4,11 | 29.65 (±<br>10.132) | 34.81 (±<br>15.738) |  |  |
| CD45+CD3+CD8+CD69-CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999)  | 26.77 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69-CD107-; D8;<br>n=1,3,0,5,4,8     | 29.90 (±<br>2.006)  | 39.24 (±<br>13.864) |  |  |
| CD45+CD3+CD8+CD69-CD107-;<br>D15;S1; n=1,3,1,5,4,9 | 33.49 (±<br>1.695)  | 40.83 (±<br>20.434) |  |  |
| CD45+CD3+CD8+CD69-CD107-;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8+CD69-CD107-; D29;<br>n=1,3,1,4,4,8    | 28.48 (±<br>3.302)  | 37.82 (±<br>15.640) |  |  |
| CD45+CD3+CD8+CD69-CD107-;<br>FU;n=1,2,0,3,1,4      | 28.91 (±<br>99999)  | 27.74 (±<br>14.176) |  |  |
| CD45+CD3+CD8+CD69-CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69+;D1pre;<br>n=1,3,1,5,4,9             | 63.78 (±<br>9.470)  | 57.37 (±<br>19.984) |  |  |
| CD45+CD3+CD69+;D1;1<br>h;n=1,3,1,5,4,9             | 62.71 (±<br>13.023) | 55.80 (±<br>21.386) |  |  |
| CD45+CD3+CD69+;D1;6<br>h;n=1,3,1,5,4,11            | 63.26 (±<br>12.922) | 60.07 (±<br>19.171) |  |  |
| CD45+CD3+CD69+; D2; n=0,0,1,2,0,1                  | 99999 (±<br>99999)  | 62.93 (±<br>99999)  |  |  |
| CD45+CD3+CD69+; D8; n=1,3,0,5,4,8                  | 65.73 (±<br>6.597)  | 51.29 (±<br>13.826) |  |  |
| CD45+CD3+CD69+; D15;S1;<br>n=1,3,1,5,4,9           | 58.46 (±<br>3.564)  | 53.38 (±<br>21.988) |  |  |
| CD45+CD3+CD69+; D15;S2;<br>n=0,0,1,0,0,0           | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69+; D29;<br>n=1,3,1,4,4,8              | 63.88 (±<br>5.978)  | 53.68 (±<br>19.308) |  |  |
| CD45+CD3+CD69+; FU;n=1,2,0,3,1,4                   | 64.95 (±<br>99999)  | 67.21 (±<br>17.378) |  |  |
| CD45+CD3+CD69+; USC;n=0,0,1,0,0,0                  | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD107+;D1pre;<br>n=1,3,1,5,4,9            | 8.92 (± 4.982)      | 8.99 (± 4.894)      |  |  |
| CD45+CD3+CD107+;D1;1<br>h;n=1,3,1,5,4,9            | 6.79 (± 3.717)      | 7.91 (± 4.880)      |  |  |
| CD45+CD3+CD107+;D1;6<br>h;n=1,3,1,5,4,11           | 7.25 (± 3.529)      | 11.04 (±<br>4.474)  |  |  |
| CD45+CD3+CD107+; D2;<br>n=0,0,1,2,0,1              | 99999 (±<br>99999)  | 9.61 (± 99999)      |  |  |
| CD45+CD3+CD107+; D8;<br>n=1,3,0,5,4,8              | 9.81 (± 6.276)      | 10.61 (±<br>7.576)  |  |  |
| CD45+CD3+CD107+; D15;S1;<br>n=1,3,1,5,4,9          | 8.13 (± 4.504)      | 10.75 (±<br>6.692)  |  |  |
| CD45+CD3+CD107+; D15;S2;<br>n=0,0,1,0,0,0          | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD107+; D29;<br>n=1,3,1,4,4,8             | 10.30 (±<br>6.320)  | 10.79 (±<br>4.881)  |  |  |
| CD45+CD3+CD107+; FU;n=1,2,0,3,1,4                  | 5.11 (± 99999)      | 12.44 (±<br>10.953) |  |  |
| CD45+CD3+CD107+;<br>USC;n=0,0,1,0,0,0              | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69+CD107+;D1pre;<br>n=1,3,1,5,4,9       | 8.62 (± 4.781)      | 8.55 (± 4.996)      |  |  |
| CD45+CD3+CD69+CD107+;D1;1<br>h;n=1,3,1,5,4,9       | 6.42 (± 3.287)      | 7.43 (± 4.929)      |  |  |
| CD45+CD3+CD69+CD107+;D1;6<br>h;n=1,3,1,5,4,11      | 6.89 (± 3.217)      | 10.03 (±<br>4.618)  |  |  |

|   |                     |                     |  |  |
|---|---------------------|---------------------|--|--|
| CD45+CD3+CD69+CD107+; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999)  | 9.57 (± 99999)      |  |  |
| CD45+CD3+CD69+CD107+; D8;<br>n=1,3,0,5,4,8          | 9.36 (± 5.904)      | 9.58 (± 6.752)      |  |  |
| CD45+CD3+CD69+CD107+; D15;S1 ;<br>n=1,3,1,5,4,9     | 7.74 (± 4.077)      | 10.13 (±<br>6.879)  |  |  |
| CD45+CD3+CD69+CD107+; D15; S2;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69+CD107+; D29;<br>n=1,3,1,4,4,8         | 9.88 (± 5.888)      | 9.56 (± 4.499)      |  |  |
| CD45+CD3+CD69+CD107+;<br>FU;n=1,2,0,3,1,4           | 4.98 (± 99999)      | 11.70 (±<br>9.912)  |  |  |
| CD45+CD3+CD69+CD107+;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69+CD107-;D1pre;<br>n=1,3,1,5,4,9        | 55.15 (±<br>13.699) | 48.82 (±<br>16.871) |  |  |
| CD45+CD3+CD69+CD107-;D1;1<br>h;n=1,3,1,5,4,9        | 56.29 (±<br>13.709) | 48.37 (±<br>18.392) |  |  |
| CD45+CD3+CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11       | 56.37 (±<br>14.071) | 50.04 (±<br>16.622) |  |  |
| CD45+CD3+CD69+CD107-; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999)  | 53.35 (±<br>99999)  |  |  |
| CD45+CD3+CD69+CD107-; D8;<br>n=1,3,0,5,4,8          | 56.37 (±<br>8.661)  | 41.72 (±<br>11.909) |  |  |
| CD45+CD3+CD69+CD107-; D15; S1;<br>n=1,3,1,5,4,9     | 50.72 (±<br>6.589)  | 43.25 (±<br>18.831) |  |  |
| CD45+CD3+CD69+CD107-; D15;<br>S2;n=0, 0, 1, 0, 0, 0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69+CD107-; D29;<br>n=1,3,1,4,4,8         | 54.00 (±<br>11.624) | 44.11 (±<br>17.898) |  |  |
| CD45+CD3+CD69+CD107-;<br>FU;n=1,2,0,3,1,4           | 59.97 (±<br>99999)  | 55.52 (±<br>16.825) |  |  |
| CD45+CD3+CD69+CD107-;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69-CD107+;D1pre;<br>n=1,3,1,5,4,9        | 0.30 (± 0.324)      | 0.44 (± 0.537)      |  |  |
| CD45+CD3+CD69-CD107+;D1;1<br>h;n=1,3,1,5,4,9        | 0.36 (± 0.477)      | 0.48 (± 0.459)      |  |  |
| CD45+CD3+CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11       | 0.36 (± 0.349)      | 1.01 (± 1.233)      |  |  |
| CD45+CD3+CD69-CD107+; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999)  | 0.03 (± 99999)      |  |  |
| CD45+CD3+CD69-CD107+; D8;<br>n=1,3,0,5,4,8          | 0.45 (± 0.458)      | 1.04 (± 1.201)      |  |  |
| CD45+CD3+CD69-CD107+; D15; S1;<br>n=1,3,1,5,4,9     | 0.39 (± 0.439)      | 0.62 (± 0.460)      |  |  |
| CD45+CD3+CD69-CD107+; D15;S2;<br>n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69-CD107+; D29;<br>n=1,3,1,4,4,8         | 0.42 (± 0.449)      | 1.22 (± 1.608)      |  |  |
| CD45+CD3+CD69-CD107+;<br>FU;n=1,2,0,3,1,4           | 0.13 (± 99999)      | 0.75 (± 1.090)      |  |  |
| CD45+CD3+CD69-CD107+;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69-CD107-;D1pre;<br>n=1,3,1,5,4,9        | 35.93 (±<br>9.242)  | 42.20 (±<br>19.537) |  |  |
| CD45+CD3+CD69-CD107-;D1;1<br>h;n=1,3,1,5,4,9        | 36.93 (±<br>12.789) | 43.72 (±<br>21.074) |  |  |
| CD45+CD3+CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11       | 36.38 (±<br>12.700) | 38.92 (±<br>18.214) |  |  |
| CD45+CD3+CD69-CD107-; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999)  | 37.04 (±<br>99999)  |  |  |

|   |                     |                     |  |  |
|---|---------------------|---------------------|--|--|
| CD45+CD3+CD69-CD107-; D8;<br>n=1,3,0,5,4,8        | 33.83 (±<br>6.576)  | 47.67 (±<br>13.646) |  |  |
| CD45+CD3+CD69-CD107-; D15;S1;<br>n=1,3,1,5,4,9    | 41.15 (±<br>3.409)  | 46.00 (±<br>21.556) |  |  |
| CD45+CD3+CD69-CD107-; D15;<br>S2;n=0,0,1,0,0,0    | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD69-CD107-; D29;<br>n=1,3,1,4,4,8       | 35.70 (±<br>5.601)  | 45.10 (±<br>18.361) |  |  |
| CD45+CD3+CD69-CD107-;<br>FU;n=1,2,0,3,1,4         | 34.92 (±<br>99999)  | 32.05 (±<br>17.570) |  |  |
| CD45+CD3+CD69-CD107-;<br>USC;n=0,0,1,0,0,0        | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69+;D1pre;<br>n=1,3,1,5,4,9        | 58.78 (±<br>9.546)  | 52.12 (±<br>20.035) |  |  |
| CD45+CD3+CD8-CD69+;D1;1<br>h;n=1,3,1,5,4,9        | 59.04 (±<br>12.906) | 51.86 (±<br>22.844) |  |  |
| CD45+CD3+CD8-CD69+;D1;6<br>h;n=1,3,1,5,4,11       | 59.18 (±<br>13.744) | 56.19 (±<br>18.029) |  |  |
| CD45+CD3+CD8-CD69+; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999)  | 51.49 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69+; D8;<br>n=1,3,0,5,4,8          | 64.59 (±<br>10.317) | 42.80 (±<br>13.006) |  |  |
| CD45+CD3+CD8-CD69+; D15;<br>S1;n=1,3,1,5,4,9      | 53.99 (±<br>7.004)  | 49.92 (±<br>22.128) |  |  |
| CD45+CD3+CD8-CD69+; D15;<br>S2;n=0,0,1,0,0,0      | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69+; D29;<br>n=1,3,1,4,4,8         | 59.41 (±<br>7.751)  | 50.71 (±<br>19.479) |  |  |
| CD45+CD3+CD8-CD69+;<br>FU;n=1,2,0,3,1,4           | 64.72 (±<br>99999)  | 59.43 (±<br>17.448) |  |  |
| CD45+CD3+CD8-CD69+;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD107+;D1pre;<br>n=1,3,1,5,4,9       | 9.40 (± 9.095)      | 8.89 (± 7.406)      |  |  |
| CD45+CD3+CD8-CD107+;D1;1<br>h;n=1,3,1,5,4,9       | 10.14 (±<br>11.064) | 5.52 (± 3.023)      |  |  |
| CD45+CD3+CD8-CD107+;D1;6<br>h;n=1,3,1,5,4,11      | 11.10 (±<br>12.927) | 8.49 (± 3.930)      |  |  |
| CD45+CD3+CD8-CD107+; D2;<br>n=0,0,1,2,0,1         | 99999 (±<br>99999)  | 12.25 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD107+; D8;<br>n=1,3,0,5,4,8         | 6.89 (± 3.550)      | 7.20 (± 3.406)      |  |  |
| CD45+CD3+CD8-CD107+; D15;<br>S1;n=1,3,1,5,4,9     | 6.66 (± 4.113)      | 10.03 (±<br>7.687)  |  |  |
| CD45+CD3+CD8-CD107+; D15;S2;<br>n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD107+; D29;<br>n=1,3,1,4,4,8        | 8.29 (± 3.475)      | 8.07 (± 5.728)      |  |  |
| CD45+CD3+CD8-CD107+;<br>FU;n=1,2,0,3,1,4          | 4.78 (± 99999)      | 16.10 (±<br>11.466) |  |  |
| CD45+CD3+CD8-CD107+;<br>USC;n=0,0,1,0,0,0         | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-<br>CD69+CD107+;D1pre; n=1,3,1,5,4,9 | 8.70 (± 8.036)      | 8.49 (± 7.511)      |  |  |
| CD45+CD3+CD8-CD69+CD107+;D1;1<br>h;n=1,3,1,5,4,9  | 9.37 (± 9.954)      | 5.08 (± 3.208)      |  |  |
| CD45+CD3+CD8-CD69+CD107+;D1;6<br>h;n=1,3,1,5,4,11 | 10.26 (±<br>11.433) | 7.64 (± 3.879)      |  |  |
| CD45+CD3+CD8-CD69+CD107+; D2;<br>n=0,0,1,2,0,1    | 99999 (±<br>99999)  | 11.90 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69+CD107+; D8;<br>n=1,3,0,5,4,8    | 6.68 (± 3.439)      | 6.35 (± 3.062)      |  |  |



|  |                     |                     |  |  |
|--|---------------------|---------------------|--|--|
| CD45+CD3+CD8-CD69+CD107+; D15;<br>S1;n=1,3,1,5,4,9 | 6.42 (± 3.978)      | 9.27 (± 7.216)      |  |  |
| CD45+CD3+CD8-CD69+CD107+;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69+CD107+; D29;<br>n=1,3,1,4,4,8    | 8.03 (± 3.389)      | 6.92 (± 4.718)      |  |  |
| CD45+CD3+CD8-CD69+CD107+;<br>FU;n=1,2,0,3,1,4      | 4.63 (± 99999)      | 14.87 (±<br>10.444) |  |  |
| CD45+CD3+CD8-CD69+CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69+CD107-;D1pre;<br>n=1,3,1,5,4,9   | 50.08 (±<br>9.719)  | 43.63 (±<br>15.780) |  |  |
| CD45+CD3+CD8-CD69+CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 49.68 (±<br>9.756)  | 46.78 (±<br>20.420) |  |  |
| CD45+CD3+CD8-CD69+CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 48.93 (±<br>11.819) | 48.55 (±<br>16.115) |  |  |
| CD45+CD3+CD8-CD69+CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999)  | 39.59 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69+CD107-; D8;<br>n=1,3,0,5,4,8     | 57.91 (±<br>9.965)  | 36.45 (±<br>12.237) |  |  |
| CD45+CD3+CD8-CD69+CD107-;<br>D15;S1; n=1,3,1,5,4,9 | 47.58 (±<br>6.986)  | 40.65 (±<br>18.749) |  |  |
| CD45+CD3+CD8-CD69+CD107-;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69+CD107-; D29;<br>n=1,3,1,4,4,8    | 51.37 (±<br>5.812)  | 43.79 (±<br>19.299) |  |  |
| CD45+CD3+CD8-CD69+CD107-;<br>FU;n=1,2,0,3,1,4      | 60.09 (±<br>99999)  | 44.55 (±<br>12.109) |  |  |
| CD45+CD3+CD8-CD69+CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69-CD107+;D1pre;<br>n=1,3,1,5,4,9   | 0.70 (± 1.089)      | 0.41 (± 0.541)      |  |  |
| CD45+CD3+CD8-CD69-CD107+;D1;1<br>h;n=1,3,1,5,4,9   | 0.77 (± 1.174)      | 0.43 (± 0.496)      |  |  |
| CD45+CD3+CD8-CD69-CD107+;D1;6<br>h;n=1,3,1,5,4,11  | 0.85 (± 1.537)      | 0.85 (± 1.277)      |  |  |
| CD45+CD3+CD8-CD69-CD107+; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999)  | 0.35 (± 99999)      |  |  |
| CD45+CD3+CD8-CD69-CD107+; D8;<br>n=1,3,0,5,4,8     | 0.21 (± 0.194)      | 0.85 (± 0.855)      |  |  |
| CD45+CD3+CD8-CD69-CD107+;<br>D15;S1; n=1,3,1,5,4,9 | 0.25 (± 0.179)      | 0.76 (± 0.966)      |  |  |
| CD45+CD3+CD8-CD69-CD107+;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69-CD107+; D29;<br>n=1,3,1,4,4,8    | 0.23 (± 0.117)      | 1.15 (± 1.764)      |  |  |
| CD45+CD3+CD8-CD69-CD107+;<br>FU;n=1,2,0,3,1,4      | 0.15 (± 99999)      | 1.22 (± 1.319)      |  |  |
| CD45+CD3+CD8-CD69-CD107+;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69-CD107-;D1pre;<br>n=1,3,1,5,4,9   | 40.53 (±<br>9.843)  | 47.48 (±<br>19.639) |  |  |
| CD45+CD3+CD8-CD69-CD107-;D1;1<br>h;n=1,3,1,5,4,9   | 40.19 (±<br>13.401) | 47.70 (±<br>22.541) |  |  |
| CD45+CD3+CD8-CD69-CD107-;D1;6<br>h;n=1,3,1,5,4,11  | 39.98 (±<br>14.362) | 42.96 (±<br>17.217) |  |  |
| CD45+CD3+CD8-CD69-CD107-; D2;<br>n=0,0,1,2,0,1     | 99999 (±<br>99999)  | 48.16 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69-CD107-; D8;<br>n=1,3,0,5,4,8     | 35.20 (±<br>10.279) | 56.36 (±<br>12.433) |  |  |
| CD45+CD3+CD8-CD69-CD107-;<br>D15;S1;n=1,3,1,5,4,9  | 45.76 (±<br>6.941)  | 49.32 (±<br>21.812) |  |  |

|  |                     |                     |  |  |
|--|---------------------|---------------------|--|--|
| CD45+CD3+CD8-CD69-CD107-;<br>D15;S2; n=0,0,1,0,0,0 | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3+CD8-CD69-CD107-; D29;<br>n=1,3,1,4,4,8    | 40.37 (±<br>7.766)  | 48.14 (±<br>18.661) |  |  |
| CD45+CD3+CD8-CD69-CD107-;<br>FU;n=1,2,0,3,1,4      | 35.13 (±<br>99999)  | 39.35 (±<br>17.631) |  |  |
| CD45+CD3+CD8-CD69-CD107-;<br>USC;n=0,0,1,0,0,0     | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD19+CD69+;D1pre;<br>n=1,3,1,5,4,9        | 66.51 (±<br>16.098) | 60.06 (±<br>14.370) |  |  |
| CD45+CD3-CD19+CD69+;D1;1<br>h;n=1,3,1,5,4,9        | 67.42 (±<br>15.190) | 61.79 (±<br>14.941) |  |  |
| CD45+CD3-CD19+CD69+;D1;6<br>h;n=1,3,1,5,4,11       | 63.22 (±<br>18.089) | 66.22 (±<br>20.094) |  |  |
| CD45+CD3-CD19+CD69+; D2;<br>n=0,0,1,2,0,1          | 99999 (±<br>99999)  | 58.57 (±<br>99999)  |  |  |
| CD45+CD3-CD19+CD69+; D8;<br>n=1,3,0,5,4,8          | 66.95 (±<br>20.328) | 52.90 (±<br>52.90)  |  |  |
| CD45+CD3-CD19+CD69+; D15;S1;<br>n=1,3,1,5,4,9      | 61.50 (±<br>12.596) | 61.77 (±<br>61.77)  |  |  |
| CD45+CD3-CD19+CD69+;<br>D15;S2;n=0,0,1,0,0,0       | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD3-CD19+CD69+; D29;<br>n=1,3,1,4,4,8         | 65.80 (±<br>7.211)  | 61.49 (±<br>61.49)  |  |  |
| CD45+CD3-CD19+CD69+;<br>FU;n=1,2,0,3,1,4           | 73.22 (±<br>99999)  | 70.54 (±<br>70.54)  |  |  |
| CD45+CD3-CD19+CD69+;<br>USC;n=0,0,1,0,0,0          | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD14+CD69+;D1pre;<br>n=1,3,1,5,4,9            | 99.19 (±<br>1.046)  | 99.39 (±<br>0.407)  |  |  |
| CD45+CD14+CD69+;D1;1<br>h;n=1,3,1,5,4,9            | 99.51 (±<br>0.658)  | 99.37 (±<br>0.725)  |  |  |
| CD45+CD14+CD69+;D1;6<br>h;n=1,3,1,5,4,11           | 99.11 (±<br>1.442)  | 99.24 (±<br>0.942)  |  |  |
| CD45+CD14+CD69+; D2;<br>n=0,0,1,2,0,1              | 99999 (±<br>99999)  | 99.06 (±<br>99999)  |  |  |
| CD45+CD14+CD69+; D8;<br>n=1,3,0,5,4,8              | 99.78 (±<br>0.241)  | 98.64 (±<br>1.993)  |  |  |
| CD45+CD14+CD69+; D15; S1;<br>n=1,3,1,5,4,9         | 99.50 (±<br>0.435)  | 97.67 (±<br>3.444)  |  |  |
| CD45+CD14+CD69+; D15; S2;<br>n=0,0,1,0,0,0         | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |
| CD45+CD14+CD69+; D29;<br>n=1,3,1,4,4,8             | 99.68 (±<br>0.225)  | 98.98 (±<br>1.950)  |  |  |
| CD45+CD14+CD69+; FU;n=1,2,0,3,1,4                  | 99.47 (±<br>99999)  | 99.65 (±<br>0.288)  |  |  |
| CD45+CD14+CD69+;<br>USC;n=0,0,1,0,0,0              | 99999 (±<br>99999)  | 99999 (±<br>99999)  |  |  |

Notes:

[110] - PD Population

[111] - PD Population

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AEs and SAEs were collected from the start of study treatment until 45 days or 5 half-lives from the last dose of study treatment (median of 6.143 weeks of drug exposure).

Adverse event reporting additional description:

AEs and SAEs were collected in the All Treated Population which comprised of all participants who received at least one dose of GSK2849330. Treatment groups with same dose and administration frequency were combined as pre-specified in RAP.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 20.1 |
|--------------------|------|

### Reporting groups

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | GSK2849330 1.4 mg/kg weekly |
|-----------------------|-----------------------------|

Reporting group description:

Participants were administered a weekly dose of 1.4 mg/kg GSK2849330 as intravenous infusion for 28 days

|                       |                                  |
|-----------------------|----------------------------------|
| Reporting group title | GSK2849330 3 mg/kg every 2 weeks |
|-----------------------|----------------------------------|

Reporting group description:

Participants were administered 3 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

|                       |                           |
|-----------------------|---------------------------|
| Reporting group title | GSK2849330 3 mg/kg weekly |
|-----------------------|---------------------------|

Reporting group description:

Participants were administered a weekly dose of 3 mg/kg GSK2849330 as intravenous infusion for 28 days.

|                       |                                   |
|-----------------------|-----------------------------------|
| Reporting group title | GSK2849330 10 mg/kg every 2 weeks |
|-----------------------|-----------------------------------|

Reporting group description:

Participants were administered 10 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days.

|                       |                                   |
|-----------------------|-----------------------------------|
| Reporting group title | GSK2849330 30 mg/kg every 2 weeks |
|-----------------------|-----------------------------------|

Reporting group description:

Participants were administered 30 mg/kg GSK2849330 as an intravenous infusion every 2 weeks for 28 days

|                       |                            |
|-----------------------|----------------------------|
| Reporting group title | GSK2849330 30 mg/kg weekly |
|-----------------------|----------------------------|

Reporting group description:

Participants were administered a weekly dose of 30 mg/kg GSK2849330 as intravenous infusion for 28 days. The arm included participants receiving 30 mg/kg weekly from both Part 1 (dose-escalation cohort) and Part 2 (dose expansion cohort).

| Serious adverse events                            | GSK2849330 1.4 mg/kg weekly | GSK2849330 3 mg/kg every 2 weeks | GSK2849330 3 mg/kg weekly |
|---|-----------------------------|----------------------------------|---------------------------|
| Total subjects affected by serious adverse events |                             |                                  |                           |
| subjects affected / exposed                       | 0 / 1 (0.00%)               | 1 / 3 (33.33%)                   | 0 / 2 (0.00%)             |
| number of deaths (all causes)                     | 0                           | 0                                | 0                         |
| number of deaths resulting from adverse events    |                             |                                  |                           |
| Investigations                                    |                             |                                  |                           |

|  |                |                |                 |
|--|----------------|----------------|-----------------|
| Ejection fraction decreased<br>subjects affected / exposed | 0 / 1 (0.00%)  | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0           |
| <b>Gastrointestinal disorders</b>                          |                |                |                 |
| Abdominal pain<br>subjects affected / exposed              | 0 / 1 (0.00%)  | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0           |
| Intestinal obstruction<br>subjects affected / exposed      | 0 / 1 (0.00%)  | 1 / 3 (33.33%) | 0 / 2 (0.00%)   |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 1          | 0 / 0           |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0           |
| Melaena<br>subjects affected / exposed                     | 0 / 1 (0.00%)  | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0           |
| <b>Infections and infestations</b>                         |                |                |                 |
| Escherichia sepsis<br>subjects affected / exposed          | 0 / 1 (0.00%)  | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0           |
| Urosepsis<br>subjects affected / exposed                   | 0 / 1 (0.00%)  | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences causally related to<br>treatment / all         | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to<br>treatment / all              | 0 / 0          | 0 / 0          | 0 / 0           |
| <b>Serious adverse events</b>                              |                |                |                 |
| Total subjects affected by serious<br>adverse events       |                |                |                 |
| subjects affected / exposed                                | 1 / 5 (20.00%) | 1 / 4 (25.00%) | 3 / 14 (21.43%) |
| number of deaths (all causes)                              | 0              | 0              | 1               |
| number of deaths resulting from<br>adverse events          |                |                |                 |
| <b>Investigations</b>                                      |                |                |                 |
| Ejection fraction decreased                                |                |                |                 |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Gastrointestinal disorders</b>               |                |                |                |
| Abdominal pain                                  |                |                |                |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Intestinal obstruction                          |                |                |                |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Melaena   |                |                |                |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Infections and infestations</b>              |                |                |                |
| Escherichia sepsis                              |                |                |                |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| Urosepsis                                       |                |                |                |
| subjects affected / exposed                     | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | GSK2849330 1.4 mg/kg weekly | GSK2849330 3 mg/kg every 2 weeks | GSK2849330 3 mg/kg weekly |
|---|-----------------------------|----------------------------------|---------------------------|
| Total subjects affected by non-serious adverse events |                             |                                  |                           |
| subjects affected / exposed                           | 1 / 1 (100.00%)             | 3 / 3 (100.00%)                  | 2 / 2 (100.00%)           |
| Vascular disorders                                    |                             |                                  |                           |
| Hypertension  |                             |                                  |                           |

|  |               |                |                 |
|--|---------------|----------------|-----------------|
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                                    | 0             | 0              | 0               |
| Vena cava thrombosis                                 |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                                    | 0             | 0              | 0               |
| General disorders and administration site conditions |               |                |                 |
| Fatigue  |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 2 / 3 (66.67%) | 2 / 2 (100.00%) |
| occurrences (all)                                    | 0             | 2              | 2               |
| Non-cardiac chest pain                               |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 1 / 2 (50.00%)  |
| occurrences (all)                                    | 0             | 1              | 2               |
| Chest pain   |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                                    | 0             | 0              | 0               |
| Chills   |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)   |
| occurrences (all)                                    | 0             | 1              | 0               |
| Malaise  |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                                    | 0             | 0              | 0               |
| Oedema peripheral                                    |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                                    | 0             | 0              | 0               |
| Chest discomfort                                     |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                                    | 0             | 0              | 0               |
| Discomfort   |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)   |
| occurrences (all)                                    | 0             | 1              | 0               |
| Influenza like illness                               |               |                |                 |
| subjects affected / exposed                          | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 1 / 2 (50.00%)  |
| occurrences (all)                                    | 0             | 0              | 1               |
| Mucosal inflammation                                 |               |                |                 |

|   |                    |                     |                     |
|---|--------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 0 / 2 (0.00%)<br>0  |
| Pain<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Pyrexia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Reproductive system and breast disorders<br>Vaginal haemorrhage<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 0 / 2 (0.00%)<br>0  |
| Vulvovaginal pruritus<br>subjects affected / exposed<br>occurrences (all)   | 0 / 1 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 0 / 2 (0.00%)<br>0  |
| Respiratory, thoracic and mediastinal disorders<br>Dyspnoea<br>subjects affected / exposed<br>occurrences (all)     | 0 / 1 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 1 / 2 (50.00%)<br>1 |
| Pleural effusion<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 1 / 2 (50.00%)<br>1 |
| Asthma<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Epistaxis<br>subjects affected / exposed<br>occurrences (all)   | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Nasal congestion<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Pulmonary embolism<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Upper-airway cough syndrome   |                    |                     |                     |

|  |                    |                     |                     |
|--|--------------------|---------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)   | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Wheezing<br>subjects affected / exposed<br>occurrences (all)   | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Psychiatric disorders<br>Insomnia<br>subjects affected / exposed<br>occurrences (all)                    | 0 / 1 (0.00%)<br>0 | 1 / 3 (33.33%)<br>1 | 0 / 2 (0.00%)<br>0  |
| Product issues<br>Device dislocation<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Investigations<br>Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Aspartate aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Gamma-glutamyltransferase increased<br>subjects affected / exposed<br>occurrences (all)                  | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 1 / 2 (50.00%)<br>1 |
| Weight decreased<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Blood alkaline phosphatase increased<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Blood bilirubin increased<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |
| Blood lactate dehydrogenase increased<br>subjects affected / exposed<br>occurrences (all)                | 0 / 1 (0.00%)<br>0 | 0 / 3 (0.00%)<br>0  | 0 / 2 (0.00%)<br>0  |



|  |               |                |                 |
|--|---------------|----------------|-----------------|
| Injury, poisoning and procedural complications |               |                |                 |
| Infusion related reaction                      |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 1 / 2 (50.00%)  |
| occurrences (all)                              | 0             | 0              | 1               |
| Thermal burn                                   |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                              | 0             | 0              | 0               |
| Cardiac disorders                              |               |                |                 |
| Aortic valve disease                           |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                              | 0             | 0              | 0               |
| Nervous system disorders                       |               |                |                 |
| Headache                                       |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 2 / 3 (66.67%) | 2 / 2 (100.00%) |
| occurrences (all)                              | 0             | 3              | 3               |
| Dizziness                                      |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)   |
| occurrences (all)                              | 0             | 1              | 0               |
| Dysgeusia                                      |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                              | 0             | 0              | 0               |
| Paraesthesia                                   |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                              | 0             | 0              | 0               |
| Peripheral sensory neuropathy                  |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                              | 0             | 0              | 0               |
| Tremor   |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)   |
| occurrences (all)                              | 0             | 0              | 0               |
| Cough  |               |                |                 |
| subjects affected / exposed                    | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)   |
| occurrences (all)                              | 0             | 1              | 0               |
| Blood and lymphatic system disorders           |               |                |                 |
| Anaemia  |               |                |                 |

|  |                      |                      |                     |
|--|----------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                         | 0 / 1 (0.00%)<br>0   | 0 / 3 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  |
| Eye disorders  |                      |                      |                     |
| Vision blurred<br>subjects affected / exposed<br>occurrences (all)       | 0 / 1 (0.00%)<br>0   | 0 / 3 (0.00%)<br>0   | 1 / 2 (50.00%)<br>1 |
| Glaucoma<br>subjects affected / exposed<br>occurrences (all)             | 0 / 1 (0.00%)<br>0   | 0 / 3 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  |
| Retinal haemorrhage<br>subjects affected / exposed<br>occurrences (all)  | 0 / 1 (0.00%)<br>0   | 0 / 3 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  |
| Gastrointestinal disorders   |                      |                      |                     |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)            | 1 / 1 (100.00%)<br>1 | 3 / 3 (100.00%)<br>4 | 1 / 2 (50.00%)<br>3 |
| Abdominal pain<br>subjects affected / exposed<br>occurrences (all)       | 0 / 1 (0.00%)<br>0   | 2 / 3 (66.67%)<br>2  | 0 / 2 (0.00%)<br>0  |
| Nausea<br>subjects affected / exposed<br>occurrences (all)               | 0 / 1 (0.00%)<br>0   | 0 / 3 (0.00%)<br>0   | 1 / 2 (50.00%)<br>2 |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)             | 0 / 1 (0.00%)<br>0   | 1 / 3 (33.33%)<br>1  | 1 / 2 (50.00%)<br>1 |
| Constipation<br>subjects affected / exposed<br>occurrences (all)         | 1 / 1 (100.00%)<br>1 | 0 / 3 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  |
| Abdominal discomfort<br>subjects affected / exposed<br>occurrences (all) | 0 / 1 (0.00%)<br>0   | 0 / 3 (0.00%)<br>0   | 0 / 2 (0.00%)<br>0  |
| Abdominal distension<br>subjects affected / exposed<br>occurrences (all) | 1 / 1 (100.00%)<br>1 | 1 / 3 (33.33%)<br>1  | 0 / 2 (0.00%)<br>0  |
| Abdominal pain upper   |                      |                      |                     |

|  |                 |                |               |
|--|-----------------|----------------|---------------|
| subjects affected / exposed            | 0 / 1 (0.00%)   | 1 / 3 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0             |
| Abdominal pain lower                   |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0             |
| Dry mouth                              |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0             |
| Oesophageal obstruction                |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0             |
| Ascites                                |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0             |
| Dyspepsia                              |                 |                |               |
| subjects affected / exposed            | 1 / 1 (100.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 1               | 0              | 0             |
| Gingival pain                          |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 1 / 3 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0             |
| Impaired gastric emptying              |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0             |
| Mouth ulceration                       |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0             |
| Oral pain                              |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 1 / 3 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 1              | 0             |
| Stomatitis                             |                 |                |               |
| subjects affected / exposed            | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 0               | 0              | 0             |
| Tongue coated                          |                 |                |               |
| subjects affected / exposed            | 1 / 1 (100.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)                      | 1               | 0              | 0             |
| Skin and subcutaneous tissue disorders |                 |                |               |

|                             |                 |                |                |
|-----------------------------|-----------------|----------------|----------------|
| Pruritus                    |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 1 / 2 (50.00%) |
| occurrences (all)           | 0               | 0              | 4              |
| Dry skin                    |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 1 / 3 (33.33%) | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 1              | 0              |
| Rash                        |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Rash maculo-papular         |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Skin fissures               |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 1 / 3 (33.33%) | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 1              | 0              |
| Blister                     |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Dermatitis acneiform        |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Onychomadesis               |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Psoriasis                   |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Rash macular                |                 |                |                |
| subjects affected / exposed | 1 / 1 (100.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 1               | 0              | 0              |
| Skin hyperpigmentation      |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |
| Skin ulcer                  |                 |                |                |
| subjects affected / exposed | 0 / 1 (0.00%)   | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)           | 0               | 0              | 0              |

|   |               |                |                |
|---|---------------|----------------|----------------|
| Musculoskeletal and connective tissue disorders |               |                |                |
| Myalgia   |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 1 / 2 (50.00%) |
| occurrences (all)                               | 0             | 1              | 1              |
| Back pain                                       |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 0              | 0              |
| Arthralgia                                      |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 0              | 0              |
| Flank pain                                      |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 1              | 0              |
| Musculoskeletal pain                            |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 0              | 0              |
| Groin pain                                      |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 1              | 0              |
| Muscle twitching                                |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 0              | 0              |
| Muscular weakness                               |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 0              | 0              |
| Musculoskeletal chest pain                      |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 0              | 0              |
| Neck pain                                       |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 0              | 0              |
| Pain in extremity                               |               |                |                |
| subjects affected / exposed                     | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                               | 0             | 0              | 0              |
| Infections and infestations                     |               |                |                |

|                                    |               |                |                |
|------------------------------------|---------------|----------------|----------------|
| Lung infection                     |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 0              | 0              |
| Upper respiratory tract infection  |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 1              | 0              |
| Cystitis                           |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 0              | 0              |
| Oral candidiasis                   |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 0              | 0              |
| Otitis externa                     |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 0              | 0              |
| Paronychia                         |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 1              | 0              |
| Respiratory tract infection        |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 0              | 0              |
| Urinary tract infection            |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 0              | 0              |
| Viral infection                    |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 0              | 0              |
| Metabolism and nutrition disorders |               |                |                |
| Decreased appetite                 |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 1 / 2 (50.00%) |
| occurrences (all)                  | 0             | 1              | 1              |
| Hypomagnesaemia                    |               |                |                |
| subjects affected / exposed        | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%)  |
| occurrences (all)                  | 0             | 1              | 0              |
| Hypoalbuminaemia                   |               |                |                |

|                             |               |                |               |
|-----------------------------|---------------|----------------|---------------|
| subjects affected / exposed | 0 / 1 (0.00%) | 0 / 3 (0.00%)  | 0 / 2 (0.00%) |
| occurrences (all)           | 0             | 0              | 0             |
| Hypokalaemia                |               |                |               |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all)           | 0             | 1              | 0             |
| Hypophagia                  |               |                |               |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all)           | 0             | 1              | 0             |
| Increased appetite          |               |                |               |
| subjects affected / exposed | 0 / 1 (0.00%) | 1 / 3 (33.33%) | 0 / 2 (0.00%) |
| occurrences (all)           | 0             | 1              | 0             |

| <b>Non-serious adverse events</b>                     | GSK2849330 10 mg/kg every 2 weeks | GSK2849330 30 mg/kg every 2 weeks | GSK2849330 30 mg/kg weekly |
|---|-----------------------------------|-----------------------------------|----------------------------|
| Total subjects affected by non-serious adverse events |                                   |                                   |                            |
| subjects affected / exposed                           | 5 / 5 (100.00%)                   | 4 / 4 (100.00%)                   | 14 / 14 (100.00%)          |
| Vascular disorders                                    |                                   |                                   |                            |
| Hypertension  |                                   |                                   |                            |
| subjects affected / exposed                           | 0 / 5 (0.00%)                     | 0 / 4 (0.00%)                     | 1 / 14 (7.14%)             |
| occurrences (all)                                     | 0                                 | 0                                 | 4                          |
| Vena cava thrombosis                                  |                                   |                                   |                            |
| subjects affected / exposed                           | 1 / 5 (20.00%)                    | 0 / 4 (0.00%)                     | 0 / 14 (0.00%)             |
| occurrences (all)                                     | 1                                 | 0                                 | 0                          |
| General disorders and administration site conditions  |                                   |                                   |                            |
| Fatigue   |                                   |                                   |                            |
| subjects affected / exposed                           | 2 / 5 (40.00%)                    | 2 / 4 (50.00%)                    | 10 / 14 (71.43%)           |
| occurrences (all)                                     | 2                                 | 2                                 | 12                         |
| Non-cardiac chest pain                                |                                   |                                   |                            |
| subjects affected / exposed                           | 0 / 5 (0.00%)                     | 1 / 4 (25.00%)                    | 0 / 14 (0.00%)             |
| occurrences (all)                                     | 0                                 | 1                                 | 0                          |
| Chest pain  |                                   |                                   |                            |
| subjects affected / exposed                           | 0 / 5 (0.00%)                     | 0 / 4 (0.00%)                     | 2 / 14 (14.29%)            |
| occurrences (all)                                     | 0                                 | 0                                 | 3                          |
| Chills  |                                   |                                   |                            |
| subjects affected / exposed                           | 0 / 5 (0.00%)                     | 0 / 4 (0.00%)                     | 1 / 14 (7.14%)             |
| occurrences (all)                                     | 0                                 | 0                                 | 1                          |
| Malaise   |                                   |                                   |                            |

|   |                |                |                 |
|---|----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                               | 0              | 0              | 2               |
| Oedema peripheral                               |                |                |                 |
| subjects affected / exposed                     | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                               | 1              | 0              | 1               |
| Chest discomfort                                |                |                |                 |
| subjects affected / exposed                     | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                               | 1              | 0              | 0               |
| Discomfort                                      |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Influenza like illness                          |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Mucosal inflammation                            |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Pain  |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Pyrexia   |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Reproductive system and breast disorders        |                |                |                 |
| Vaginal haemorrhage                             |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Vulvovaginal pruritus                           |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Respiratory, thoracic and mediastinal disorders |                |                |                 |
| Dyspnoea  |                |                |                 |
| subjects affected / exposed                     | 1 / 5 (20.00%) | 1 / 4 (25.00%) | 2 / 14 (14.29%) |
| occurrences (all)                               | 1              | 1              | 2               |
| Pleural effusion                                |                |                |                 |



|                                      |                |                |                 |
|--------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed          | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)                    | 0              | 1              | 0               |
| Asthma                               |                |                |                 |
| subjects affected / exposed          | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)                    | 0              | 1              | 0               |
| Epistaxis                            |                |                |                 |
| subjects affected / exposed          | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                    | 0              | 0              | 1               |
| Nasal congestion                     |                |                |                 |
| subjects affected / exposed          | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                    | 0              | 0              | 1               |
| Pulmonary embolism                   |                |                |                 |
| subjects affected / exposed          | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                    | 1              | 0              | 0               |
| Upper-airway cough syndrome          |                |                |                 |
| subjects affected / exposed          | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                    | 0              | 0              | 1               |
| Wheezing                             |                |                |                 |
| subjects affected / exposed          | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                    | 0              | 0              | 1               |
| Psychiatric disorders                |                |                |                 |
| Insomnia                             |                |                |                 |
| subjects affected / exposed          | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 2 / 14 (14.29%) |
| occurrences (all)                    | 0              | 0              | 2               |
| Product issues                       |                |                |                 |
| Device dislocation                   |                |                |                 |
| subjects affected / exposed          | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                    | 0              | 0              | 1               |
| Investigations                       |                |                |                 |
| Alanine aminotransferase increased   |                |                |                 |
| subjects affected / exposed          | 2 / 5 (40.00%) | 0 / 4 (0.00%)  | 2 / 14 (14.29%) |
| occurrences (all)                    | 2              | 0              | 4               |
| Aspartate aminotransferase increased |                |                |                 |
| subjects affected / exposed          | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 3 / 14 (21.43%) |
| occurrences (all)                    | 1              | 0              | 4               |
| Gamma-glutamyltransferase increased  |                |                |                 |

|  |                |                |                 |
|--|----------------|----------------|-----------------|
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 4 / 14 (28.57%) |
| occurrences (all)                              | 0              | 0              | 4               |
| Weight decreased                               |                |                |                 |
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 4 / 14 (28.57%) |
| occurrences (all)                              | 0              | 0              | 5               |
| Blood alkaline phosphatase increased           |                |                |                 |
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 3 / 14 (21.43%) |
| occurrences (all)                              | 0              | 1              | 3               |
| Blood bilirubin increased                      |                |                |                 |
| subjects affected / exposed                    | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                              | 1              | 0              | 0               |
| Blood lactate dehydrogenase increased          |                |                |                 |
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                              | 0              | 0              | 1               |
| Injury, poisoning and procedural complications |                |                |                 |
| Infusion related reaction                      |                |                |                 |
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 2 / 14 (14.29%) |
| occurrences (all)                              | 0              | 0              | 2               |
| Thermal burn                                   |                |                |                 |
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)                              | 0              | 1              | 0               |
| Cardiac disorders                              |                |                |                 |
| Aortic valve disease                           |                |                |                 |
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                              | 0              | 0              | 1               |
| Nervous system disorders                       |                |                |                 |
| Headache                                       |                |                |                 |
| subjects affected / exposed                    | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                              | 2              | 0              | 2               |
| Dizziness                                      |                |                |                 |
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                              | 0              | 0              | 1               |
| Dysgeusia                                      |                |                |                 |
| subjects affected / exposed                    | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 1 / 14 (7.14%)  |
| occurrences (all)                              | 0              | 1              | 1               |
| Paraesthesia                                   |                |                |                 |

|   |                     |                     |                       |
|---|---------------------|---------------------|-----------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 5 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 14 (7.14%)<br>1   |
| Peripheral sensory neuropathy<br>subjects affected / exposed<br>occurrences (all)                   | 0 / 5 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 14 (7.14%)<br>1   |
| Tremor<br>subjects affected / exposed<br>occurrences (all)  | 1 / 5 (20.00%)<br>1 | 0 / 4 (0.00%)<br>0  | 0 / 14 (0.00%)<br>0   |
| Cough<br>subjects affected / exposed<br>occurrences (all)   | 0 / 5 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 14 (7.14%)<br>1   |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all) | 0 / 5 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 3 / 14 (21.43%)<br>3  |
| Eye disorders<br>Vision blurred<br>subjects affected / exposed<br>occurrences (all)                 | 0 / 5 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 14 (7.14%)<br>1   |
| Glaucoma<br>subjects affected / exposed<br>occurrences (all)  | 0 / 5 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 1 / 14 (7.14%)<br>1   |
| Retinal haemorrhage<br>subjects affected / exposed<br>occurrences (all)                             | 1 / 5 (20.00%)<br>1 | 0 / 4 (0.00%)<br>0  | 0 / 14 (0.00%)<br>0   |
| Gastrointestinal disorders<br>Diarrhoea<br>subjects affected / exposed<br>occurrences (all)         | 2 / 5 (40.00%)<br>2 | 3 / 4 (75.00%)<br>4 | 9 / 14 (64.29%)<br>12 |
| Abdominal pain<br>subjects affected / exposed<br>occurrences (all)                                  | 0 / 5 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 4 / 14 (28.57%)<br>7  |
| Nausea<br>subjects affected / exposed<br>occurrences (all)  | 2 / 5 (40.00%)<br>2 | 0 / 4 (0.00%)<br>0  | 4 / 14 (28.57%)<br>4  |
| Vomiting  |                     |                     |                       |

|                             |                |                |                 |
|-----------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 5 (0.00%)  | 3 / 4 (75.00%) | 1 / 14 (7.14%)  |
| occurrences (all)           | 0              | 4              | 2               |
| Constipation                |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 2 / 14 (14.29%) |
| occurrences (all)           | 0              | 1              | 3               |
| Abdominal discomfort        |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 1 / 14 (7.14%)  |
| occurrences (all)           | 0              | 1              | 3               |
| Abdominal distension        |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)           | 0              | 1              | 0               |
| Abdominal pain upper        |                |                |                 |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)           | 1              | 0              | 1               |
| Abdominal pain lower        |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 2 / 4 (50.00%) | 0 / 14 (0.00%)  |
| occurrences (all)           | 0              | 2              | 0               |
| Dry mouth                   |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)           | 0              | 0              | 2               |
| Oesophageal obstruction     |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 2 / 14 (14.29%) |
| occurrences (all)           | 0              | 0              | 2               |
| Ascites                     |                |                |                 |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)           | 1              | 0              | 0               |
| Dyspepsia                   |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)           | 0              | 0              | 0               |
| Gingival pain               |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)           | 0              | 0              | 0               |
| Impaired gastric emptying   |                |                |                 |
| subjects affected / exposed | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)           | 0              | 1              | 0               |
| Mouth ulceration            |                |                |                 |

|  |                |                |                 |
|--|----------------|----------------|-----------------|
| subjects affected / exposed            | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                      | 1              | 0              | 0               |
| Oral pain                              |                |                |                 |
| subjects affected / exposed            | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0               |
| Stomatitis                             |                |                |                 |
| subjects affected / exposed            | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                      | 0              | 0              | 1               |
| Tongue coated                          |                |                |                 |
| subjects affected / exposed            | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                      | 0              | 0              | 0               |
| Skin and subcutaneous tissue disorders |                |                |                 |
| Pruritus                               |                |                |                 |
| subjects affected / exposed            | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 2 / 14 (14.29%) |
| occurrences (all)                      | 0              | 0              | 2               |
| Dry skin                               |                |                |                 |
| subjects affected / exposed            | 1 / 5 (20.00%) | 1 / 4 (25.00%) | 1 / 14 (7.14%)  |
| occurrences (all)                      | 1              | 1              | 1               |
| Rash                                   |                |                |                 |
| subjects affected / exposed            | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 2 / 14 (14.29%) |
| occurrences (all)                      | 0              | 0              | 3               |
| Rash maculo-papular                    |                |                |                 |
| subjects affected / exposed            | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                      | 0              | 0              | 3               |
| Skin fissures                          |                |                |                 |
| subjects affected / exposed            | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                      | 0              | 0              | 1               |
| Blister                                |                |                |                 |
| subjects affected / exposed            | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                      | 1              | 0              | 0               |
| Dermatitis acneiform                   |                |                |                 |
| subjects affected / exposed            | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                      | 1              | 0              | 0               |
| Onychomadesis                          |                |                |                 |
| subjects affected / exposed            | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                      | 0              | 0              | 1               |

|   |                |                |                 |
|---|----------------|----------------|-----------------|
| Psoriasis                                       |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Rash macular                                    |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Skin hyperpigmentation                          |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                               | 0              | 0              | 1               |
| Skin ulcer                                      |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 1              | 0               |
| Musculoskeletal and connective tissue disorders |                |                |                 |
| Myalgia   |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 2 / 14 (14.29%) |
| occurrences (all)                               | 0              | 1              | 4               |
| Back pain                                       |                |                |                 |
| subjects affected / exposed                     | 1 / 5 (20.00%) | 1 / 4 (25.00%) | 3 / 14 (21.43%) |
| occurrences (all)                               | 1              | 1              | 3               |
| Arthralgia                                      |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 2              | 0               |
| Flank pain                                      |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 1              | 0               |
| Musculoskeletal pain                            |                |                |                 |
| subjects affected / exposed                     | 1 / 5 (20.00%) | 0 / 4 (0.00%)  | 1 / 14 (7.14%)  |
| occurrences (all)                               | 1              | 0              | 1               |
| Groin pain                                      |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 0 / 4 (0.00%)  | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 0              | 0               |
| Muscle twitching                                |                |                |                 |
| subjects affected / exposed                     | 0 / 5 (0.00%)  | 1 / 4 (25.00%) | 0 / 14 (0.00%)  |
| occurrences (all)                               | 0              | 1              | 0               |
| Muscular weakness                               |                |                |                 |

|                                   |                |               |                |
|-----------------------------------|----------------|---------------|----------------|
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all)                 | 0              | 0             | 1              |
| Musculoskeletal chest pain        |                |               |                |
| subjects affected / exposed       | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all)                 | 1              | 0             | 0              |
| Neck pain                         |                |               |                |
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all)                 | 0              | 0             | 1              |
| Pain in extremity                 |                |               |                |
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all)                 | 0              | 0             | 1              |
| Infections and infestations       |                |               |                |
| Lung infection                    |                |               |                |
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all)                 | 0              | 0             | 2              |
| Upper respiratory tract infection |                |               |                |
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all)                 | 0              | 0             | 1              |
| Cystitis                          |                |               |                |
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all)                 | 0              | 0             | 1              |
| Oral candidiasis                  |                |               |                |
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all)                 | 0              | 0             | 1              |
| Otitis externa                    |                |               |                |
| subjects affected / exposed       | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all)                 | 1              | 0             | 0              |
| Paronychia                        |                |               |                |
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all)                 | 0              | 0             | 0              |
| Respiratory tract infection       |                |               |                |
| subjects affected / exposed       | 0 / 5 (0.00%)  | 0 / 4 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all)                 | 0              | 0             | 1              |
| Urinary tract infection           |                |               |                |
| subjects affected / exposed       | 1 / 5 (20.00%) | 0 / 4 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all)                 | 1              | 0             | 0              |

|  |                     |                     |                      |
|--|---------------------|---------------------|----------------------|
| Viral infection<br>subjects affected / exposed<br>occurrences (all)    | 1 / 5 (20.00%)<br>1 | 0 / 4 (0.00%)<br>0  | 0 / 14 (0.00%)<br>0  |
| Metabolism and nutrition disorders                                     |                     |                     |                      |
| Decreased appetite<br>subjects affected / exposed<br>occurrences (all) | 2 / 5 (40.00%)<br>2 | 2 / 4 (50.00%)<br>2 | 3 / 14 (21.43%)<br>3 |
| Hypomagnesaemia<br>subjects affected / exposed<br>occurrences (all)    | 0 / 5 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 1 / 14 (7.14%)<br>1  |
| Hypoalbuminaemia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 5 (0.00%)<br>0  | 1 / 4 (25.00%)<br>1 | 0 / 14 (0.00%)<br>0  |
| Hypokalaemia<br>subjects affected / exposed<br>occurrences (all)       | 0 / 5 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 14 (0.00%)<br>0  |
| Hypophagia<br>subjects affected / exposed<br>occurrences (all)         | 0 / 5 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 14 (0.00%)<br>0  |
| Increased appetite<br>subjects affected / exposed<br>occurrences (all) | 0 / 5 (0.00%)<br>0  | 0 / 4 (0.00%)<br>0  | 0 / 14 (0.00%)<br>0  |



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date              | Amendment  |
|-------------------|--|
| 10 September 2014 | <p>Four molecularly-defined, tumor histology groups were added for study during Part 2. Additional inclusion criteria for participants in Part 2 were added to clarify the number of prior lines of therapy allowed for study entry and to require participants to undergo pre and on-treatment tumor biopsies. References to cohorts of participants in Part 2 were removed and replaced with groups of participants. An additional cohort of participants was added to Part 1. This cohort will receive weekly treatment with 30 milligrams per kilogram (mg/kg) GSK2849330, with an option to reduce dosing frequency to every 2 weeks after 24 weeks. The approximate number of participants in Part 1 was changed from 10 to 13, to accommodate the additional weekly cohort. The anticipated number of participants in Part 1 is now 34. The rationale for adding a weekly dosing regimen was added. The exclusion criteria for participants with untreated brain or meningeal metastases and participants treated for stable brain metastases were clarified. PK sampling times were revised for participants in Part 1 enrolled under this amendment and for participants enrolled in Part 2. Preclinical and nonclinical findings on HER3 antibodies from recent studies and abstracts were added, including the rationale for the tumor types selected for Part 2. The predicted half-life of GSK2849330 was changed from 8-9 days to 7 days at 30 mg/kg. The expected dosing frequency was changed from <math>\geq 2</math> weeks to 1-2 weeks. Preliminary noncompartmental and population PK parameters for the 1.4 mg/kg, 3 mg/kg, and 10 mg/kg doses were added. Permitted and prohibited medications (growth factors, anticoagulants, and corticosteroids) were clarified. The recommendations for management of diarrhea were expanded. The requirement for a sample for selected cytokines in participants experiencing suspected infusion-related reactions was added. The criterion for withholding of study treatment for QTc prolongation was clarified.</p> |
| 09 January 2015   | <p>The inclusion criteria were modified for Molecularly Defined Tumor Histology Groups 1, 2 and 4 in Part 2 to remove the statement that participants would be eligible for inclusion into the study if they had not received standard therapy when such therapy was not available to them commercially or via a clinical trial. The definition of DLT for participants with thrombocytopenia was expanded to include Grade 3 events of thrombocytopenia associated with bleeding in addition to all Grade 4 events. The statements regarding obtaining paired tumor biopsies have been modified to include that all biopsies should be obtained from tumor easily accessible to biopsy using a procedure that is safe for the participant. The total volume of blood to be collected within the first 30 days of participation has been modified to account for the increased PK sampling. Inconsistencies were corrected in the Time and Events Tables in Section 7. Minor grammatical and formatting changes were made throughout the document.</p>   |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported